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Glycoproteins are highly relevant as drugs in the biomedical field and new 
glycosylation strategies are crucial for efficient therapeutic proteins manufacturing. 
Analogues of monosaccharides can be incorporated into glycopeptides and mimetics 
from activated sugar nucleotide donors using glycosyltransferases which can be 
additionally subjected to rounds of directed evolution to tolerate a variety of 
substrates. 
We have developed a novel chemoenzymatic strategy to GDP-azidodeoxymannoses 
which differ from the natural substrates of mannosyltransferases of the Leloir type 
due to the presence of an azide group instead of hydroxyl functionality on the 
mannopyranose ring. We first chemically synthesized 2-, 3-, 4-, and 6-azidodeoxy-a-
D-mannose-1-phosphates, and then tested them as substrates for a recombinant 
GDP-Mannose Pyrophosphorylase from Salmonella enterica produced as 
polyhistidine-tagged fusion protein in E.coli. This enzymatic step yielded all the 
corresponding GDP-azidodeoxymannoses in 41%, 52%, 55%, and 63% yields 
respectively, which were characterised by high resolution MS, 'H- ' 3C and 31 P NMR. 
Furthermore, we have optimised a high throughput colourimetric screen (via 
malachite green dye) which allows for indirect monitoring of this enzymatic reaction, 
and could be applied in future studies of enzymatic directed evolution to improve the 
efficiency of unnatural products formation. 
The GDP-azidodeoxymannoses so formed were tested as substrates for the soluble 
fragment of an a-i ,2-Mannosyltransferase (Kre2p/Mntlp) from S.cerevisiae which we 
produced in E.coli. Our preliminary data demonstrated that GDP-4-
azidodeoxymannose was the most efficient donor substrate when transferred to a 
mannose a-methyl glycoside acceptor, as monitored by electrospray ionisation mass 
spectrometry, and we foresee that the other isomers may find similar applications on 
further enzymes. Consequently, GDP-azidodeoxymannoses may serve as valuable 
tools for glycobiological studies using bioorthogonal azide chemistry. 
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Chapter 1 
Introduction 
Glycosylation of proteins and lipids has been at the centre of attention of 
scientists from diverse fields of research, including chemistry, biology, and drug 
discovery. 141 In the past decade, the knowledge of carbohydrates science has 
developed at a fast pace. [51 
First, researchers explored the biological role of glycans, and discovered they 
were involved in an unexpected array of cell-cell communication events. 
Glycosylation is essential for the correct folding, delivery, solubility and 
hydrolysis of certain proteins. 16' Moreover, it is crucial for their biological 
recognition and their functions; thus, it influences biological processes ranging 
from infection and immune response, to cellular development and molecular 
uptake into cells. 171,181  In biomedical terms, this is a stimulating area for drug 
discovery in the fields of immunology and oncology. 191  
Later, the attention was focussed on the synthesis of such elaborate structures. 
The challenge is to achieve a fast and cheap large-scale production of not only 
complex glycoconjugates, but also monosaccharide derivatives: their synthesis in 
vitro can be challenging. Diverse approaches have been investigated: chemical 
and enzymatic methods, as well as solid-phase synthesis. [10-131 
As a result, we have witnessed an outbreak of publications and investments in 
this field. Glycosylation presents challenging complexity compared to the 
assembly of nucleotides and peptides: the number of monosaccharides and the 
possible ways of linking them together can lead to an immense diversity in the 
glycan structure. As a proof of the relevance and amplitude of carbohydrates 
research, the new term of glycomics has been designated ad hoc. 
1 
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1.1 Biosynthesis and role of glycoproteins in biology 
1.1.1 Structure and biosynthesis of glycoproteins 
The vast majority of natural proteins occur as g1ycoconjugates.' 4' The structure 
exhibits a covalent bond between carbohydrates and peptides, and depending on 
the nature of the aglycon acceptor, glycoproteins can be classified into: 
* N-glycosylated, when the saccharide is linked to the nitrogen of the side chain 
amide group of an asparagine (Asn) residue embedded in the consensus 
sequence Asn-XXX-Ser/Thr; 115 ' 161 
* O-glycosylated, when it is the hydroxyl group of a serine (Ser) or threonine 
(Thr), of a proline-rich region, to be involved in the linkage; U 5 l78l 
* C-glycosylated, when there is a C-C linkage between the carbohydrate moiety 
and the peptide; there are examples of tryptophan (Trp) indole bound to 
monosaccharides[15 19] and of amino terminal isoleucine (Tie) backbone bound 
to methyl-deoxy-fructose;" 51 
* P-glycosylated, when either a phosphonamide or a phosphodiester hinge is 
joined to various aminoacids or giycopeptides;'5' 201 
* S-glycosylated, when the carbohydrate is joined through a thioglycosidic 
linkage to the side chain of a cysteine (Cys),115' 21231  or through a thiazolidine 
linkage, typical of ADP-ribosylation determined by toxins. [21 221 
The most common glycoproteins belong to the first two groups, the biosynthesis 
of which will be the focus of this chapter. 
1.1.1.1 N-linked glycoproteins biosynthesis 
N-giycosylation is an essential co-translational modification of proteins of the 
secretory pathway, and it is highly conserved in eukaryotic systems (Scheme 
1. The oligosaccharide chain is assembled by addition of single 
monosaccharide units to dolichol, a polyisoprenoid lipid localised on the rough 
ER (RER) membrane (Scheme 1.1, left). Initially, two GlcNAc and five 
2 
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mannose residues are added one by one from nucleotide-activated donors to a 
dolichol phosphate at the cytosolic face of the RER. The lipid is subsequently 
flipped to the lummal face (Scheme 1.1, top), where it receives another four 
mannose and three glucose units from dolichol-phosphate linked glycosyl 
donors (Scheme 1.1, centre). 125 Next, the core saccharide is transferred in toto 
by the oligosaccharyltransferase enzyme complex to the Asn residue of a 
nascent growing polypeptide. 261 The three glucose units and one terminal 
2 
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Scheme 1.1: N-glycosylation pathway in the ER. 
mannose are then trimmed away (Scheme 1.1, bottom) by three different 
enzymes: ER a-1,2-glucosidase I, a-1,3-glucosidase II, and a-1,2-mannosidase. 
This deglycosylation process is a signal that the protein can be transported to 
the Golgi apparatus for further processing. Alternatively, a Golgi endo a-
mannosidase cleaves an internal glycosidic linkage to produce Man8GlcNAc2 
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Scheme 1.2: N-glycosylation pathway in the Golgi apparatus. 
from G1c 1 .3Man9GlcNAc2 J27' If the protein is improperly folded, another 
glucose is added and the chaperone calnexin recognises it, binds it, and impedes 
the export of the polypeptide until it reaches the correct fold. [28, 29] 
After the processing in the ER, the high-mannose type glycoprotein is transported 
in membranous vescicles to the Golgi apparatus. In this organelle, further 
glycosylation/deglycosylation events might occur, depending on the final 
destination of the glycoprotein (Scheme 1.2). Each cisterna of the Golgi stack, 
from the cis to the medial to the trans, contains sets of processing enzymes. 
Typically, in the cis apparatus, three units of mannose are cleaved away from 
secreted and membrane proteins by a-i ,2-mannosidases IA, TB and mannosidase 
II (that cleaves a-1,3- and a-1,6-mannose); [30]  interestingly, these enzymes present 
a broad cell-type dependent distribution, and can be found also in the medial and 
trans Golgi. 31 ' The phosphotransferase (G1cNAcT I) adds a phospho-N-G1cNAc 
unit to the position 6 of a mannose, 32' and then a phosphodiesterase removes it 
to form mannose-6-phosphate, which is the signal to direct proteins to 
lysosomesJ331  In the medial cistemae, other two mannose units are removed by 
ru 
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mannosidase II, and two G1cNAc and one fucose residues are added by 
G1cNAcT II and fucosyltransferase respectively. I'l Finally, in the medial and 
trans Golgi, other glycosyltransferases add GlcNAc, galactose, and/or sialic acid 
residues to form complex oligosaccharidesJ 35' As a result, the highly 
heterogeneous products can be classified into four major groups, presenting: 
high-mannose, complex, hybrid or poly-N-acetyllactosamine N-linked oligosaccharides 
(Scheme 1.3); all of them feature the same common core pentasaccharide 
(indicated in blue). 361 The number and identity of monosaccharide units that 
constitute the carbohydrate moiety determines a wide array of glycans, 
characteristic of each species. 137 ' 381 
1.1.1.2 0-linked glycoproteins 
Human 0-linked glycoproteins can be classified into seven major groups 
depending on the nature of the monosaccharide linked to the hydroxyl group of 
a serine, threonine, or hydroxylysine (hLys) of a polypeptide [171  
Mucin-type O-glycosylation constitutes the major group and features GaINAc as 
the first monosaccharide linked to the protein backbone. Mucins have highly 
heterogeneous glycans and are expressed either as transmembrane proteins at the 
cell surface or as secreted oligomeric molecules to form a protective gel. They 
can be found in the gastrointestinal and respiratory tracts, where they play a 
cytoprotective role against the gastric juice, deleterious exogenous agents 
(pathogens, drugs), and mechanical damage. [391 
Another recurrent sugar is G1cNAc, which reversibly decorates many 
nucleocytoplasmic glycoproteins, including transcription factors, kinases, 
cytoskeletal and nuclear pore proteins. Its postulated roles range from nutrient 
sensing to the regulation of proteasomal degradation and gene silencing; 
moreover, aberrant 0-G1cNAc modification has been linked to several 
pathological states, including cancer, diabetes and Alzheimer's disease, and 
genetic knock-out was lethal in mice. [40] 
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Scheme 1.3: Types of N-linked oligosaccharides. The common core is indicated in blue. 
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O-galactosylation is found on hydroxylysine residues of collagens, and the extent 
of this modification influences the three dimensional structure of the protein, 
which is important to exert its biological function in tissue regeneration. [411 
O-fucosylation and O-glucosylation represent a less common pattern, which 
initially was thought to occur exclusively within epidermal growth factor (EGF) 
domains, where it modulates biological activity.' 421 Recently, new O-fucosylated 
patterns have been identified within thrombospondin type-i repeats (TSR) 
structural motifs, suggesting a functional role in cell-adhesion. 431 
O-mannosylation is best known as a yeast-type modification and only recently 
has been found among mammals, where it occurs especially in the brain, 
nerves, and skeletal muscles. Particular interest has been directed on a-
dystroglycan, a component of the dystrophin-glycoprotein complex (DGC) in 
the skeletal muscle, where aberrant glycosylation is related to neuromuscular 
diseases.' 451 
Finally, 3-O-xylosides appear abundantly both on the cell surface and in 
the extracellular matrix. The saccharidic portion is mainly constituted 
by glycosaminoglycan (GAG) chains, which contain amino sugars and 
uronic acids. These highly diverse proteoglycans interact with proteins and 
signalling molecules, and therefore exert important modulating biological 
functions. [46, 471 
From the biosynthetic point of view, O-glycosylation is a reversible post-
translational modification that occurs mainly in the Golgi compartments. 
Except for O-fucose and 0-glucose transfers, consensus sites have not yet been 
found, but epigenetic regulatory mechanisms, which can be mediated by enzyme 
competition, have been suggested. 17' As an example, 0-Ga1NAc transfer tends 
to occur in proline-rich regions, influencing protein conformation by promoting 
3 structures (turns and sheets) versus a helices. (48] 
VA 
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1.1.2 Glycans function in glycoproteins in health and disease states 
As mentioned above, the saccharidic portion of glycoproteins is engaged in a 
large panel of cellular and tissutal functions. 
At the cellular level, it regulates all the steps from maturation, to intracellular 
sorting, to clearance of glycoproteins. N-linked glycans influence protein folding 
by steric effects, and prevent unfolded glycoproteins from leaving the ER by 
lectin binding to chaperones. 1211  Then, the structural diversity acquired in the 
Golgi regulates intracellular trafficking, predominantly (but not only) along the 
secretory pathway. 135' For instance, lysosomal delivery of acid hydrolases is 
determined by the presence of mannose-6-phosphate on N-glycans. 149' Finally, 
glycoproteins turnover by the liver is regulated through binding of insufficiently 
glycosylated structures to a specific receptor. 150]  More importantly, physiological 
effects will follow the clearance of bioactive molecules. As an example, 
ovulation and embryo implantation are modulated by glycoprotein hormones, 
which are cleared through binding to the Man/Ga1NAc-4-SO 4 receptor on 
macrophages and endothelial cells. 1511 
At the tissutal level, glycans are involved in cell adhesion and cell-cell 
communication, especially by binding to surface receptors. The related 
processes are numerous, first of all self/non self recognition, thus activation of 
the immune system. 1521 Secondly, receptor binding has emerged as a mechanism 
of establishing growth factor gradients and thus specify cell differentiation during 
embryogenesis. 153' Thirdly, glycosylation of proteoglycans and collagens has an 
important structural function. [141  Moreover, the interactions between collagens 
and highly glycosylated integrins are involved in cell adhesion processes and 
therefore also in the proliferation of malignant cells. 1 Furthermore, it is known 
that mice defective of the mannose receptor developed high levels of 
glycoproteins involved in inflammation and wound healing. [561 
As might be expected, disruption of the biosynthesis of the oligosaccharides can 
lead to various disease states, and the links between altered glycans and 
pathologies are increasing. When the alteration impacts the early stages of the 
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pathway, the resulting syndrome can be devastating for the whole organism, and 
is generally better characterised. On the other hand, defects at later stages can 
lead to complex phenotypes which are difficult to recognise and correlate to the 
molecular origin of the disease: biomedical connections to glycobiology 
constitute an emerging field. [121  The better characterised group of pathologies 
comprehends all the phenotypes determined by alteration of the N-linked 
glycoproteins biosynthetic machinery: the Congenital Disorders of Glycosylation 
(CDG, formerly known as Carbohydrate Deficient Glycoprotein Syndromes, 
CDGS), which can have lethal consequences.' 5 ' In recent years, a second group 
of illnesses, related to defective O-mannosylation of a-dystroglycan, has 
emerged: the congenital muscular dystrophies (CMD), which mainly affect 
muscles and brain tissues. 158' Defects in the catabolic steps are generally related to 
glycosidase deficiencies, and they form the molecular basis for Lysosomal 
Storage Disorders (LSD).' 59 ' 60' Moreover, the absence of mannosidase ii in mice 
induced a syndrome diagnostic of systemic lupus erythematosus.' 61' Recently, a 
number of other less common diseases has been found to be related to lack of 
functional glycosyltransferases: spondylocostal dystosis, 162' an infantile form of 
epilepsy, [631  a hereditary type of cartilaginous tumor, [641  and a phenotype of 
nocturnal hemoglobinuria.' 65' It is therefore not surprising the increasing interest 
towards the development of a screening method to monitor protein glycosylation 
pathways. 1661 
1.2 Glycosyltransferases (GTs) 
The discovery of diverse biological roles for glycoproteins is fuelling interest in 
the development of chemical tools to understand and modulate their formation 
and function. [61111  In particular, enzymes that can be used for glycosylation are 
an attractive target for research studies, since they offer competitive advantages 
compared to oligosaccharides chemical synthesis, as we will see in Chapter 4. 
It is well known that many glycosyltransferases (GT5) tolerate different sugar 
donors and acceptors: the investigation of the conditions and limits for their 
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activity offers a high potential for biomedical applications. [10-751  New GTs with 
different substrate acceptance continue to be identified and can be used to obtain 
an increasing variety of oligosaccharides. 780' Typically, highly stringent 
demands of most GTs regard the nucleotide portion of the donor, while various 
non-natural sugar analogues can be tolerated.81' 82]  On the one hand, these 
enzymes can be used for the synthesis in vitro of glycosylated drugs; on the other, 
monitoring their activity is a useful tool for the diagnosis of pathological states 
associated with aberrant glycosylation. [83-86] 
1.2.1 Reaction mechanism of GTs 
Specific members of this superfamily sequentially transfer the monosaccharide 
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Scheme 1.4: Reaction mechanism of an inverting GT. 87881 
are usually named after the carbohydrate moiety they transfer, are classified into 
subfamilies according to the linkage they catalyse. There are two possible 
pathways for the transfer of the saccharide residue determining the configuration 
at the anomeric centre: the transfer can either take place with inversion (by 
inverting GTs) or with retention (by retaining GTs) of the configuration. While 
the mechanism for the former pathway has been elucidated (Schemel.4), 
debates on the latter are still on-going. 
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The two most widely accepted hypotheses rationalise the retention of 
configuration invoking either a double displacement dependent on acidic/basic 
residues on the enzyme (Scheme 1.5) or through a direct attack of the aglycon 
with concomitant release of the NDP in a SNj mechanism, which involves an 
"internal return" intermediate (Scheme 1.6).(87 88) 
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Scheme 1.6: Proposed SNj mechanism of a retaining GT. 187,881 
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1.2.2 Mannosyltransferases (ManTs) 
1.2.2.1 Biochemistry of mannosyl transfer 
Mannose is present in a wide variety of glycoforms, attached through: 
* 0-linkages, to other sugars or to inositol (a or P glycosidic bonds) or 
to the hydroxyl groups of Ser or Thr residues of peptides (a 
linkage), 
* C-linkages, to Trp residues of protein chains (a linkage), 1191 
* P-linkages, through monophosphate units, to other carbohydrates or 
polyisoprenoids (the dolichol lipid, through 13 linkage in humans).' 891 
ManTs transfer mannose units only from two different natural donor substrates: 
either GDP-mannose, or dolichol-phosphate-mannose. Experiments to test the 
substrate tolerance generally show that ManTs are more stringent as regards the 
nature of the glycosyl donor,t 90 ' 911 but can accept a number of acceptors. 192 ' 931 For 
instance, dolichol-phosphate-mannose synthase can accept as substrates shorter 
chain polyprenols, and even phenyl phosphate, although its kinetics will vary 
accordingly: higher turnovers correspond to longer unsaturated chains. [94,95]  Also 
ManTs involved in the attachment of Man 5 to GlcNAc (in the dolichol pathway 
of N-linked glycoproteins) do not require a long chain dolichol as showed in in 
vitro experiments. 196 ' 971 
1.2.2.2 Human ManTs 
ManTs can be classified on the basis of the pathway they are involved in (N-
glycosylation, 0-glycosylation, or GPI anchoring) and of the nature of the 
glycosidic linkage they form (a-1,2, a-1,3, a-1,4, a-1,6, 13-1,2 or 13-1,4). This 
diversity is reflected in the common core of N-linked glycoproteins (Figure 1.7), 
which is built by different enzymes, named after the bond they form. Since 
many conserved eukaryotic ManT genes were originally identified in 
Saccharomyces cerevisiae (aig genes), it is not surprising that yeast nomenclature is 
mainly used. Human ManTs with identified activity are: 
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* -1 ,4-ManT or Algip: transfers mannose from GDP-man to dolichol- 
PP-GIcNAc 2 at the cytoplasmic face of the ER membrane. 98 
* a-1,34u-1,6-ManT or Alg2p: adds one a-1,3- and one a-1,64mked 
mannose to the trisaccharide-PP-dolichol, at the cytosolic face of the 
ER membrane.' 
* a-1,2-ManT or Aiglip: uses GDP-mannose to add the next two 
mannose units to form the heptasaccharide-PP-dolichol, which is then 
flipped to the other side of the 
* dol-P-Man synthase or Dpmlp: transfers mannose from GDP to 
dolichol-P which will serve as a donor in the dolichol, GPI anchoring, 
0- and C-glycosylation pathways. The enzyme is a n-inverting 
transferase highly conserved among eukaryotes. In humans it forms a 
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Scheme 1.7: Detailed core structure of Winked glycoproteins showing the diverse 
mannose-linkages and the associated ManTs. 1991 
13 
Chapter 1: Introduction 
* a-1,3-ManT or Alg3p: is the first ManT to add a mannose from the 
dolichol-P donor to the heptasaccharide-PP-dolichol at the luminal 
face of the ER membrane in the N-glycosylation pathway." ° " 
* a-1,2-ManT or Alg9p: adds two mannose units to the growing 
oligosaccharide by using the dolichol-P-man as a donor. [1021  This 
protein has a high homology with GPI-MT-I (PIG-Mp), GPI-MT-ll 
(PIG-Vp), GPI-MT-ffl (PIG-Bp), and GPI-MT-IV (SMP3p) which 
sequentially add the four mannose units to the GPI anchor. [1031  They 
are all localised on the luminal face of the ER membrane. 
* a-1,6-ManT or AIgl2p: adds another mannose to the lipid-linked 
oligosaccharide, and has high homology with the Alg9p-like group. [1041 
* POMT1 and POMT2: they form a heterocomplex which 0- 
mannosylates a-dystroglycan in the ER, by using dolichol-P-man. 1051 
1.2.2.3 ManTs families 
ManTs are generally membrane proteins: they present one or more 
transmembrane helices and are therefore highly hydrophobic. The catalytic 
domain can face either the organelle lumen (ER dolichol-dependent ManTs and 
yeasts' Golgi GDP-dependent ManTs) or the cytosol (ER GDP-dependent 
ManTs). As far as the aminoacid sequence is concerned, ManTs are highly 
diverse, but generally present a signature: the "DXD" motif, crucial for activity, 
and involved in manganese binding; rarely, it can feature a mutation of the first 
D for a glutamate or histidine. It is often part of the Rossmann fold, which 
contains the nucleotide-binding region that recognises the mannose donor. [1061 
Another less recurrent motif displays two glutamates in the sequence "E(X) 7E" of 
many a-ManTs: these nucleophiles are probably involved in the retaining GTs 
reaction mechanism. [1071  
The modern approach to protein homology studies structurally-related 
tridimensional functional domains. Based on this information, particularly on the 
14 
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structure of the catalytic site, human ManTs can be grouped into families (Table 
1. 1), according to the Carbohydrate Active enzymes (CAZy) database. [1081 
GT GT Human ManT Pathway Mechanism 
Superfamily Family name  
A 2 Dpml N-glycosylation Inverting 
B 33 AlgIp N-glycosylation Inverting 
B 4 Alg2p N-glycosylation Retaining 
Algi Ip N-glycosylation  
C 58 Alg3p N-glycosylation Inverting 
C 22 A1g9 N-glycosylation Inverting 
AIg 12 N-glycosylation 
GPI-MT-111 (PIG-Bp) GPI-anchor 
GPI-MT-IV (SMP3p) GPI-anchor  
n.d. 50 GPI-MT-1 	(PIG-Mp) GPI-anchor Inverting 
n.d. 76 GPI-MT-II (PIG-Vp) GPI-anchor Inverting 
C 39 POMTI 0-glycosylation Inverting 
POMT2 0-glycosylation I  
Table 1.1: Human Manls grouped into superfamily and family functional domains. 
n.d. not determined. 11081 
1.2.2.4 ManTs relevance in the biomedical field 
We have seen how ManTs represent a large class of enzymes which is still 
poorly characterised, mainly due to the intrinsic handling difficulties associated 
with the presence of the hydrophobic transmembrane domains. Indeed, only 
one eukaryotic ManT crystal structure has been deposited to date, 1091 and there 
are still many unanswered questions regarding these enzymes and their 
regulation. For instance, human ManTs responsible for C-mannosylation have 
yet to be identified, 11101 and the online databases present entries for ManT 
sequences with still unknown function. 
ManTs are attracting more and more interest from the scientific community, 
especially because recent findings highlighted their involvement in diverse 
human pathological conditions. We have seen that defective human ManTs are 
associated with disease states, [58, 111-1181 and it is known that the interaction 
between mannose and its receptor on macrophages and endothelial cells is a 
fundamental mechanism involved in abnormal immunological response, from 
15 
Chapter 1: Introduction 
the failed clearance of pathogens to autoimmune reaction. 11191 This receptor is 
involved in tumour proliferation [491  and it is also targeted for the successful 
uptake of vaccines 11201  and even drugs for gene therapy. 112 ' 1 Therefore, it is not 
surprising that recent studies emphasised the potential of ManTs as novel drug 
targets as they are crucial for the virulence of pathogens responsible for 
malaria, 11223  tuberculosis, [1211  leishmaniasis ,h1241  salmonellosis,t 12 and infections by 
Candida,' 261 and Cryptococcus. 11271 Finally, new ways to modulate ManT 
activity are most sought after to solve the hypermannosylation issue related to 
the production of therapeutic recombinant glycoproteins in yeast: there is an 
intense scientific effort towards the generation of yeast mutants defective of 
glycosylation and towards GTs engineering by directed evolution methods.1128' 129] 
In this context, a high throughput screen (HTS) to identify ManT inhibitors, 
substrates, or to be applied to the enzyme directed evolution, would be highly 
valuable. At present, there are a number of studies that show how this issue may 
be tackled, yet there is not a convenient assay that can be universally applied to 
ManTs in vitro and in vivo. In the next section, the recent findings in the field of 
available screens for GTs will be analysed in detail. 
1.3 Screening for glycosyltransferase activity 
GTs catalyse the transfer of a glycosyl group from a high energy donor (a 
nucleotide or a lipid-phosphate) to an acceptor molecule (a peptide, lipid or 
oligosaccharide). The enzyme kinetics can be studied by monitoring the 
depletion of either the donor or the acceptor, or the formation of either the 
glycoconjugate or the deglycosylated donor. Various assays have been used to 
date to study GTs kinetics, including the use of radiochemical, immunological, 
spectrophotometric, chromatographic, fluorometric methods, and, recently, also 
mass spectroscopy. 21 The ideal assay should be continuous, and generate data in 
real-time. However, discontinuous protocols are mainly adopted. Analyses can 
be made either on different aliquots at repeated time intervals, or simply after the 
16 
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reaction has been stopped. The latter case is preferable, as it is suitable for a 
HTS format in multi-well plates. [1301 
1.3.1 Radioactive assay 
Radiochemical assays are widely used as they are quantitative and highly 
sensitive. Usually the radioactive source is a labelled nucleotide sugar donor, as 
they are commercially available. Product separation can be performed by an 
array of techniques: ion-exchange columns, ' 314331 HPLC/TLC/affmity/size 
exclusion chromatography,197' 134-1431  solvent extraction, [144, 145] membrane 
filtration, [14&1481  electrophoresis. Quantification is accomplished by scintillation 
counting, autoradiography," 481 antibody recognition (by using lectins) or 
immunoradiographic techniques. [135, 149, 1501 These methods are rapid, but not 
drawback-free: background values can be very high due to decomposition of the 
sugar donors, and there are also health/safety hazards related to the use and 
disposal of radioactive species. 
1.3.2 Immunological assay 
Immunological techniques have the advantage of identifying the product by 
using highly specific antibodies (e.g. ELISA or Enzyme-Linked ImmunoSorbent 
Assay). Products are separated by chromatography, and quantified by 
immunostaining."49' 151-153]  This technique has also been adapted to automated 
format for HTS: the acceptor is immobilised on the surface of a microtiter 
plate, so that after removal of the reaction mixture and addition of primary and 
secondary antibodies, the product can be detected directly on the wells. [134, 154-1601 
The extent of immunological binding clearly depends upon the extent of product 
glycosylation, but highly sensitive chemiluminescencet 1611661 or [1671  
detection are also possible. Unfortunately, these assays are not ideal to study 
enzymatic kinetics, since only a limited amount of acceptor can be immobilised 
on the plate, and thus only low concentrations can be achieved. Moreover, 
antibodies/acceptor-conjugates are not often commercially accessible. 
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1.3.3 ELLA (Enzyme-Linked Lectin Assa 
A recent variation of the ELISA is the ELLA (Enzyme-Linked Lectin Assay) 
developed by Bertozzi et al. [ 168. 1691  Lectins are proteins that selectively bind 
specific carbohydrates and can be used for the detection of the glycosylated 
product. They can be conjugated to enzymes such as HRP (horse radish 
peroxidase) which, in the presence of the substrate (H 202), forms free oxygen. 
Concomitant addition of a dye gives a coloured /luminescent product that allows 
for detection. This assay has been developed for automated HTS: the GT 
substrate is conjugated to biotin and immobilised onto a neutravidin-coated 
multiwell plate. The GT reaction is carried out in solution, and after washing 
away the reagents, only the biotin-conjugated substrate is bound to the plate. 
Subsequent addition of an HRP-conjugated lectin (that recognises only the 
glycosylated product) allows for detection and measurement of the enzymatic 
reaction in a multi-well plate reader. 1"91 Advantages and drawbacks of this 
technique are very similar to those of the immunological assay. 
1.3.4 Spectrohotometric assay 
Mammalian glycosyltransferases that use a nucleotide donor ("Leloir type") give 
NDP as a byproduct. This can be phosphorylated to the respective NTP by a 
pyruvate kinase (PK), which uses phosphoenolpyruvate as a phosphate source 
Decrease in the Abs 0 
glycosyltransferase  
byproduct 
NADH lactate NAD 
clehydrogenase  
kinase 
phosphoenolpyruvate 	pyruvate 	 lactate 
Scheme 1.8: A spectrophotometric assay can be developed by coupling 
glycosyltransferase activity with other enzymatic reactions, resulting in a decrease in 
absorbance at 340 nm. 
(Scheme 1.8, left). The pyruvate thus generated can then be reduced by a lactate 
dehydrogenase (LDH), which uses NADH as a hydride donor (Scheme 1.8, 
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right). Finally, the oxidation of NADH determines a decrease in absorbance at 
340 rim, which is proportional to the amount of active GT. Overall, it is possible 
to study the enzyme kinetics by coupling GT reactions with PK and LDH, via 
spectrophotometric measurements. 1 ` For sialyltransferases, which produce 
CMP, an additional step is required: CMP is converted to CDP by a nucleoside 
monophosphate kinase (NMPK), which offers the advantage of increasing the 
assay sensitivity two-fold. [WI This method is suitable for automated HTS via 
microtiter plates and also allows continual monitoring of the enzymatic reaction. 
However, since small absorbance changes cannot be determined accurately (due 
to the small NADH extinction coefficient), kinetics of substrates with Km < 5 
tM cannot be studied. In addition, the assay applicability is limited also by the 
presence of NADH oxidases in crude extracts and by the relatively large 
amounts of enzymes required. Finally, the glycosylated product is not directly 
identified.' °1 Recently, another example of high throughput assay on whole 
cells has been reported for the identification of glycosyltransferases activity, but it 
requires similarly complicated coupled reactions. (1711  
1.3.5 Chromatographic assa 
A wide array of chromatographic techniques [1721  can be used to purify 
glycosylated products. These include: TLC, ion exchange, [1731  size exclusion, 
lectin affinity methods as well as electrophoresis. The most advantageous are 
HPLCI 171.  "I and capillary electrophoresis ' [ 176, 1771 which can be applied to HTS by 
using automated injectors. These techniques can also be coupled to laser-induced 
fluorescence detection, which is: quantitative, accurate, and more sensitive than 
radioactive assays. [17' 1 Both fluorescently labelled donors and acceptors have 
become available in the market. They are usually conjugated with fluorescein 
derivatives to allow detection in the low attomolar range (10"). [179-181]  In 
conclusion, chromatographic techniques can be very useful, but they do not 
constitute a complete screening assay and require coupling to other methods; 
moreover, they can be applied only to simple in vitro systems. 
II, 
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1.3.6 Fluorescent assay 
Continual assay methods based on fluorogemc substrates have been developed in 
recent years. ' 82 ' 85' For instance, 8-arylated analogues of GDP-mannose can be 
readily obtained via Suzuki-Miyaura coupling; variation of the aromatic 
substituent introduced on the purine can be exploited to modulate the fluorescent 
properties of the enzyme substrate. 1186 Alternatively, glycosyl donors can be 
covalently attached to a naphtylmethyl group (Scheme 9, in violet on the top left) 
with the aid of a linker; in this case, the fluorophore emission peak overlaps with 
the absorbance of a dansyl group, that can be attached to the aglycon acceptor 
(Scheme 9, in grey, bottom left). A GT catalyses the coupling reaction between 




























Scheme 1.9: Fluorescent assay on a sialyltransferase. Only the dansyl group in the 
product molecule (blue) is close enough to the naphtylmethyl moiety (violet) to allow 
for fluorescence resonance energy transfer (FRET), resulting in emission at 525 nm. 
(FRET), the emission peak of the naphtylmethyl moiety decreases, while the 
fluorescence of the dansyl group increases (Scheme 1.9, on the right). This 
experiment shows that if the fluorescent conjugates are processed by the enzymes 
(despite their steric and electronic difference compared to the natural substrate) 
they allow for continuous monitoring of the enzymatic activity, with no need for 
products purification from the reaction mixture J'87] Another recent elegant 
example of real-time assay is given by the use of an organometallic chemosensor 
which selectively coordinates to the NDP byproduct, resulting in intense 
KII 
Chapter 1: Introduction 
fluorescence. 1881 This kind of HTS assays have also been applied to whole cells, 
in combination with FACS technique and mutagenesis, for the directed 
evolution of GTs. 11891 
1.3.7 Spectroscopic assay 
Mass spectroscopy has been widely adopted in both proteomics and glycomics, 
due to its effectiveness in terms of rapidity and product identification. For 
instance, ESI-MS has been used for multiple reactions monitoring with 
unlabelled substrates. [190-1931  Another example is given by the elegant application 
of MALDI to a rhodamine-saccharide conjugate substrate, which enhanced the 
sensitivity of the assay 100-fold. 11941 Obvious drawbacks of this technique are 
associated with the instrumental costs, limited chemical compatibility (e.g. to 
buffers and salts required by enzymatic reactions), and the limited structural 
information they provide. The latter issue can be addressed by coupling MS 
with other analytical techniques, to help product structure determination. For 
instance, glycoforms separated by capillary electrophoresis can be individually 
subjected to enzymatic hydrolysis by glycosidases, to confirm the presence of the 
neo-formed saccharidic linkage. [1951  Another option is given by affinity 
chromatography with immobilised GTs: Ks can be measured by detection of 
the eluted product, inhibitor, and substrate. ' 96 ' 
1.3.8 Carbohydrate microarravs 
The emerging technique of microarrays has been just recently applied to 
carbohydrates for the HTS of GTs activity. Acceptors bound to resin-coated 
glass beads can be assayed, and the products detected for instance by using 
specific lectins that bind the transferred sugar." Microarrays are already 
widely adopted in genomics and transcriptomics, but for the same reason that 
makes them very informative, they are associated with prohibitive costs and very 
long analytical times (to process the vast amounts of data produced). 
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1.3.9 Chemoselective labelling 
This is an elegant approach to avoid the issues associated with the previous 
methods. It is based on the use of unnatural substrate analogues with minimal 
steric and electronic perturbation (compared to fluorophores), which display a 
functional group that is absent in natural systems, and therefore can be detected 
via a bioorthogonal or chemoselective reaction with a reporter molecule (e.g. 
fluorophore or antigenic peptide, Scheme 1.10). Recent examples involve the 
use of azide chemistry and subsequent detection via the Staudinger ligation to 
phosphines,' 981 or modified Huisgen cycloaddition to alkynes (copper catalysed 
or strain promoted)i 199 I The technique has been applied also to in vivo 
experiments [2001  and to a number of different GTs, but not at present to ManTs. 













Scheme 1.10: Chemoselective labelling of glycoproteins based on the use of 
unnatural azidosugars. These probes can diffuse into mammalian cells, undergo a 
number of metabolic modifications, and are finally incorporated into surface 
glycoproteins. The azide group (red) is detected by selective ligation with a reporter 
molecule (blue). 
1.4 Chemo selective labelling of azides 
Azide chemistry has been recently widely applied to the biological sciences, [2011  
because of the many advantages it offers. Firstly, azide chemistry is well-known 
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and characterised, especially in the field of carbohydrate chemistry as a route to 
the naturally occurring N-acetyl groups. Secondly, azides are easily introduced 
by nucleophilic substitution, they are stable when not activated, they offer a wide 
variety of potential modifications, and they are easily characterised by cheap 
spectroscopic analysis (e.g. the unique IR absorption peak at 2100 crrf 1).[2021 
Their use for the chemoselective labelling of glycoproteins is generally applied in 
combination with the selective reaction with either phosphines or alkynes, as we 
will now see in more detail. 
1.4.1 The Staudinger ligation 
1.4.1.1 Origin of the Staudinger ligation: the Staudinger reaction 
In 1919 Staudinger and Meyer reported the formation of iminophosphoranes 
from azides and triaryl phosphines.' 2031 The reaction runs smoothly under mild 
conditions and is almost quantitative. At first, the phosphorous is believed to 
attack the azide to give a phosphazide; then, an intramolecular rearrangement 
(via a four-membered-ring transition state) yields to an aza-ylide, with loss of 
nitrogen (Scheme 1.11). The iminophosphorane so obtained offers a wide 
variety of uses in organic synthesis: not only can the highly nucleophilic nitrogen 
potentially react with a range of electrophiles, but also it is an amine precursor 
0 9 
R3P + NN—N—R' 
R3P0 + H2N—R 	
HO 
0 	 9 
- RP—N=N—N—R' 
[ 
R0 e I .P N2 	[R —N—R' 	 I I R' \ R 	 R 
Scheme 1.11: Mechanism of the Staudinger reaction. 
when the reaction is carried out in aqueous media. Interestingly, the overall rate 
is determined by the inductive effect of the substituents on the phosphorous and 
on the azide, but little steric influence has been observed. 204 ' 2051 
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1.4.1.2 Mechanism of the Staudinger ligation 
In 2000, Saxon and Bertozzi 2061 designed a variant of the original reaction 
(Scheme 1.12). When an electrophiic trap (i.e. an ester function) is introduced 
on the phosphine, the aza-ylide intermediate is captured by intramolecular 
cyclisation. 20 This process would ultimately produce a stable amide bond. In 
addition, if the phosphine is equipped with a functionality that acts as a probe, 
this will be covalently linked to the molecule initially bearing the azide. 
o h2 b -R 	0 	Ph2 
PPh2 
PROBE PROBEjç PROBE 1-R 










- MeOH PROBE 
'1fJ\NR 
Probe is covalently linked to product 	
Q 	 eOMe°  
Scheme 1.12: Mechanism of the Staudinger ligation. 
1.4.1.3 Applications of the Staudinger ligation 
Amongst the chemoselective labelling reactions, the Staudinger ligation offers 
the advantage that the chemistry involved is compatible with living organisms in 
terms of minimal toxicity and side reactions: azides are stable enough to react 
with the probe even in the complex cellular environment, and also over a range 
of pH (58.5).1201I  The ligation is so reliable that it has been applied to the 
modification of cellular surfaces via metabolic engineering (Scheme 1.10). After 
incubation of mammalian cells with a modified sugar precursor (ManNAz, N-
azidoethylacetate mannosamine), this was metabolised to azido-sialic acid, 
which was then expressed on the cells surface. The subsequent addition of the 
phosphine-probe led to covalent tagging via the Staudinger ligation. The probe 
used is a short peptide sequence (FLAG, Scheme 1.13) which is selectively 
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Scheme 1.13: FLAG peptide phosphine probe. 
recognised by a specific antibody ((x-FLAG) conjugated with peroxidase (HRP). 
The subsequent addition of the peroxidase substrate, together with a dye/ 
chemoluminescent precursor (which is oxidised by the oxygen so formed), leads 
to a coloured precipitate/light emission that serves for detection. This protocol 
is equally effective in vivo: mice treated with ManNAz, and then injected with 
the FLAG-phosphine, exhibited strong labelling on the cells surface, especially 
in tissues involved in first-pass metabolism. 20 In a similar experiment, GaINAz 
was inserted into O-glycoproteins, then labelled and detected via the same 
procedure. 2081 Furthermore, this approach has also been adapted for HTS: a 
biotinylated protein acceptor is adsorbed on a neutravidin-coated multi-wells 
plate, and its glycosylation with an azidosugar is easily monitored via the same 
protocol. 169 
Finally, Tirrell and Bertozzi described a similar procedure for protein labelling 
and detection from unpurified crude cells lysate. An aminoacid analogue 
bearing the azide functionality is effectively transferred by E.coli endogenous 
enzymes into a growing protein. Addition of the phosphine-probe to the cell 
lysate, followed by specific antibody recognition processes, led to specific 
labelling of the azido-protein. ' 2° 
1.4.2 Huisgen azide-alkvne 1.3-dipolar cycloaddition 
In 1963 Huisgen firstly described 1,3-dipolar cycloadditions as a useful group of 
exoergonic fusion reactions to yield 5-membered heterocycles. [210, 2111 In 
tR 
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particular, the one between azides and acetylenes required inconvenient long 
reaction times and high temperatures, leading to a mixture of 1,4- and 1,5-
regioisomer products. 12121 Only recently, these issues have been tackled and 
successfully overcome by an accurate revision of the original protocol: as a 
result, azide chemistry has been widely applied not only in organic synthesis, but 
also for biological applications. 
1.4.2.1 Cu(I) catalysed azide-alkyne 1,3-dipolar cycloaddition 
In 2002 the groups of Meldal and Sharpless independently reported that catalytic 
amounts of copper (I) accelerated the reaction and improved its regioselectivity, 
yielding almost exclusively 1,4-substituted triazoles (Scheme 1.14). [213, 2141 
Nevertheless, the reaction is not flawless: the Cu(I) is thermodynamically 
unstable and is easily oxidised to Cu(II) or can disproportionate to Cu(II) and 
Cu(0), compromising the scope of the reaction conditions. For this reason, 






t 	 [CuL]® 
R'_____ 
	
R' - H 
0 1 
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Scheme 1.14: Proposed mechanism for the Cu(l) catalysed 1,3-dipolar 
cycloaddition between a terminal alkyne and an azide. 12141 
(e.g. ascorbic acid), or ligands (typically tris-(benzyltiazolylmethyl)amine or 
TBTA) that can preserve the Cu(I) species. 12111  Since the conditions have been 
optimised for biological applications, this reaction has been widely used, also in 
the field of carbohydrates. [2161  The popularity it achieved due to its simplicity led 
to the widespread use of the term "click chemistry". This terminology was 
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introduced by Sharpless himself, although originally to indicate a general group 
of efficient reactions with broad scope, and that are particularly convenient, fast, 
and reliable also in complex environments. [21 
1.4.2.2 Strain promoted azide-alkyne 1,3-dipolar cycloaddition: in vivo use 
Despite being an efficient and convenient reaction protocol, the one described 
above has yet one drawback that precludes its application in living organisms: 
the mandatory use of the toxic copper. For this reason, Bertozzi and co-workers 
looked at alternative means of activating the acetylene, and reported that the 
introduction of ring strain yielded efficient (2+3) cycloaddition in a catalyst-free 
environment: the reaction is driven by the strain relief obtained from the 
transformation of the alkyne in a cyclooctyne derivative. Moreover, the reaction 
was validated with the successful labelling of living cells with no apparent 
harmful effect. 218  Indeed, they showed the effective metabolic incorporation of 
an azido-sugar derivative into a recombinant glycoprotein (G1yCAM-1/Ig 
kimera) expressed on mammalian cells surface; subsequent addition of the 
strained alkyne, conjugated to biotin, allowed for the ligation with the azido-
glycoprotein (AzG1yCAM-1/Ig kimera); finally, detection was accomplished 
with the a-biotin-HRP system (Scheme 1.15)J219 












cell 	 cell cell 
Scheme 1.15: Strain promoted (2+3) azide-alkyne cycloaddition of recombinant 
AzGIyCAM-1/Ig kimera (in blue) expressed on CHO cells surface. Detection is 
accomplished with a-biotin-HRP system (in pink). 
27 
Chapter 1: Introduction 
1.5 Synthesis of GTs substrates 
Whether the scope is to use GTs synthetically or to develop a screening assay to 
test for their activity, a key requirement is access to their substrates. 
Unfortunately, these molecules and their synthetic derivatives are often not 
commercially available, and therefore have to be prepared. For the purposes of 
this project, we will focus on the different strategies that can be adopted to obtain 
sugar-nucleotide donors, and close synthetic analogues. In particular, we will 
analyse the key final steps required to obtain the sensitive diphosphate bridge 
between the monosaccharide and the nucleoside unit. 
1.5.1 Chemical synthesis 
Direct coupling of a glycosyl donor to a nucleoside-diphosphate (NDP) has been 
reported, but this approach is quite uncommon due to intrinsic synthetic 
difficulties. [220, 2211 Instead, the general strategy consists of preparing the 
monosaccharide-a-l-phosphate first, and then coupling it with an activated 
nucleoside-monophosphate (NMP) species. The anomeric phosphate derivative 
can be prepared in a number of ways. One of the oldest and cheapest methods is 
the MacDonald reaction with phosphoric acid, which requires harsh 
conditions. 12221  Better yields are achieved by substitution of an anomeric leaving 
group with other P(Y) species, usually diphenyl/dibenzyl chlorophosphate; 
sometimes the monosaccharide is used as a free anomeric hydroxyl group, with 
the aid of a coupling reagent (e.g. DMAP).' 223' A popular strategy is based on the 
use of P(III) chemistry and subsequent oxidation. This methodology usually 
relies on the phosphoramidite approach, originally designed by Beaucage for 
nucleotide synthesis, and soon applied to other (2241  
The critical step is the coupling with NMP, which is usually achieved via 
morpholidate/N-methylimidazolide intermediate. [225, 2261 By introducing 1-H-
tetrazole as activating agent, Wong optimised the reaction to 76% yield (Scheme 
1.16). [1271 Despite this promising report, the protocol requires strict dry conditions 
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Scheme 1.16: Synthesis of GDP-Man optimised by Wong. [2271 
and elaborate purification procedures besides a several-days-long reaction time: 
not surprisingly, alternative synthetic routes are still sought after. 228 ' 2291 
1.5.2 Enzymatic synthesis 
The enzymatic route to GDP-Man (Scheme 1.17) involves different enzymes: 
hexokinase, to transform D-mannose into Man-6-P, 
phosphoglucomutase orphosphomannomutase, to form Man- i-P from Man-6-P, 
GDP-mannosepyrophosphoiylase (GDPManPP), to finally obtain GDP-Man, 
inorganic pyrophosphorylase (iPPase), which hydrolyses the inorganic 
pyrophosphate (PPi), to shift the equilibrium of GDP-man formation 
towards the product, and to avoid GDPManP inhibition by PPi, otherwise 
abundantly present. [92] 
pyruvate 	PEP C® 
yruvat0P-0H 
uv kinase 0 OH 	






or 	 OH 




11 0—P— - 
01-1 
GDPJ1I GTP 
H2/PPi ase • 2 P 
Scheme 1.17: Enzymatic synthesis of GDP-Man. 230 PEP= phosphoenolpyruvate. 
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The first and last two steps run smoothly, but the second is more problematic. 
On the one hand, phosphoglucomutase is commercially available, but the turnover 
for Man-6-P is very low compared to its natural substrate Glc-6-P. On the other, 
phosphomannomutase (not accessible on the market), required laborious 
purification from natural sources or overexpression from cloned genes. (2301 
1.5.3 Chemoenzymatic synthesis 
A chemoenzymatic approach for the synthesis of GDP-Man seemed to us the 
best option. Man-a-i-P is easily achievable by chemical synthesis, [2271  and then 
GDP-ManPP can catalyse its coupling to GDP. [2101  Whitesides et al. adopted this 
strategy and reported a remarkable 53% yield for the final enzymatic step, for 
which they used brewer's yeast extract as protein source. 12311 ' 12321 
A successful chemoenzymatic route to deoxy-analogues of GDP-Man has also 
been reported using a recombinant GDP-ManPP enzyme from S.enterica cloned 
in E.coli: if this enzyme has a broad substrate tolerance, it will prove a valuable 
means of accessing semi-synthetic molecules in a convenient final coupling in 
water. [2331 
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1.6 Conclusions and aims of the project 
We have seen that mannosyltransferases are poorly characterised and offer many 
potential applications in the medicinal field. High throughput screens to study 
these enzymes are highly valuable, and current techniques present various 
drawbacks. These issues can be overcome by using the novel approach of 
che,noselective labelling, which proved successful to study other 
glycosyltransferases in vitro and in vivo. 
With these facts in mind, we reasoned that the application of chemoselective 
labelling to study mannosyltransferase activity would be very valuable as in the 
future it could be applied to evolve enzyme isoforms with acquired novel 
activitiy. For instance, mannosyltransferases able to glycosylate a glycoprotein, 
which is not the natural substrate, could be very useful for the production and 
remodelling of therapeutic glycoproteins. 
In order to develop this technology, firstly mannosyltransferases donor substrates 
bearing the unnatural azide group will have to be synthesised. Next, they could 
be applied to test for enzymatic activity. 
Of the possible substrates for mannosyltransferases, we decided to focus on 
GDP-mannose, for which we aim to prepare the azidodeoxy analogues, where 
an azide group substitutes one hydroxyl functionality. In particular, we decided 
to attempt a chemoenzymatic synthesis of these compounds, first by chemically 
preparing the azidodeoxymannose-o-1-phosphates (Chapter 2), then by 
subjecting these compounds to the enzymatic activity of a recombinant GDP-
Mannose Pyrophosphorylase (Chapter 3). Next, if we obtain at least one of 
these GDP-azidomannoses we will optimise a high throughput colourimetric 
screen (Chapter 3) which we can apply for future directed evolution studies on 
the GDP-mannose pyrophosphorylase, to improve the synthesis of these 
unnatural compounds. Finally, we aim to express one mannosyltransferase onto 
which we can test our unnatural substrates, for the future development of a 
detection system based on azide chemistry (Chapter 4). 
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Chapter 2 
Chemical synthesis 
of D-azidomannose-cx- 1-phosphates 
2.1 Carbohydrate chemistry: challenges and strategies 
This chapter will discuss the carbohydrate chemistry which has been carried out 
during this project. In order to understand the rationale behind our synthetic 
strategy we shall first discuss the recent developments in the field. In particular, 
we will see how standard chemical procedures involve mandatory 
protection/deprotection steps, which set practical limits to the automation and 
efficiency of carbohydrate chemistry. A useful alternative (as we shall see in the 
next chapter) is provided by emerging bioengineering techniques, which allow 
for the use of carbohydrate processing enzymes. In this case, appropriate 
substrates will have to be prepared, and in the case of Leloir 
mannosyltransferases," this inevitably involves phosphorus chemistry, a field 
which was originally developed for the automation of oligonucleotide synthesis. 
2.1.1 Classic carbohydrate chemistry: the protection/deprotection strategy 
Carbohydrates are polyhydroxyl compounds with functional groups that display 
similar polarity and nucleophilicity. Therefore, an efficient protection/ 
deprotection strategy is crucial to satisfy the stereo- and regio-selectivity required 
by the synthetic target. Protective groups possess specific requirements: ability to 
be introduced only on the desired positions on the saccharide ring, stability 
towards subsequent reactions conditions, and finally, ability to be efficiently 
removed when desired. Furthermore, protecting groups can alter also the 
molecule reactivity, and can influence its stereochemical outcome. [2, 31 In this 
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regard, Fraser-Reid introduced the concept of "armed" (alkyl protected and 
electronically rich) or "disarmed" (acyl protected and electronically poor) 
compounds, which could be employed to achieve selective reactivity in 
glycosylations. 141 Later, Boons and Ley developed dispiroketals (dispoke) as 
"semi-disarmed" protection groups, to further enrich the pool of functionalities 
that could be used in one-pot sequential reactions. 151 Boons worked also on 
orthogonal protection groups to simplify the protection/deprotection 
manipulations. The concept was further developed by Wang, who elegantly 
applied it to selectively protect each position of glucose in a one-pot, one-catalyst 
reaction (Scheme 2.1). EI 
Fraser-Reid was also the first who noted that besides the stereocontrol by 
neighbouring group participation over anomeric reactions, there was also 
regiocontrol, in the case of carbohydrates with two unprotected hydroxyl 
groups. 1 ' 3 This concept has been further explored by a French group who studied 
how the protection on the primary alcohol of glucose affects the reactivity of the 
Ph 










TMSO 0 / \ 	
D TBAF 




OH  j 
Scheme 2.1: Orthogonal protection groups allow for a one-pot, one-catalyst reaction 
to give access to each hydroxyl group on glucose. 
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secondary alcohols, and thus can potentially be exploited to tune regiocontrol 
without complete protection of the monosaccharide.' 91 
Although these efforts towards a one-pot protocol proved successful in some 
instances, there is not yet a synthetic solution that can be universally applied to 
all carbohydrates. For this reason, it is still general practice to follow the more 
traditional and well-studied protection/deprotection sequences in order to gain 
access to each hydroxyl group of the monosaccharide under study, as we will see 
in the case of mannose. 
2.1.2 Phosphorus chemistry: from nucleotides to carbohydrates 
As mentioned at the beginning of this chapter, and as we will see in a few pages 
for our compounds, the inevitable step towards nucleotide-activated 
monosaccharides is through phosphorus chemistry. As illustrated in the 
introduction, various approaches can be used to install the phosphate 
functionality at the anomeric centre, and most of them originate from the field of 
oligonucleotide synthesis. 
In 1992 Beaucage produced a detailed review on oligonucleotides synthetic 
procedures, which are currently still applied. 10' Before him, various 
methodologies were being developed, each presenting a number of issues that 
prevented the automation of the process. Todd's "H-phosphonate" approach 
involved the use of O-benzylphosphorus-O, O-diphenylphosphoric anhydride to 
install a protected phosphonate on deoxyribose. Subsequent activation by N-
chiorosuccinimide to a phosphorochioridate and addition of the second 
nucleoside, followed by deprotection, yielded the desired product (Scheme 2.2)." 
ci 	
HO  ffA, 
 ACO,,a PhO'OOBn AcO _ff 	_0 




then NCS 	 2,6iutidine 
 0_~ 	HO 
-V—Off 
O=P1—OBn 	 O'—OBn 	 O=—OH 
CI 0_0 
	
OAc 	 OH 
Scheme 2.2: Dinucleotide synthesis by the H-phosphonate approach introduced by 
Todd etal. (T = thymine).1111 
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°x° 	X 	X 
Scheme 2.3: The H-phosphonate can be activated, reacted, and oxidised without 
the use of protection groups (T = thymine, A = adenine). 12' 
Later, it was found that the phosphonate could be more simply activated by 
diphenyl-phosphorochioridate, reacted with another nucleoside, and oxidised by 
N-chlorosuccinimide to the diester (Scheme 2.3).112]  However, the synthesis of 
oligonucleotides became widely applied only with the chemical procedure 
introduced by Khorana. His "phosphodiester" approach was based on the use of 
two orthogonal protection groups (trityl and acetyl, acid- and base-labile 
respectively) and coupling of a nucleoside with a nucleotide in the presence of a 











Scheme 2.4: Khorana's phosphodiester approach to oligonucleotide synthesis (T = 
thymine)i 13 
deprotected and reacted with another nucleotide to elongate the DNA chain. 
Unfortunately, the ionic nature of these compounds rendered the purification 
particularly tedious, involving several passages through ion-exchange resin. 1101 In 
order to overcome this issue, Letsinger developed the "phosphotriester" 
approach, which was based on the use of the convenient cyanoethyl protection 
group (Scheme 2.5)."1 A few years later, he reported also the "phosphite 
triester" methodology (Scheme 2.6), whose efficiency revolutionised the 
synthesis of oligonucleotides, but was still unsuitable for automation due to the 
reactive nature of chlorophosphites. 1151 
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Scheme 2.5: Phosphotriester approach for oligonucleotide synthesis (T = thymine). 114 
Scheme 2.6: Phosphite triester approach for oligonucleotide synthesis (1= thymine).' 15' 
The automation of the synthesis of oligonucleotides was made possible thanks to 
Beaucage's introduction of phosphoramidites: they were stable enough to be 
stored for prolonged times, and could be promptly activated by 1-H-tetrazole for 
efficient couplings (Scheme 2.7).h161 
HO 	T 	 RO RO 
RO 	 RO 	 l_oJ1 
MeOPCINMe2 	Iç3J 	OR' 	 12/ H2O 	9 
1-tetroIe 	I 	 OP—OMe OH 	
i-Pr2NEt 




OR' 	 OR' 
Scheme 2.7: Phosphoramidite approach for oligonucleotide synthesis (1 = 
thymine). 15 
The only significant advance to Beaucage's protocol was the subsequent 
introduction of the NN-diisopropyl group instead of the NN-dimethylamino 
functionality on the phosphoramidite; this feature was particularly important for 
the automation of the process, as it noticeably improved the properties of these 
compounds (solubility, stability, coupling efficiency)." 7' Phosphoramidite 
chemistry is indeed very convenient to use, as we will see for the synthesis of our 
GDP-azidodeoxymannoses. 
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2.2 Synthesis of D-azidodeoxymannose-a- 1-phosphates 
There are four different geometric isomers of D-azidomannose-cL-1-phosphates, 
depending on the position of the azide group on the mannose ring (Scheme 2.8). 
We decided to attempt to prepare all of them by adopting the same synthetic 
strategy. Firstly, the azide could be introduced on the various positions on 
mannose by nucleophilic substitution of sodium azide on suitably protected 
triflate/tosylate precursors. Secondly, selective deprotection at the anomeric 
centre would be essential to install an a-phosphate group, the stereochemistry 
of which would be determined by the anomeric effect. Phosphorylation could 
be achieved by a number of different methods. The most common is based on 
the formation of benzyl-phosphate esters which are subsequently deprotected 
via palladium / hydrogen chemistry. Since the latter is not compatible with the 
azide functionality (which would be reduced to an amine), we decided instead 
to opt for the phosphoramidite method which has already been successfully 
applied to other azidosugar- 1 . 1 181 
We will now see how the azide was introduced on each different position on 
mannose, and how the anomeric phosphorylation was accomplished in the 
same manner for all of the isomers. As the stereochemistry at the anomeric 
centre is of particular relevance for our future enzymatic studies, a brief 
introductory note will now explain why mannose (compared to glucose or other 
































Scheme 2.8: The four isomers of azidomannose-a-1 -phosphates. 
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2.2.1 Mannose anomeric stereoselectivity: why the a-configuration is preferred 
It is well-known that the anomeric effect strongly influences the stereochemistry 
at the anomeric centre, where the a-configuration is generally preferred for 
electronegative substituents (X) at C-i. Interestingly, explanation of this 
phenomenon has been a controversial subject for many years. Initially, it was 
proposed that the destabilising orientation of dipole moments (or lone pair-lone 
pair repulsion) in the -anomer makes it disfavoured (Scheme 2.9, left). This 
explanation agrees with the fact that such interactions are reduced in solvents 
with high dielectric constants, where indeed the highest proportion of 0 versus a 
isomer is generally found. Nevertheless, this fails to explain the observed 
patterns of different bond lengths and angles, which are characteristic of 
conformers. The accepted explanation is that the lone pair of electrons of the 
oxygen on the pyranose ring is periplanar to the C(1)-X bond, and thus it is 
partially donated to the C(1)-X anti-bonding orbital (Scheme 2.9, centre). The 
net effect of electronic delocalisation strongly stabilises the anomer where X is in 
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Scheme 2.9: Anomeric effect favours the a-conformer for electronegative 
substituents (X) at C-1. 1'91  
Later, this effect has been named more precisely "endoanomeric effect" as 
opposed to the "exoanomeric effect", the latter being exerted by lone pairs 
present on the substituents at C-i (Scheme 2.9, right). The "exoanomeric effect" 
is present in both a and (3 conformers, and therefore it does not determine per se 
the preferred anomeric configuration. For this reason, the general term 
"anomeric effect" refers to the "endoanomeric effect".1191 
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What is less-known is the E2 effect, which is the influence on the anomeric 
equilibrium exerted by substituents at the 2-position. As a result, the anomeric 
effect is generally increased when the substituent at C-2 is axial (as in the 
mannose configuration). Also in this case, the phenomenon can be explained in 
terms of unfavourable dipole-dipole interactions in the case of 3-anomers of 
electronegative substituents at C-i, or in terms of partial overlap of the anti-
bonding orbitals of the C(2)-0(2) bond and the C(1)-X(1) bond (Scheme 2.10). 
The new, lowered in energy, C(1)-X(l) o orbital is thus more accessible to the 
lone pair of electrons of the pyranose oxygen, hence the endoanomeric effect is 
increased. The net result is an overall stabilisation of the a-anomer, which is the 
predominant form. 1191 
OH OH 
H O a 














Scheme 2.10: A2 effect favours mannose a-conformer. 191 
Of course there also other factors playing a role in the anomeric equilibrium, 
such as the temperature and the nature of the solvent just to name a few, but 
generally for mannose derivatives with electronegative substituents at C-i, the o:- 
form is the only one recovered, as we will see in the synthetic procedures 
described over the next few pages. 
2.2.2 Introduction of the azide at different positions on mannose 
2.2.2.1 Introduction of azide at C-6 
The preparation of the first azidosugar bearing a phosphate on the anomeric 
centre was based on the protocol described by Bertozzi. 1181 Initially, p-toluene- 
sulfonyl chloride selectively reacted with the primary alcohol function of a- 
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methyl-D-mannopyranoside to yield 1 (Scheme 2.11). Next, 1 was treated with 
sodium azide in DMF, in order to substitute the tosyl group at C-6 leading to the 
formation of the azide 2. The hydroxyl groups were then protected as acetate 
esters by a mixture of acetic anhydride and acetic acid in the presence of sulfuric 
acid as catalyst. In the same reaction, an acetate group substituted the methyl 
glycoside at the anomeric position: the fully acetylated 6-azido-6-deoxy-a-D-
mannopyranose 3 was obtained in 72 % yield over the two steps. At this point, 
the presence of the acetate electron withdrawing groups increased the separation 
amongst 'H NMR signals and allowed for specific protons identification. 
Selective deprotection on the anomeric centre was accomplished by treatment 
with benzylamine under an argon atmosphere at 50 °C for 24 h. The 
deprotected hemiacetal 4 was then ready for anomeric phosphorylation. 
OH 	 OTs 
OH 	TsCI,DMF 	 OH 









100 2C HO— 1 
2 We 
/2o AcOH, H2SO4 0 C - r.t. 
/ 	72%over2steps 
N3 	 N3 
OAc 	BnNH2, THF 	' OAc 
AcO—kQ 50 C AcO..—I-q 
AcO.....PL 	
81 % 	AcO-.\...'L. 
OH 	 OAc 
Scheme 2.11: Four steps are required to prepare 2,3,4-tri-O-acetyl-a-D-manno-
pyranoside 4, ready for anomeric phosphorylation. 
2.2.2.2 Introduction of azide at C-2 
An example for the selective introduction of the azide on the 2-position of 
mannose was given by Popelova et aL 201 (Scheme 2.12) who adopted the same 
protocol previously described by Knapp et al. ,1211  although without achieving the 
same high yields. Once the azido functionality was selectively installed, the 
synthesis involved the same steps described above: first, full acetylation of the 
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Ph-O 	 Tf20, pyr Ph-0 	 NaN3, DMF Phç-Q----\ % 
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/7-1 % over 2 steps 
OAc 	 OAc 
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	 ACL 
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OH 	 OAc 
Scheme 2.12: Synthesis of the tetra- O-acetylated-2-azidoman nose. '20' 211 
molecule, then selective deprotection of the anomeric centre to allow for 
subsequent prosphorylation. 
We decided to adopt this synthetic protocol and therefore used the methyl-4,6-0-
benzylidene-cs-D-glucopyranoside as starting material (Scheme 2.12). The first 
step consisted of introducing a trifluoromethanesulfonyl group on the 2-hydroxyl 
of the glucoside. Interestingly, even though there were two free secondary 
alcohols (at C-2 and C-3 on mannose) that could potentially react, the 2-0-
monotrifluoromethanesulfonate 5 was selectively obtained in 69 % yield, and the 
only byproduct that could be recovered was the 2,3-di-0-
trifluoromethanesulfonyl-cz-D-glucopyranoside.' 21 ' 
It has been suggested that the discriminating reactivity was related to the cis 
configuration of the vicinal oxygen at the anomeric centre, which allowed for 
hydrogen bonding to the proton of the reacting hydroxyl group. [221 
Consequently, the alcohol functionality at C-2 turned out to be more electron-
rich than the one at C-3. Moreover, the intramolecular removal of the 2-
hydroxyl proton (by the cis, vicinal glycosidic oxygen) facilitated the 
sulfonylation. In addition, this trend in relative reactivity was well correlated 
with other pyranose and also furanose structures, displaying analogous cis 
configurations. Explanations based on steric hindrance, or on the electronic 
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This selectivity had a high synthetic value, since it saved two steps: protection 
and deprotection of the 3-hydroxyl group. Interestingly, it also appeared to be 
the most critical step for this synthetic route to the peracetylated 2-azido-2-
deoxy-a-D-mannopyranoside 7: the high yield reported by Knapp was not later 
reproduced by Popelova et al. ' 12' 1 but after optimisation of the reaction 
conditions, we accomplished intermediate results compared with the two groups. 
Compound 5 was next treated with sodium azide in DMF at 100 °C: the azide 
functionality was successfully introduced at the C-2 in mannoside configuration 
(quantitative yield). Next, 6 underwent acetolysis: complete acetylation in a 
one-pot reaction with acetic anhydride and sulfuric acid led to 1 ,3,4,6-tetra-0- 
acetyl-2-azido-2-deoXy-OC-D-mannose  7 as the sole isomer recovered. When we 
treated 7 with benzylamine with the same protocol adopted for 1 ,2,3,4-tetra-0- 
acetyl-6-azido-6-deoXy-(X-D-mannose,  unfortunately we did not obtain selective 
deprotection as expected: spectroscopic analysis revealed the presence of various 
byproducts. This difference in reactivity, compared to the 6-azidomannose, 
could be rationalised considering that this isomer had the azide (instead of the 
acetyloxy) group at C-2, and azides are incapable of performing neighbouring 
group participation. 1131  As a result, the predominant electron-withdrawing effect 
of the azide (which can be considered a "pseudohalide")' 241 in 2-azidomannose 
made the anomeric centre more susceptible to nucleophilic attack by 
benzylamine. Therefore, milder reaction conditions were used for anomeric 
deprotection to give 8: use of secondary dimethyl amine (instead of the primary 
benzylamine) and cooling at 0 °C (instead of heating). 1211  After anomeric 
deprotection, compound 8 was then phosphorylated to lead to the 2-
azidomannose-a- 1-phosphate. 
2.2.2.3 Introduction of azide at C-3 
Compared to the previous two isomers, the synthetic route to 3-azido-3-
deoxymannose was less straightforward. Retrosynthetic nucleophiic 
substitution would involve inversion of configuration at C-3, leading to the 
monosaccharide altrose, which is not easily accessible. Furthermore, the 
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orientation of the other hydroxyl groups on mannose does not allow for 
immediate selective protection following standard procedures. It is therefore not 
surprising that there are very few reports on this compound. 2&281  The synthetic 
challenge posed by this small molecule has been highlighted by Klaffke et al., 
who reported two variants of an elaborate route to access this key precursor of 
aminosugars (Scheme 2.13). [261 
1. NaOMe/MeOH 
o 2. H2SO4,  dioxane 	0 	 0 	 0 




2. Ac20, pyr J3. Ac O, pyr NaOMe/MeOH 	
1.0.1 N NaOH 
0 ft 
OTs Ts 	 OAc OTs
J;00 
FOH aN3 , DM   1. 
Ac20, pyr 
O 	 o 	1.Tf20,pyr 	 0 
1,43 	A 	
2. NaOAc, DMF 
lcalase  3. AcO, pyr 
AC 
Ac OH OAc 
Scheme 2.13: Two variants for the synthesis of the tetra-O-acetylated-3-azido-
mannose. [26] 
A simpler route to 3-azido-3-deoxymannose has been proposed by Wong. [2' 1 The 
compound was obtained after inversion of the configuration at C-2 of a suitably 
protected derivative of 3-azido-3-deoxy-glucose, which in turn was prepared 
from the commercially available diacetone glucose, with overall double inversion 
of configuration (and insertion of the azide) at C-3 (Scheme 2.14). [21,2'1 Despite 
the apparent complexity, this route offered many advantages compared to 
Kiafike's protocol. First of all, multiple steps could be performed in one pot. 
Secondly, the purification was often simple and did not involve column 
chromatography. Thirdly, the spectroscopic analysis of the products was quite 
straightforward, and they could be easily distinguished from the reagents (in 
contrast with the notoriously complex identification of anhydrosugar isomers, as 
highlighted by Kiaffice himself). 261 
OAc 
OAc 
Ac20, HCI04 ACOI 
OAc 
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OBZ 1. V20, pyr 	PhO 	 1. HCI, MeOH 
0 	
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85% 
OMe Me OH OH 
Scheme 2.14: Wong's route to 3-azidodeoxymannose.128' 29) 
With these facts in mind, we decided to employ a slightly modified Wong's route 
(Scheme 2.16). The initial oxidation/reduction of diacetone glucose to 
diacetone allose 9 was accomplished by using the cheap and readily available 
pyridinium chlorochromate (PCC) as oxidant (instead of the ruthenium 
tetraoxide generated in situ), followed by the use of sodium borohydride as 
stereoselective reductant (as in Wong's procedure)?" 
OH 	1. PCC, molec. sieves, 







commerically 9 10 
available 
2N HCI 
1. TfO, pyr, DCM AcCI, MeOH 
OA 	2. CsAc, toluene 










13 12 11 
Ac20, AcON, 
o 	C - r.t. 
OAc 	 Oft 
OAc 	BnNH2 ,THF 	I OAc 
50 2C AcO Ac 	 Q  	NLA 
81% 
OAc 	 OH 
14 	 15 
Scheme 2.15: Our route to 3-azidodeoxymannose. 
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In particular, our initial concerns about the separation of possible isomeric 
byproducts from the oxidation/reduction step were soon cleared: indeed if the 
oxidation by PCC was driven to completion, no traces of the reagent could be 
detected, and the ketone was quantitatively reduced to the desired alcohol 9 with 
allose configuration, the only product recovered. 
At this stage, the remaining free hydroxyl group of 9 could undergo easy 
triflation, and subsequent conversion to the azide, in the same fashion as 
described above for the 2-azidodeoxymannose: the inversion of configuration at 
C-3 led again to the glucose configuration of 10, which then needed to be 
deprotected. Unfortunately, in our hands, the resin-catalysed full deprotection of 
diacetone 3-azidodeoxyglucose led to complete recovery of the unreacted 10, 
probably due to unsuccessful activation of the resin, which required extensive 
washings of appropriate saline solutions in order to be activated and charged 
with H ions. 
We therefore explored alternative protocols employing other acidic reagents. 
The use of refluxing sulfuric acid, either in dioxane or in THF, unfortunately 
produced a complex mixture of non-identified polar compounds. Instead, 
treatment with 2N hydrochloric acid at room temperature for one day finally 
yielded the desired unprotected monosaccharide 11 in a quantitative manner. 
Addition of catalytic amounts of acetyl chloride in methanol resulted in 
anomeric protection, as well as CSA-catalysed reaction with dimethoxy-
benzaldehyde acetal protected altogether the positions at C-4 and C-6 to yield 12. 
For the invertion of configuration at C-2, we employed caesium acetate as 
nucleophile. [31]  Next, the methyl 2-O-acetyl-3-azido-4,6-O-benzylidene-3-deoxy-
a-D-manno-pyranoside 13 was fully acetylated to 14 (74%), and then 
anomerically deprotected to 15 (86%), with the same protocol used previously 
for the 6-azidomannose isomer. The final 2,4,6-tri-O-acetyl-3-azido-3-deoxy-cx-
D-mannopyranose 15 was now ready for the anomeric phosphorylation. 
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2.2.2.4 Introduction of azide at C-4 
The synthesis of 4-azido-4-deoxymannose could be achieved from the cheap and 
readily available methyl-a-mannoside in eight steps (Scheme 2.16). The strategy 
was similar to the one adopted for the 3-azido substituted isomer: mannose was 
firstly protected by standard procedures to 16, leaving access to the position at C-
4; PCC oxidation, followed by stereoselective NaBH 4 reduction inverted the 
configuration at C-4 to 17; triflation and substitution with sodium azide gave 
access to the corresponding 4-azido-4-deoxymannose 18, still protected on the 
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Scheme 2.16: Synthetic route to 4-azidodeoxymannose 1321 and 2,3,6-tri-O-acetyl-4-
azido-4-deoxy-a-D-mannopyranose. 
When we tried to reproduce the published method, we were pleased by the 
simplicity of the reaction procedures which indeed, when carefully dry 
conditions were maintained, could be nicely followed by TLC to nearly 
quantitative yield in most cases. The only relatively low yielding step (for which 
Davis reported 64% yield), the nucleophiic substitution by sodium azide, was 
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improved to 90% yield over two steps. Initially, TLC monitoring of the reaction 
showed that the triflation was not proceeding to completion. We reasoned that 
probably this was due to the steric hindrance exerted by the protecting groups, all 
facing the same side of the ring as the hydroxyl function to react. When we 
increased the equivalents of triflic anhydride, we did not observe any 
improvement in the yield. However, a twofold increase of the amount of 
pyridine determined further product formation until no traces of the reagent 17 
could be detected by TLC. This fact correlated well with our hypothesis that the 
bulkiness of the protecting groups did not hinder the attack of the hydroxyl 
group onto the triflic anhydride, but it rather hindered the access to pyridine of 
the intermediate oxonium species. 
The desired 3-azidomannose 18 was next subjected to stepwise deprotection to 4-
azido-4-deoxy-a-D-mannopyranose (following Davis' procedure). As previously 
seen for the 6- and the 3-azidomannose, also in this case the 4-azido-4-deoxy-a-
D-mannopyranose was next fully acetylated and reacted with benzylamine to 
yield the 2,3 ,6-tri-O-acetyl-4-azido-4-deozy-a-D-mannopyranose 21, ready for 
anomeric phosphorylation. 
2.2.3 Anomeric phosphorviation of azidodeoxymannoses 
Having prepared all the desired isomers of azido-deoxymannose, we next 
explored the chemical synthesis of the corresponding (x-1 -phosphates. These key 
compounds will then be tested as substrates for GDP-mannose 
pyrophosphorylase activity. 
The MacDonald reaction is one of the oldest and cheapest protocols for the 
anomeric phosphorylation of suitably protected sugars, and as we have seen in 
the introduction, it involves treatment with dry phosphoric acid, and subsequent 
neutralisation with a strong base. Despite its apparent simplicity, the protocol 
involves extensive drying of the acid, employment of harsh conditions, and 
careful monitoring to avoid formation of byproducts and complete loss of the 
desired a-i-phosphates. For all these reasons, we decided to opt for alternative 
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procedures with the characteristics of being more reproducible, and involving the 
use of milder conditions. 
In particular, we were initially intrigued by phosphonate chemistry, which combines 
the advantages of phosphorus ifi chemistry (high yields, mild conditions, simple 
protocols) with the economic convenience of phosphorus V compounds (being 
phosphorus III reagents generally more expensive due to their sensitive nature to 
air and moisture). 1331 We reasoned that reaction with the cheap diphenyl 
phosphonate, followed by oxidation, would lead to the desired phosphate. 
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Scheme 2.17: Phosphoriate approach to azidomannose-a-1 -phosphates. 
Unfortunately, even before work-up, the diester a was systematically hydrolysed 
to the monoester b (Scheme 2.17), which then resisted all our oxidation attempts 
(12/H20, mCPBA, tBuOOH) to the corresponding phosphate c. From the 
literature, an alternative solution involves subsequent silylation of the 
phosphonate monoester b: this alters the phosphite/phosphonate tautomeric 
equilibrium by "locking" the phosphite in d, which then can be readily oxidised 
to the desired phosphate. [331 
Since we were primarily interested in the shortest route to the desired a-i-
phosphates, we decided not to pursue the phosphonate approach any further, 
and did not perform any experiment on the silylation step. Instead, we adopted 
standard phosphorus III chemistry and subsequent oxidation to phosphorus V. 
Initially, we employed NN- diisopropyl-di-teii-butyl-phosphoramidite in the 
presence of 1-H-tetrazole, followed by mCPBA-mediated oxidation in one-pot 
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(Scheme 2.18). The reaction proceeded smoothly, but the 'H NMR analysis of 
22 could not be carried out with the desired level of detail, due to the strong 
peaks of the nine methyl groups of the di-tert-butyl phosphate ester which 
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Scheme 2.18: Phosphoramidite approach to azidomannose -a- 1 -phosphates. 
N,N-diisopropyl-diallyl-phosphoramidite is a similar reagent which circumvents 
this issue. Furthermore, possibly due to the electron-withdrawing nature of the 
allyl groups (versus the tett-butyl) the reaction proceeded far more efficiently 
(72% versus 44%). This time we were also able to identify the nature of a 
contaminant which was consistently present, the diailylphosphonate (di-teiD-butyl 
phosphonate when using the previous reagent). This species could originate 
from undesired hydrolysis of the azidomannose-1-phosphite diallyl (or di-ter-
butyl) diester, which is the intermediate obtained prior the oxidation step 
(Scheme 2.19); nucleophilic attack by water at the anomeric carbon would result 
in displacement of the phosphite diester from the monosaccharide; the phosphite 
diester would then equilibrate towards the more stable phosphonate tautomer, 
that cannot be further oxidised by mCPBA. 
(iPr)2N-P(OR)2, 	 N 
 + 
IH-tetrazole H20 	 OH 
OH 	
0OR hydrolysis 
DCM  0 
OR 	 H O—P 
OR 	- W \OR 
Scheme 2.19: Proposed mechanism for the formation of the phosphonate byproduct. 
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Purification by column chromatography would yield to a single spot as seen by 
anisaldehyde dip and UV analysis, but 31P NIMR analysis of 23 (Scheme 2.20) 
indicated the presence of another phosphorus species. In the 'H NMR spectrum, 
the phosphonate species could be better identified by the characteristic P-H 
doublet which displays a 'JPH = 705 Hz, while the allyl signals would simply 
overlap with those corresponding to the desired product. 
A second chromatographic purification with a different solvent system allowed 
for the separation of the phosphonate byproduct, which now could be seen as a 
transient blue spot also after visualisation with anisaldehyde dip. 






- ii 	 .; 
Scheme 2.2o.. 31  P NMR analysis for the phosporylated product revealed presence 
of the phosphonate contaminant. 
The fully protected 6-azidomannose-a-l-phosphate 23 so obtained (72%) was 
next deprotected in a one-pot reaction. Indeed, also for the deprotection step, we 
found that the conditions required for 22 were not ideal, since the acidic 
hydrolysis of the tert-butyl groups proceeded with low yields, failed to remove 
the acetyl groups in the same step, and therefore led to 24 (Scheme 2.21), which 
we found particularly difficult to handle and purify. 
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Scheme 2.21: Different strategies for the phosphate protection and then 
deprotection on the tn- O-acetylated 6-azidomannose-a-1 -phosphate. 
In contrast, the allyl moiety was smoothly removed from 23 by tetrakis 
triphenyiphosphine palladium with p-toluensulfmic acid sodium salt as a 
nucleophile; next, addition of MeOH/water/TEA in a 5:2:1 ratio hydrolysed the 
acetyl protecting groups in the same pot. The crude was dissolved in water, 
washed with DCM, and lyophilised to give the fully unprotected 6-
azidomannose-a-1-phosphate triethylammonium salt 25 as a pale yellow 
powder. 
The same protocol was successfully applied to all the other azidomannose 
isomers. Interestingly, for the 2-azido isomer, traces of the 3-1-phosphate (5%) 
were also formed (possibly due to the absence of the participating hydroxyl 
group at C-2), as seen by 'H-NMR. This isomer was successfully separated 
during chromatography, prior to the deprotection step. 
Having prepared all the desired isomers of azidodeoxymannose-a-1-phosphate 
(protected compounds 26-28, and unprotected compounds 29-31, see 
Experimental Section) we were now keen to produce the recombinant GDP-
mannose pyrophosphorylase and test them as substrates, in order to develop a 
novel method for the production of GDP-azidodeoxymannoses. 
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Having prepared all the four isomers of D-azidodeoxymannose-a-1-phosphates, 
we were keen to use them as key precursors to the corresponding GDP-
azidodeoxymannoses, to be later tested for mannosyltransferase activity. In 
particular, as mentioned in the introduction, it was our aim to investigate a 
chemoenzymatic strategy, which involves the testing of azidomannose-cx-1-
phosphates as unnatural substrates for GDP-Mannose Pyrophosphorylase (GDP-
ManPP).[1] In the current chapter, we will discuss the successful introduction of 
this gene into an appropriate vector to express the recombinant enzyme in 
E.coli, and the tests performed to establish its enzymatic activity on our 
unnatural substrates both on analytical and semipreparative scale. 
3.1 Expression of recombinant GDP-ManPP in E.coli 
3.1.1 Preparation of the construct pET16b-GDP-ManPP 
E.coli was the expression host of choice for heterologous proteins: protein 
expression is fast and often allows for high levels of production. The choice of 
pET16b as recombinant vector was due to the simplicity of the pET system and 
to its effectiveness in producing inducible recombinant proteins in enabled host 
strains. In the pET system, the gene of interest is cloned behind the T7 RNA 
polymerase promoter. Compatible expression hosts are lysogens for the 
bacteriophage DE3, and contain the lacI gene and a copy of the T7 RNA 
polymerase, under the control of the lacUV5 promoter. This is inducible by 
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IPTG, a lactose analogue which cannot be metabolised. Therefore, after the 
addition of IPTG to the culture medium, the DE3 lysogenic hosts produce T7 
RNA polymerase, which then transcribes the gene in the pET vector that is 
under the control of the T7 RNA polymerase promoter. In addition, the pET16b 
vector encodes for Hisio-tagged fusion proteins: the N-terminus of the desired 
protein is linked to a sequence of 10 histidines. This allows for facile protein 
purification by immobilised metal affinity chromatography (IMAC). 
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Scheme 3.1: Map of the pET16b expression vector. [2)  
Elling et al. reported the overexpression of the GDP-ManPP protein in E.coli 
without a tag, since they used a different vector; the subsequent purification 
protocol was laborious, as it involved several steps.E 31 We therefore opted for a 
different strategy. The gene RJbM encoding GDP-ManPP was already inserted in 
the cloning vector pT7-6 from Prof. Elling. First, we PCR amplified the RJbM 
gene from S. typhimurium, using carefully designed primers, containing the 
consensus sites for the restriction enzymes Nde! and BamHI (Scheme 3.2). 
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FORWARD PRIMER 
Ndel 
5 GGT GGT CAT ATG TCT UT CU CCC 3' 
5' ATG TCT T1T OTT CCC ... AAT GM CGT AGT TM 	3 
3 TAC AGA AM GM GGG .. .TTA CU GCA TCA AU 5' 
3' UA CU GCA TCA AU CCTAGG TGG TGG 5' 
BamHI 
REVERSE PRIMER 
Scheme 3.2: Primers designed for PCR amplification of RfbM gene (dark red), 
containing the consensus sequences for Ndel (blue) and BamHI (green) enzymes. 
At this point we cut both the amplified gene and the new vector pET16b with 
the restriction enzymes Nde! and BamHi (Scheme 3.3, top). After gel extraction 
of the desired DNA fragments, their sticky ends so generated were successfully 
ligated to form the new construct RJbM-pET16b, which was used to transform 
the cloning host E. coil TOP10 (Scheme 3.3, bottom). Colonies were screened 
on agar-plates containing ampicillin: only E. co/i cells containing the exogenous 
DNA with the ampicillin-resistance gene would survive. To confirm the 
successful introduction of the plasmid construct into the cloning host, the 
recombinant DNA was first purified from cells (by using the Qulagen 
cloning vector 
	














Scheme 3.3: Preparation of the DNA construct to express H1s 10-GDP-ManPP in 
E.coli. The RfbM gene (GDP-ManPP) contained side sequences coding for NdeI 
and BamHI consensus sites (pink). 
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miniprep kit), cut with Ndei and BamHI, and observed on an electrophoresis-gel 
(Figure 3.1). Next, it was fully sequenced: this confirmed the presence of all the 
1440 bp of the RJbM gene just behind the Hisiotag sequence (see Appendix A). 
M 	1 2 3 4 5 
Kb 
	
pETI 6b vector (5.7 kb) 
RfbM gene (1.5 kb) 
Figure 3.1: Electrophoresis-gel of digested DNA from five different colonies of 
E.coIi. The DNA sample in lane 4 did not have the insert RfbM. M = markers. 
3.1.2 Expression of Hisip-GDP-ManPP 
E. coil BL21(DE3) competent cells, transformed with the RJbM-pET16b 
construct, were grown in LB medium at 37 °C until the A600 reached 0.6, and 
then induced under different conditions of time, temperature, and IPTG 
concentration, in order to investigate the best value for each variable. The 
experiment was conducted at 37, 30, 25 and 20 °C, for 3, 5, 7 and 20 h, and at 
IPTG concentrations of 0.1, 0.5, 1.0 and 1.5 mM. Optimal induction conditions 
were observed to be 30 °C for 5 hours (Figure 3.2): at higher temperatures or 
longer expression times, the protein could not be purified as a single band, 








6.5 - ____ 
Legend: 
Lane M: molecular weight markers. 
Lane 1: wash (50 mM imidazole). 
Lane 2-3: elute (500mM imidazole). 
Note: His 10tagged-GDPMP has a 
molecular weight of 57.5 kDa. 
Figure 3.2: Affinity purification (nickel column) of His-tagged GDP-ManPP, 
expressed at 30 °C for 5 h in E.coli. 
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possibly due to degradation byproducts which started to elute with GDP-ManPP 
during the affinity chromatography. Moreover, different E.coli (DE3) strains 
were tested as expression hosts: besides BL21, also B834 and ER2566 have been 
used, in combination with LB or TB as growing medium. The protease deficient 
ER2566 strain, grown in TB, allowed for the best yields, typically giving 1.1 mg 
of protein per litre of culture. 
Purification of GDP-ManPP was achieved by affinity chromatography from the 
soluble proteins fraction. First, cells were harvested by centrifugation, 
resuspended in binding buffer (see Experimental Section for recipe) with 10 mM 
PMSF, and lysed by sonication. Then, 0.1% Triton X-100 was added to 
complete the disruption of the cells membrane. After a brief incubation period 
(10 mm.) with the detergent, the sonication step was repeated and the cell debris 
was separated by centrifugation. Next, the supernatant (cell free extract, CFE) 
was loaded onto a nickel colunin. 1'l Proteins were eluted with increasing 
imidazole gradient (50 mM), until the eluent was protein-free. The Histidine-
tagged GDP-ManPP was last eluted with 500 mM imidazole buffer. Elution 
fractions were subjected to SDS-PAGE and stained with Coomassie Brilliant 
Blue (Figure 3.2), concentrated to a final volume of 1 ml per litre of culture (by 
using a 30 Wa MWCO Vivaspin column previously passivated with 5% Tween 
20), and dyalised against Tris buffer, pH 7.6 with 1 mM DTT, 8 MM MgCl 2 . 
GDP-ManPP identity was confirmed by SDS-PAGE (expected molecular weight 
of 57.5 kDa) and Western blot, by using the a-His-tag antibody (Figure 3.3). 











Lanes 1-5: SIDS-PAGE. 
Lanes 6-10: Western blot. 
Lanes 1, 6: MW markers. 
Lanes 2, 7: CFE. 
Lanes 3,4, 8,9: wash. 
Lanes 5, 10: concentrated 
fraction containing Hisio- 
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3.2 Enzymatic activity assay via malachite green 
3.2.1 Hisip-GDP-ManPP activity assay: detection via malachite green 
Hisio-GDP-ManPP activity was next assayed on a 96-wells plate, under 
conditions similar to those reported for other enzymes of this class (see 
Experimental Section).[ 5I As a detection method, instead of the normally used 
radioactive techniques,[ 6- I we opted for a spectrophotometric assay based on 
malachite green, a method suitable for high throughput screening and which has 
already been validated for GDP-ManPP.15' 121 
Malachite green is a triphenyl methanol -based dye with pH-dependent colour 
(Scheme 3.4). When dissolved in acidic solutions, the predominant form of the 
dye is the di-cation which displays a yellow colour. As the pH increases, the 
equilibrium is shifted towards the monocation, which shows a green colour with 
an absorbance maximum at 618 nm.[ 13] If molybdate and inorganic phosphate 
ion are present in solution, the dye binds electrostatically to the 




pH 	 I I 	 I I 
Scheme 3.4: Malachite green dye pH-dependent colour change. [131 
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molybdophosphate ion. The complex so formed shifts the maximum 
absorbance of the dye to 620-650 nm, resulting into a colour change to blue-
green. 
Amongst the triphenyl methane dyes, malachite green is the one with the highest 
reactivity towards molybdophosphate ion, and due to its high extinction 
coefficient (1.02 x 10 M 1 cm-1 at 618 nm) it is widely used for the 
spectrophoto metric determination of inorganic phosphate.[ 13] Typically, the 
malachite reagent consists of an acidic yellow solution of malachite and 
molybdate; when increasing amounts of phosphate ion are added, the resulting 
solutions develop an intense blue-green colour (Figure 3.4). 
Phosphate concentration 
5 mM 1 m 0.5mM 101iM 5pM 11M blank 
•44 
Figure 3.4: Malachite green and molybdate (malachite reagent) give a yellow 
solution (on the right), but if phosphate is added, the colour turns green-blue (from 
right to left increasing phosphate concentrations). 
This method is highly sensitive: it detects the phosphate ion at the order of 
magnitude of picomoles, and the linear correlation between light absorption 
and phosphate ion concentration allows for good accuracy of phosphate 
measurement (Chart 3.1).[141  Maximum linearity is obtained when absorbance 
is measured after 15 minutes: after longer times, precipitation might occur, thus 
altering the recorded absorbance values. However, different groups reported 
the use of this detection method under diverse conditions, and often the 
absorbance was read only after 5 or 10 minutes from the addition of the 
malachite reagent. [5, 12] 
The phosphate ion to be detected was generated as shown in Scheme 3.5: GDP- 
ManPP produced GDP-Man and inorganic pyrophosphate (PPi) from GTP and 
we 
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mannose; if inorganic pyrophosphatase (iPPase) is present, then PP1 is 
hydrolysed to Pi, detected via malachite green assay. 
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Chart 3.1: Phosphate calibration curve for the malachite green reagent. 
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Scheme 3.5: Detection of GDP-ManPP activity via malachite green assay. 
In order to obtain reliable values, it is clearly crucial to minimise contamination 
with phosphate ions other than those produced by the desired reaction. In 
particular, nucleotide hydrolysis (i.e. GTP) significantly affects phosphate levels, 
and therefore compromises the assay fidelity if the reaction is carried out under 
conditions of high levels of NTPs, or if the acidic reagent is allowed to develop 
for too long (more than 30 minutes). 
With the above facts in mind, we assessed the activity of our His-tagged GDP- 
ManPP with its natural substrate mannose-a-1-phosphate. Reactions were 
performed in 100 t1 volumes at 37 °C; after different time intervals, they were 
70 
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stopped by the addition of 100 tl of the acidic malachite reagent.[ 12I The 
experiment was carried out in triplicates, and compared with various controls: 
absence of GDP-ManPP (blank), GTP, mannose-1-phosphate, iPPase. We were 
pleased to see that, despite the presence of the tag, the enzyme was 
active and the colourimetric screen was a robust detection method; after only 5 
minutes of enzymatic reaction, 50% of mannose-1-phosphate had already been 
transformed into the desired product GDP-mannose (Scheme 3.6). 
Unfortunately, under the same conditions, we could not detect any activity when 
the tests were carried out on our unnatural 6-azidomannose-1-phosphate. 
However, it could be argued that if the unnatural product was formed with much 
lower efficiency, its detection under the conditions used could be negligible. The 
difference in absorbance between the positive control (reaction on the natural 









0.2 After 5 minutes, the enzymatic 
reaction 	is 	stopped 	by 	the 
acidic pH of malachite green 
reagent. The malachite reagent 
0.1 
is allowed to develop for 5 mm, 
______ then the Abs0 nm is read. 
Scheme 3.6: GDP-ManPP activity assay via malachite green on the natural 
substrate mannose-1 -phosphate. 
For example, if the unnatural GDP-azidomannose was formed in 20% yield 
compared to the natural GDP-mannose, the resulting absorbance value (which 
would be 0.08 units) would fall within the range of instrumental error and 
therefore could not be discriminated against a negative result. We reasoned 
Total Volume _________ 100 pL 
GDP-ManPP 0.1 pg 
iPPase 0.01 U 
GTP 100 PM 





MgCl2 8 mM 
Temperature 37 °C 
pH 7.6 
Time 5 mm 
Total Volume 100 pL 
Malachite Green 0.03% 
NH4 molybdate 0.20% 
Triton X 0.05% 




Time 5 mm 
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that, if any GDP-azidomannose was formed at all, it could be more likely 
detected by increasing the amount of enzyme used in the reaction. 
Delightfully, we did observe the development of green colour also for the reaction 
on our unnatural azidomannose when the test was carried out with more protein 
(10 tg). Although extremely encouraging, a direct quantitative comparison 
(between the natural and unnatural compounds) was not yet possible. Under the 
same conditions, the reaction with the natural substrate was leading to the 
formation of enough phosphate for the phosphomolybdate-malachite complex to 
precipitate, compromising the spectrophotometric analysis. 
A robust colourimetric assay would be valuable for us to screen for enzymatic 
activity on analytical scale. Ideally, it would allow for a direct quantitative 
comparison of the formation of each GDP-azidomannose against the natural 
product. We therefore decided that it was worth optimising the malachite reagent 
formulation, or the reaction conditions, in order to be able to compare and measure 
the activity of both natural and unnatural compounds at the same time. 
3.2.2 Optimisation of the malachite green reagent: formulation 
Our preliminary results highlighted the instability of the malachite-phospho-
molybdate complex, which tends to precipitate at high phosphate levels, leading to 
colour fading.[15] We reasoned that a revision of the choice and amount of detergent 
used might be an appropriate approach to improve the stability of the complex in 
aqueous solutions, hence we planned a new set of experiments (Table 3.1). 





1 Fl Triton X- 100 34 mg/1 OOml 50 lil 50 gl 
2 Fl Triton X-lOO 34 mg/iOOml 100 Al 100 jil 
3 F2 Glycerol 34 mg/1 OOml 50 jil 50 tl 
4 F2 Glycerol 34 mg/i OOml 100 d 100 uI 
5 F3 Tween 20 34 mg/i OOml 50 tl 50 pi 
6 F3 Tween 20 34 mg/1 OOml 100 Id 100 A l 
7 F4 Tween 20 20 mg/i OOml 50 jil 50 p1 
8 F4 Tween 20 20 mg/i OOmI 100 gl 100 tl 
Table 3.1: New set of experiments to optimise the malachite reagent. 
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We increased the amount of detergent to 1% v/v and analysed the effects of 
Triton X-100 (Formulation 1, Fl), glycerol (Formulation 2, 1 7 2), and Tween 20 
(Formulation 3, F3). Furthermore, since in most studies in the literature, use of 
Tween 20 as stabiliser is reported (indicating that this will likely be the more 
appropriate additive) we decided to further explore it under different 
formulation conditions relative to the malachite amount. More specifically, we 
added another series of experiments with 1% Tween 20, but with less malachite 
(20 mg/lOOml, instead of 34mg/100ml, Formulation 4, F4). The reason behind 
this last choice is that the preparation of the reagent involves a filtration step (to 
filter off the undissolved malachite green dye) that we were hoping to avoid by 
sensibly reducing the amount of dye used. 
We assayed these formulations with the same set of phosphate standards used 
before (see Chart 3.1), but we also looked at the effects of scaling down: two 
series of experiments were performed for each formulation, one employing 50 
p1 phosphate standards + 50 j.tL of malachite reagent, and one 100 tL 
phosphate standards + 100 tL of malachite reagent (Table 3.1). 
In particular, we looked at the appearance of the blank (colour, homogeneity, 
presence of bubbles, see Figure 3.5), and the accuracy and precision of the 
calibration curve we could obtain for each experiment (as seen in Chart 3.1). 
Precisely, the latter was obtained by plotting the absorbance values at 650 nm 
versus the phosphate amount at a specific time point (i.e. exactly 15 minutes 
after addition of the malachite mix). For our investigations, we looked more 
generally at how the absorbance values of all the standard solutions would change 
50 1j1 dH20 + 50 p1 malachite reagent 100 p1 dH20 + 100 p1 malachite reagent 
Fl 	F2 	F3 	F4 Fl 	F2 	F3 	F4 
44 
i5- 
Figure 3.5: Formulations 1-4 (F1-F4) appeared different already when added to the 
blank (deionised water). 
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over time (i.e. from the addition of the malachite reagent for 15 minutes, as shown 
in Schemes 3.7 and 3.8). Next, we looked at the precision and accuracy of the 
calibration curve that could be obtained at different time points (after 5, 10 or 15 
minutes, not shown), in order to establish which time point was the best one. 
An immediate indication that Triton X-100 (Fl) was not fit for purpose was 
given by the appearance of the blank (Figure 3.5), which showed an undesirable 
green colour. This affected the facility of monitoring the reaction by eye, as the 
colour change (from yellow to green) was compromised. An additional 
drawback was the reagent tendency to form bubbles (thus altering the 
absorbance values read by the spectrophotometer). 
Unexpectedly, the addition of Triton X-100 at 1% v/v also altered the 
correlation between the phosphate levels and the absorbance at 650 nm of the 
malachite green-phosphomolybdate complex: all the wells appeared intensely 
green at both volumes tested (Scheme 3.7, left), and the linearity of the 
relationship between absorbance and phosphate amount was completely lost 
(Scheme 3.7, right). 
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Scheme 3.7: Triton X-100 (Formulation 1) was not indicated as a stabiliser: the 
formulation displayed the tendency to form bubbles (left), and linearity of the 
relationship between complex absorbance values and phosphate amount was 
disrupted (right). 
Chapter 3: Enzymatic synthesis of GDP-a-D-azidodeoxymannoses 
The formulation with 1% glycerol (F2) appeared to be more promising, at least 
by judging from the appearance of the blank, which displayed a bright yellow 
colour (allowing for a chromatic change after reaction which was perceptible by 
eye) and absence of bubbles. Unfortunately, in contrast with the previous 
formulation, this one still presented solubility issues. As the colour developed 
over time precipitation started to occur (Scheme 3.8, left), and the absorbance 
values consequently dropped (Scheme 3.8, right). 
50 p1 standard + 50 pl malachite reagent 
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Scheme 3.8: Glycerol (Formulation 2) at 1% v/v did not solve the precipitation issue 
(left). As the reagent developed the green colour over time, the absorbance values 
at 650 nm increased steadily until precipitation occured (right). 
The detergent Tween 20 (F3 and F4) appeared to be the most suitable stabiliser 
when used under appropriate conditions (F3, experiment 5 as shown in Table 
3.1). Surprisingly, lower levels of malachite green (F4) displayed precipitation 
of the complex (Scheme 3.9, left), while higher levels (F3) dissolved more 
readily (Scheme 3.9, right). 
Furthermore, the use of smaller volumes of reagent (50 pJ instead of 100 i1, 
experiment 5 versus experiment 6 as shown in Table 3.1) produced lighter- 
coloured blanks, allowing a more readily identification by eye (Scheme 3.9, top 
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50 p1 standard + 50 tl malachite reagent 
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Scheme 3.9: Tween 20 (Formulations 3 and 4) at 1% v/v did not solve the 
precipitation issue for low-levels of malachite (20 mg/lOOml, F4, left). When more 
malachite dye was used (34 mg/lOOml, F3) Tween 20 was an effective stabiliser 
(right). 
right). Once the colour had fully developed (15 mm.), a plot of the absorbance 
values against the phosphate amounts of the standard solutions yielded a linear 
calibration curve, which was reproducible over another 15 minutes (not shown, 
for reference see Chart 3.1). 
3.2.3 Assay validation: iFPase activity assay (part 11 
After optimisation of the formulation for the malachite reagent, we moved into 
its validation on the inorganic pyrophosphorylase (iPPase) enzyme. This 
enzyme is well studied and uses a cheap and readily available substrate 
(pyrophosphate). Moreover, since we used iPPase on our activity assay for 
GDP-ManPP, this was also a convenient method to confirm the efficiency of the 
iPPase reaction over its potential limiting effect: only if the PPi enzymatic 
hydrolysis was fast and quantitative the colourimetric readout would reflect 
GDP-ManPP turnover. 
We prepared a master-mix iPPase reaction (iPPase 0.05 U, MgCl2  8 mM, DTT 1 
mM, 100 i.LM K4P207) in 500 tl of IRIS 50 mM pH 7.6, and at different time 
intervals we took 10 p.l samples which were diluted with deionised water up to 
50 p.1 in a 96-well plate containing 50 p.1 of malachite reagent (Formulation 1, 
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with 1% Tween 20). Under the same conditions used for the phosphate 
standards calibration, the absorbance at 650 nm was read after 15 minutes. After 
addition of the samples to the wells, a marked difference in colour between the 
reactions and the blanks could immediately be observed. Surprisingly, as the 15 
minutes passed, the blanks (without enzyme) developed a green colour, too 
(possibly due to the chemical hydrolysis of the unreacted pyrophosphate). As a 
result, the final reading did not reflect the enzymatic activity, and once subtracted 
from the blank, it corresponded to values <0.1 (Chart 3.2). 
This disappointing finding came as a surprise, since the successful and 
convenient use of malachite assays for iPPase activity had been previously 
reported.E 161 However, the volume ratio between the dye reagent and the 
samples used in this literature study was 4:1 (100 jd of dye mix versus 25 tl 
samples), our investigation was based on a 1:1 ratio (50 lal of dye versus 50 .tl 
samples). With this evidence in hand, the way forward presented itself: we 
started exploring the use of different volumes of samples and of reagent, in 
order to find the optimal conditions for our experiments, hopefully leading to 
reliable absorbance readouts. 
PP ass reaction after Ih 
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After lh at 37 °C, a 10 p1 
sample of the iPPase reaction 
was diluted up to 50 p1 with 
deionised water and tested 
with 50 p1 of malachite 
reagent. Unexpectedly, the 
blanks developed a green 
colour over time, so that when 
the absorbance was read after 
15 minutes, the difference 
between the reactions and the 
blanks was <0.1. Moreover, 
under these conditions, the 
plateau for the formation of the 
malachite complex was not 
reached after 15 mm. 
Chart 3.2: When used to test for iPPase enzymatic activity, the malachite assay did 
not give the expected results. The blanks developed a green colour over time, and 
the reaction with the malachite failed to reach a plateau within 15 minutes. 
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3.2.4 Further optimisation of the malachite green assay 
We assayed samples undiluted and diluted up to 25 il or 50 .tl with 50, 75, 100, 
or 150 p.1 of the malachite reagent. Use of the dye solution in large excess 
(typically with volume ratios of 3:1 or 4:1 compared to the sample), resulted in 
an absorbance difference between the samples and the blanks which was 
consistent over time. 
Unfortunately, under these conditions, we could still see (just like in Chart 3.2) 
that the plateau for the malachite complex formation was not achieved within 
the first 15 minutes (as expected) but the absorbance was still notably 
increasing over 30 minutes. We decided to carry out a more detailed analysis of 
the calibration data, in order to look for some insight into this bewildering 
phenomenon. We prepared a fresh batch of malachite reagent, but when we 
repeated the calibration curve on phosphate standards under the new 
optimised conditions (25 p.1 samples against 100 p.1 of dye solution), we could 
barely see any difference between the standards (Chart 3.3). 
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Chart 3.3: Under the new conditions for the malachite assay (25 p1 samples against 
100 p.1 of malachite reagent), there was a minimum difference in absorbance at 650 
nm for the set of phosphate standards. 
At this stage, serendipity came to our aid. Upon a replica of the experiment the 
next day, a slight difference in the result caught our attention (Chart 3.4), 
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although we could still not unambiguously ascertain whether such a difference 
was due to a real phenomenon or it was within the range of instrumental error. 






Chart 3.4: The same experiment as above, repeated after 24h. 
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Chart 3.5: The same experiment as Chart 3.3, repeated after 48h. 
We repeated again the experiment on the same batch of reagent the following 
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Clearly, the malachite reagent reacted differently with phosphate as it aged. It is 
possible that the components of the dye solution now required longer time to 
reach a stable equilibrium. This was confirmed by repeating the experiment (on 
the same batch) over the following days. We were now keen to establish the 
time required for the solution to become stable enough to yield reproducible 
results. Subsequent experiments (Chart 3.6) confirmed that after seven days 
the solution had reached stability and could be reproducibly used for three 
weeks. After this time, the absorbance values started displaying scattering, 
which would increase over time and affect the readouts. 
In conclusion, we established that in the time frame between seven and thirty 
days after having prepared a fresh solution of malachite reagent, we could 
reproducibly obtain a calibration curve on phosphate standards showing a 
linear correlation between the absorbance at 650 nm and the amount of 
phosphate present in the solution (as reference, see Chart 3.1). As it turned out 
that the conversion factor slightly changed from batch to batch, the calibration 
curve would be repeated each time. 
After AAays from the preparation of the malachite reagent 
Colour development over time for phosphate standards 
After 7 days from the preparation of the malachite reagent 
Colour development over time for phosphate standards 
- 
0 	5 	30 
Tme (min j 
Chart 3.6: The same experiment as Chart 3.3, repeated after 4 days (left) and 7 
days (right) from the preparation of the malachite reagent. 
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3.2.5 Assay validation: iPPase activity assay (part 21 
After having optimised the conditions for the malachite green assay, we were 
hoping that finally we could successfully validate it on iPPase, before applying it 
to the GDP-ManPP enzymatic activity test. 
We investigated reaction conditions as close as possible to the tests we envisaged 
for GDP-ManPP, but with different amounts of iPPase: this would allow us to 
determine those conditions for which iPPase activity would not be a limiting 
factor. Ideally, the iPPase catalysis should be so fast and efficient to immediately 
turn over all the possible iPP generated by GDP-ManPP, so that the absorbance 
readout would reflect GDP-ManPP (and not iPPase) activity. We found that by 
employing 0.5 U of iPPase, the enzyme activity on 100 jtM KH2PO4 was very fast, 
preventing accurate measurement of the activity even at time 0, and with the 
reaction going to completion within 10 minutes (Chart 3.7). The absorbance 
iPPase activfty assay 
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Chart 3.7: The malachite assay can now be used to test for iPPase activity. 
values we obtained were finally precise, consistent, and confirmed that, under 
conditions similar to what used for the GDP-ManPP activity assay, the iPPase 
was not a limiting factor, as the enzymatic hydrolysis of pyrophosphate was 
proceeding with very high efficiency. 
3.2.6 fliip-GDP-ManPP activity assay: detection via malachite green 
We now had a full optimisation of the malachite green assay, and its validation 
on iPPase. We were therefore ready to test for GDP-ManPP activity on the 
unnatural azidodeoxymannose- 1-phosphates. Although there were slight 
RE 
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variations in the catalytic performance from batch to batch, in general all the 
GDP-azidodeoxymannoses were consistently formed with variable efficiencies 
(Chart 3.8). Interestingly, 6-azidodeoxymannose-1-phosphate appeared to be 
the unnatural compound which was better tolerated by the 
GDP-ManPP Activity Assay 
• G2.,fjr 	 . 	• GDP-Man 






— =I I ••IkUI IIIUI II&UI IIUI III 
0 	 I 	I LJ,L.flf_Lj_jI — I LII — I Lii — I 
0 	0.5 
Time (h) 
Chart 3.8: The malachite assay confirmed that all the azidodeoxymannose-1- 
phosphates were converted to the corresponding GDP-azidodeoxymannoses, 
although with variable efficiencies. 
enzyme, possibly due to the flexibility of the primary azide on C-6. All the other 
isomers were turned into products with comparable yields. 
In conclusion, we have developed and optimised the use of malachite green to 
screen for GDP-ManPP activity in 96-well plates. This colourimetric assay is 
very convenient as it allows not only for a quantitative analysis of enzymatic 
activity, but especially because it can be easily applied to future directed 
evolution studies of GDP-ManPP aimed to improving the efficiencies of these 
enzymatic reactions. 
Moreover, we demonstrated that all the azidodeoxymannose-a-1-phosphates 
could be used as unnatural substrates for the recombinant GDP-ManPP we 
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produced, and therefore GDP-azidodeoxymannoses could be prepared by this 
convenient chemoenzymatic approach. 
3.3 Semipreparative enzymatic synthesis of GDP-
azidomannoses 
Before carrying out tests on the GDP-azidodeoxymannoses for 
mannosyltransferase activity, it was necessary to scale up their synthesis in 
order to have enough material for our following experiments and for a full 
characterisation of these novel compounds. Of course the reaction conditions 
had to be changed (GTP/substrate 20 mM, GDP-ManPP 1.6 mg, iPPase 40 U, DTT 
5 mM, BSA 4 mg), considering that analytical experiments were conducted with 
diluted solutions that would simply be too impractical to employ on a larger 
scale. We adapted the procedure conditions used by Pallanca and Turner on 
GDP-ManPP enzymatic activity on a multi-milligram scale.[ 17] 
Initially, we attempted to monitor the reaction (and later purify the products) 
by reverse phase HPLC, using a standard C 18 column. Under these conditions, 
all the components of the reaction would elute within the first minutes, 
impairing any chromatographic separation. When inorganic salts (30 mM 
KH2PO4, 5 mM TBAHS, pH 6) were used to retain the compounds on the column, 
they heavily contaminated the fractions containing the products, negatively 
affecting analysis by ESI-MS and NMR. For this reason, we explored other 
means of purification, including the use of ion-exchange resins (although not as 
convenient as HPLC methods) and amino-functionalised HPLC reverse columns, 
but all our attempts failed to achieve any significant improvement. 
Only when we employed a Strong Anion exchange column (SAX) and used it 
with an elution system based on a gradient of ammonium formate, we 
succeeded in monitoring the reaction and purifying the GDP-
azidodeoxymannoses (Scheme 3.10).[181  The gradient of ammonium formate 
revealed to be very efficient in separating the different components of the 
reaction and it could be easily removed by freeze-drying. 
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Scheme 3.10: HPLC analysis of the semipreparative enzymatic synthesis of GDP-
6-azidodeoxymannose (Sphereclone SAX column, gradient of ammonium formate, 
from 0% to 100% of B = solution of 0.6M ammonium formate). The product had tR = 
12' (m/z = 629), while GDP had tR = 18', and GTP had tR = 22'. 
GDP-6-azidodeoxymannose 32 was so prepared in 63% yield (33 mg), followed 
by all the other isomers (compounds 33-35, 55% - 41% yields). All the GDP-
azidodeoxymannoses have been characterised by accurate ESI-MS, and their 
structure confirmed by 1 H, 13C,  and 31 P-NMR analysis. 
Having prepared and characterised these novel compounds, we will now 
discuss in the next chapter their use as substrates on a recombinant 
mannosyltransferase we produced. 
MI 
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Mannosyltransferase tests 
As described in the previous chapters, we have developed a novel 
chemoenzymatic strategy to prepare all the unnatural GDP-azidodeoxy-a-D-
mannoses. These compounds will be key tools to accomplish a high throughput 
non-radioactive assay for mannosyltransferase activity, based,on azide detection 
via the Staudinger ligation or azide-alkyne cycloaddition. They could also be 
used to enzymatically introduce a mannoside linkage with an unnatural building 
block; the azidomannose could then be further chemically modified (e.g. by 
selective reaction with other unnatural saccharides) to increase the complexity of 
the carbohydrate structure. This would be particularly valuable: bioengineering 
techniques offer competitive advantages compared to the stereoselective 
chemical synthesis of glycosidic linkages, which can be rather challenging. 
In order to fully appreciate the simplicity of enzymatic methods in 
oligosaccharide synthesis, we will now briefly introduce the recent advances on 
chemical synthetic strategies, as well as the state of the art of emerging 
bioengineering techniques. Next, we will analyse in more detail the current 
availability of marmosyltransferases, and how this influenced our choice on the 
first system for our studies. Finally, we will see how the unnatural GDP-
azidomannoses performed when tested on this model, and also some preliminary 
data on the chemical detection based on azide chemistry, in order to draw our 
conclusions and set the milestones for future work. 
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4.1 Oligosaccharide preparation: chemistry and biotechnology 
4. 1.1 Chemical synthesis of oligosaccharides 
4.1.1.1 Glycosidic linkages 
We have seen in Chapter 2 how carbohydrate chemistry requires the use of 
protection groups to achieve regioselectivity in chemical synthesis, and of course 
this is further complicated by the stereoselectivity issue, especially when glycosidic 
linkages have to be formed. In this case, we would speak of a donor and an 
acceptor molecule, the first being a carbohydrate, and the second virtually being 
any structure, more often another carbohydrate, a lipid, or an aminoacid. 
The classic procedure involves activation and elimination of the anomeric 
leaving group at the donor, to generate an oxo-carbenium species (Scheme 4.1, 
left). This intermediate can be stabilised by electronic interactions, which can be 
intramolecular (e.g. anomeric effect, neighbouring group participation), or 
intermolecular (e.g. by active counter ions), and influence the stereochemical 
outcome of the glycosidic linkage to be formed. Subsequent nucleophilic attack 
by the acceptor would finally lead to formation of the glycosidic bond, provided 
that the reaction is performed under strict dry conditions (Scheme 4. 1, right). [ ' ] 
activation 
RO5 ..~\, 	 RO
) ROH 	
or 
X 	oxo-carbenium ion 	
OR 
Scheme 4.1: Classic synthesis of glycosidic bonds involves activation to the oxo-
carbeniurn species.L't 
Traditional oligosaccharide synthesis is based on Knoenigs-Knorr protocol: use 
of glycosyl bromides activated with silver saltsj 2' Due to the instability of these 
compounds, many variations were reported with alternative leaving groups (e.g. 
trichioroacetamidates and thioglycosides) and promoters (e.g. trimethylsilyl 
triflate, boron trifluoride diethyletherate, N-iodosuccinimide-triflic acid, just to 
name a few), and they are all described in a detailed review. [31 
With regard to the stereoselectivity of the anomeric linkage, the configuration of 
the C-2 substituent of the donor plays a determinant role. A number of 
87 
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neighbouring-group-assisted procedures have been developed over the years for 









xG 	 HcD\(  
1,2-trans 
neighbouring group 	 oxazoline 	 glycosidic linkage 
participation 
Scheme 4.2: Example of neighbouring-group-assisted procedure for the formation 
of 1 ,2-trans-glycosidic linkage. 111 
synthesis of the 1,2-cis glycosides, a major breakthrough was the in situ 
anomerisation procedure introduced by Lemieux: tetrabutylammonium bromide 
promotes a rapid equilibration between a and P halide donors, but the 3 
(unfavoured by anomeric effect) will be more susceptible to nucleophiic attack 
(Scheme 4.3, top). 141 For higher selectivity, it is of course essential that the 
reaction is performed in non polar solvents to avoid formation of the 
oxocarbenium ion. Another useful strategy to achieve 1 ,2-cis glycosides has been 
later developed by Boons, who reported the use of (1S)-phenyl-2-
(phenylsulfanyl)ethyl moiety at C-2 to give a quasi-stable anomeric sulfonium 
ion, which can be displaced by the acceptor molecule (Scheme 4.3, bottom). [' ] 
RO- 
Bu4NBr 	 R'OH 




activation 	 R'OH 
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e  







Scheme 4.3: 1 ,2-cis-glycosidic linkages are promoted by in situ anomerisation 141 
(top) and neighbouring group participation of a(1S)-phenyl-2-(phenylsulfanyl)ethyl 
moiety at C-2 (bottom).L5] 
Instead, when inversion of configuration is desired on a halide donor, insoluble 
salts (e.g. silver, aluminate) can be used to sequester halide ions and prevent the 
equilibrium described above, so that a n-linkage is preferentially formedJ' 
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A more complex task has been efficient -mannosylation, for which a variety of 
protocols have been developed. Pioneering work by Crich showed that an a-
sulfoxide can be converted in situ to an a-triflate, which is displaced in SN2 
fashion by an alcohol (Scheme 4.4). 161 
--_ ROL_. 	RO 	 RO.SL 	OH Ro.SL.OR 
Ph 	 TfO4'Ph 	
TfO 
Scheme 4.4: Crich's pioneering work to achieve f3-mannosylation. 6' 
Danishefsky proposed a more elaborate procedure from glycals, based on 
epoxidation, -glucoside formation, oxidation, and reduction to a J3-mannoside 
(Scheme 4.5)YI A more efficient procedure to achieve 3-mannosylation is the 
"intramolecular aglycon delivery" based on the use of a tether to link the acceptor 
to the C-2 of the mannosyl donor (Scheme 4.6). 1' , 91 Activation of the adduct leads 
to [3-glycosidation, and the rest of the tether is hydrolysed during the work-up. 







0 	 13-mannoside 
Scheme 4.5: Danishefsky's 3-mannosyIation from glucalsJ 71 
OH 	 O"OR' 	 O " OR' 	O''R' 	OH Tether (Y) 
R 09 OL -B RO5L. _TRO5 	 ROL~J ROL..OR 
X 13-mannoside 
Scheme 4.6: f3-mannosylation by intramolecular aglycon delivery (Y= CH 2, SiMe2, or 
p-methoxybenzyl (PMB). 18' 91 
4.1.1.2 Chemical assembly of oligo saccharides 
Solution-phase synthesis notably progressed thanks to the above techniques. 
Nevertheless, assembly of complex oligosaccharide structures is faster via one-
pot reactions or the solid-phase approach. In the first case, chemoselective 
glycosidation is usually achieved through the use of building blocks of different 
IM 
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reactivity, based on the use of arming/disarming protection groups (as 
mentioned in Chapter 2).hbol Following Freiser-Reid's study (based on previous 
reports by Paulsen), other groups added "latent" or "superarmed" functionalities 
to the pool of building blocks compatible with one-pot reactions." 21 The concept 
of different reactivity of glycoside donors for one-pot oligosaccharide synthesis 
has been further explored by Wong. 111.141  On the other hand, Seeberger's view is 
that the future of carbohydrates is automated synthesis on solid-phase, as history 
showed for nucleotides first, and peptides later. The major limitations of this 
approach are the availability of a varied pool of building blocks, as well as 
preparation of particularly challenging structures. (151 
4.1.2 Enzymatic synthesis of oligosaccharides 
The inherent difficulties associated with the chemical preparation of 
oligosaccharides led chemists to look for simpler alternatives. From the 
synthetic point of view, it is fascinating the ease with which nature can 
accomplish the very same structures that are so challenging for us to make: could 
we use the same efficient tools for our purpose? Indeed enzymes offer 
remarkable advantages compared to classic synthesis: they provide 
* regioselectivity (they do not require the use of protecting groups), 
* stereoselectivity, 
* no side reactions (predictable outcome and easier purification), 
* green chemistry (no use of organic solvents), 
* activity under very mild conditions (compatible with sensitive 
functional groups and convenient large-scale reactions). 1 ' 61 
Glycosyltransferases offer all these values, but present major drawbacks since most 
are not commercially available and require expensive NDP-monosaccharide 
substrates. 1  There are mainly two additional enzyme classes that can be used to 
perform glycosylations. Glycosidases (which usually hydrolyse glycosidic bonds) 
use cheap substrates, but usually offer low yields. They can be used under thermo- 
Chapter 4: Mannosyltransferase tests 
dynamic control (reverse hydrolysis), or under kinetic conditions (trans-
glycosidation), in order to obtain the formation of a glycosidic linkage. Mutagenesis 
is a useful tool to evolve a glycosidase into a "glycosynthase" which will form a 
glycoconjugate, but has lost the ability to hydrolyse it, or into a thioglycoligase, 
capable of forming thioglycosidic linkages, less susceptible to enzymatic 
hydrolysis. 20' Nevertheless, the most promising enzymes in this context are GTs, 
which are attracting more and more interest by the research community. 1211 
The potential of GTs for the preparation of natural products libraries and 
analogues was particularly emphasised by Thorson, who invented the term 
"glycorandomization" to describe the use of enzymes (together with synthetic 
techniques) to increase the diversity of glycoconjugate libraries. 1251 For instance, 
he reported the unusual and valuable activity of a glycosyltransferase capable of 
catalysing both 0- and C-glycosylations. 26' Later, he explored further the 
promiscuity of glycosyltransferases, demonstrating how the reversibility of their 
enzymatic catalysis may be applied to perform alternative reactions: the 
synthesis of unusual NDP-sugars from glycosylated natural products, the 
exchange of glycosides with exotic sugars (from NDP-activated precursors), and 
the exchange of a carbohydrate from a glycosylated product to another. 23 
Moreover, he expanded the diversity of glycosyltransferases products by 
developing a fluorescence-screen applied to enzymatic directed evolution. [241  
Similarly, Monica Palcic and David Bundle reported the synthesis of unnatural 
thio-oligosaccharides by using glycosyltransferases, although less efficiently 
compared to the natural products." In order to fully exploit and improve the 
enzymatic promiscuity for synthetic purposes, they recognised how beneficial it 
would be to understand the mechanisms of substrate recognition, binding, and 
catalysis. Later, Palcic pursued this aim with the aid of spectroscopic 
techniques, combined with mutational studies. [28-331 
In conclusion, enzymes are indeed valuable tools for modern chemists, and their 
advantageous use for the preparation of glycosylated structures should be 
pursued whenever possible. 
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4.2 a-i ,2-Mannosyltransferase Kre2p/Mntlp 
4.2.1 Availability of mannosyltransferases 
Despite the large number of enzymes belonging to the class of 
mannosyltransferases, most of them are not commercially available. A possible 
explanation is the fact that mannosyltransferases are membrane associated 
proteins, which are well-known to pose technical difficulties associated with their 
handling and water solubility. The only member of this family available on the 
market is the soluble fragment of the well-characterised Kre2p/Mntlp, an cz-1,2-
mannosyltransferase from the yeast S.cerevisiae, although it is rather expensive. 
We therefore considered the option of producing a recombinant enzyme 
ourselves, choosing a well-studied system with an established and convenient 
expression protocol. 
4.2.2 Plasmid pManFLAG20 for expression in E.coli 
Wong and co-workers deposited in the American Type Culture Collection an 
engineered plasmid (pManFLAG20) encoding for the soluble fragment 
(aminoacids 31-442) of Kre2p/Mntlp a- 1 ,2-mannosyltransferase (Scheme 
47)1341 This DNA construct allows for expression of the recombinant enzyme 
under control of the convenient tac promoter. This is a hybrid between the trp 
and the lac UV5 promoters, and it combines their consensus sequences to yield 
higher efficiency of protein expression. The trp promoter has only the -35 element 
(TTGACA), and the lac UV5 only the Pribnow box (TATAA), but both elements 
are present in the tac promoter. [35]  These sequences bind transcription factors 
called sigma factors which in turn allow the E.coli RNA polymerase to efficiently 
bind to the DNA and initiate gene transcription. [3 ' 1 Furthermore, the tac 
promoter has also the Shine-Dalgarno sequence which allows for high levels of 
















Scheme 4.7: Map of the pManFLAG20 expression vector. 1341 
In pManFLAG20, the inserted gene (encoding the aminoacids 31-442 of 
mannosyltransferase Kre2p/Mntlp) displays a double N-terminal tag. The first 
one is an ompA (outer membrane protein A) signal which is a peptide that directs 
the recombinant protein into the periplasmic space, where it is then cleaved by a 
peptidase. Secretion into the periplasm can be very convenient: the recombinant 
protein is not exposed to the cytosolic proteases, disulfide bonds are more likely 
to be formed correctly in the oxidising periplasmic environment, and protein 
purification is simpler, since only a few proteins are present in this cellular 
compartment. 37' The other tag is the immunogenic FLAG peptide, which can 
be exploited for purification or detection purposes (e.g. by Western blot). 
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4.2.3 Acceptor specificity of the soluble fragment 31-442 of Kre2p/Mntlp 
pManFLAG20 does not encode the full enzyme, but only the soluble fragment 
31-442 (without the transmembrane domain) which has been shown to display 
catalytic activity. Kre2p/Mntlp is naturally present in the Golgi of yeast 
S.cerevisiae where it is involved in the elongation of mannose-containing 
glycoproteins. Although the enzyme has been widely studied, its natural 
substrates in vivo have not been unequivocally established, as this gene product 
belongs to a family containing nine similar genes, which are probably 
complementary to each other. It has been demonstrated in vivo that 
Kre2p/Mntlp is responsible for the addition of the third mannose onto Serine or 
Threonine 0-linked mannobiose, as mutants devoid of this enzyme express 
truncated 0-linked glycoproteins. It has also been shown in vitro that the enzyme 
can accept N-glycans (Man 1530-G1cNAc) as substrates, but whether this activity is 
reproducible in vivo is still unclear. Interestingly, when this recombinant 
fragment is produced in the yeast P.pastoth, it is capable of transferring mannose 
(from GDP-mannose) to a variety of acceptors besides mannosylated 
glycoproteins: mannose, methyl-a-1,2-mannoside, a-i ,2-mannobiose and 
methyl-a-1,2-mannobiose. 1381 
Moreover, Wong and co-workers demonstrated that the active fragment 
containing aminoacids 31-442 can be produced also in E.coli on a large scale and 
it is capable of transferring mannose (from GDP-mannose) to a number of 
unnatural mannose-containing acceptors (Figure 4.1 and Figure 4.2).'' 39]  It is 
worth noting that none of these studies explored the use of unnatural mannose 
donors, possibly because while it is known that a-mannosyltransferases can 
naturally tolerate a variety of acceptors, only GDP-mannose has been shown to 
be their natural carbohydrate donor. 
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Figure 4.1: Unnatural acceptors tested on the soluble fragment of Kre2p/Mntlp 
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Figure 4.2: Unnatural acceptors tested on the soluble fragment of Kre2p/Mnt1p 
expressed in E.coli and relative activities (in brackets). (34, 391 
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4.2.4 Crystal structure of Kre2p/Mntlp 
The Kre2p/Mntlp happens to be one of the few mannosyltransferases for which 
a crystal structure is available (Figure 4.3). [411J Two protein molecules are 
present in the biological unit, both displaying one N-linked glycan, and three 
disulfide bonds. The protein displays a mixed aIf3 fold and only one Rossmann 
fold, as commonly found in class A of glycosyltransferases (GT-A). The cofactor 
manganese is coordinated by a modified DXD motif (EPD) where only the first 
acidic residue is involved in a direct interaction with the metal ion. 
The structure, together with studies of kinetics, molecular modelling, and site 
directed mutagenesis, has highlighted the importance of a Tyr residue (Tyr220) 
in the catalytic process, although the exact mechanism has not yet been 
unravelled. Double displacement and Sn 1-like reaction are both possible (see 
Introduction for more details). It is worth noting from Figure 4.3 that the 
methyl-a-mannoside acceptor, the manganese cofactor, and GDP, can all be 
clearly distinguished in the catalytic site, whereas this is not equally true for the 
mannose donor, thus leaving an open debate on which hydroxyls on the 
monosaccharide interact with the enzyme, and are therefore required for the 
catalysis to o 
Figure 4.3: Crystal structure of Kre2p/Mntlp, displaying Mn2 (purple), GDP and 
Man-a-OMe in the catalytic site (PDB codes 1S4N, 1S40, 1S4P). 401 
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Molecular modelling studies, based on crystal structures of other 
glycosyltransferases, proposed that the mannose donor is within distance for Van 
der Waals interactions (A1a362, Trp325, Met 223, Cys 224) and hydrogen bonds 
with the 'y-oxygen of Ser326, both nitrogens of Asn327, both carboxylic oxygens 
of Asp361 and the side-chain amine of Arg245. All these aminoacids form a 
binding pocket in the active site, and are invariant or well conserved amongst 
other homologous proteins. Nevertheless, only the residue Asp361 has been 
shown to be critical for activity by mutational studies. Furthermore, very little is 
known about the single interactions of the mannose donor: it is unclear how 
specific hydroxyl groups interact with single aminoacids; moreover, mannose 
could be present in different conformations in the active site. Therefore, 
although the monosaccharide is within range for hydrophobic or hydrophilic 
interactions with the enzyme, it is still not unambiguously proven that such 
interactions actually take place. [401 
4.2.5 Expression of soluble Kre2p/Mantlp in E.coli 
Wong and co-workers reported the successful expression of the recombinant 
soluble Kre2p/ Mntlp in E.coli by induction with low-levels of IPTG (5 p.M), 
and use of minimum medium enriched with 2% casaminoacids (M9-CA), at 30 
°C for 12 h. The enzymatic tests were usually carried out on a partially purified 
protein batch, obtained after isolation of the periplasmic fraction by osmotic 
shock. 34 ' 39' 
When we attempted to reproduce Wong's procedure, we could not detect any 
FLAG-tagged protein (Figure 4.4, lane B), and the enzymatic activity tests 
carried out on the periplasmic fraction with GDP-mannose and a-methyl 
mannoside led all to negative results. 
We therefore first tested other media for the cell growth and protein expression, 
and analysed whole cells for FLAG-tagged proteins (by means of Western blot 
analysis with an anti-FLAG monoclonal antibody). The employment of richer 
media such as the standard Luria-Bertani or the Terrific Broth was equally 
unsuccessful (not shown), while the use of M9-CA with the simple addition of 
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glycerol as carbon source, and magnesium as cofactor were enough for the cells 
to produce the desired soluble ManT (Figure 4.4, lane Q. Interestingly, 
detection by Western blot with an anti-FLAG monoclonal antibody resulted in 
the visualisation of a double band, instead of a single band as expected. The size 
difference between the two proteins is compatible with the incomplete removal 
of the OnipA signal, as suggested for other fusion proteins expressed with the 
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Expected molecular weight: 
- 52kDa = ompA+FLAG+ManT 
- 50kDa = FLAG+ManT 
- 49kDa = ManT 
Lane M = MW markers 
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Figure 4.4: SDS-PAGE (left) and Western blot (right) of whole E.coli cells. Soluble 
FLAG-tagged ManT appears as a doublet possibly due to incomplete removal of the 
OmpA signal sequence. [43] 
same vector pFLAG- 1, and displaying on Western blot a doublet of FLAG-
tagged bands with the same protein size difference. 43 
Subsequent experiments confirmed the presence of the doublet in whole cells 
(Figure 4.5, lane A) of which only the upper band was contained in the 
periplasmic fraction (Figure 4.5, lane B). Hence, if the doublet was due to 
incomplete removal of the OmpA signal, we would expect to find both bands in 
the periplasm. In contrast, the fact that only the upper band is transported 
through the internal membrane and that the majority of the lower band is present 
in the insoluble fraction (not shown), together with the visible traces of other 
FLAG- containing proteins of smaller size (Figure 4.5, lane A), brought us to the 
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conclusion that the recombinant ManT was probably being improperly folded or 
partially digested. 







Expected molecular weight: 
- 52kDa = ompA+FLAG+ManT 
- 50kDa = FLAG+ManT 
- 49kDa = ManT 
Lane M = MW markers 
Lane A = Whole cells content 
Lane B = Pen plasmic fraction 
Figure 4.5: Western blot of whole E.coli cells expressing the soluble FLAG-tagged 
ManT (lane A) and the partially purified periplasmic fraction (lane B). 
Nevertheless, this slight variation to Wong's protocol still allowed us to obtain 
the recombinant soluble ManT in the periplasm, and now we were keen to find 
whether it maintained any enzymatic activity. 
4.2.6 Activity assay for Kre2p/Mantlp from E.coli 
We reasoned that at this stage the most rapid and convenient method to assay 
for activity was the use of EST-MS analysis. As Hepes, Tris, or phosphate buffers 
(the typical choice for enzymatic reactions) are not ideal for mass spectrometry, 
we opted for the more volatile ammonium formate. After optimisation of the 
enzymatic reaction conditions, we found that the use of the concentrated 
periplasmic fraction (exchanged with the desired buffer) in 10 mm MnC1 2 could 
be successfully reacted for 24 h with GDP-mannose and a six-fold excess of 
methyl-cc-D-mannoside acceptor, over a range of substrates concentrations (from 
1 to 10 mM, relative to GDP-mannose). After 24 It at 30 °C, the peak 
corresponding to the desired disaccharide product (with the addition of sodium 
ion) could be detected in the ESI-MS spectrum (Figure 4.6, left). 
Having finally prepared the required ManT enzyme and found the appropriate 
conditions for the enzymatic assay and mass-spectroscopy analysis, we 
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proceeded to test our unnatural GDP-azidomannoses. We performed negative 
control reactions (without enzyme or without substrate), a positive control 
(natural GDP-mannose substrate), and the experiments on unnatural GDP-
azidodeoxymannoses. Reactions on the 2-, 3-, and 6-azidomannose derivatives 
did not show the presence for the desired products at all (not shown). ESI-MS 
analysis (negative ion mode) showed that the unnatural GDP-azidomannoses 
were still present, but no desired product could be detected (positive ion mode). 
Minor peaks corresponding to the azidomannose-l-phosphates could be 
detected, but only as traces, indicating that degradation was not a major issue. 
Notwithstanding this finding, we were very excited to see that the GDP-4-
azidomannose was successfully transferred by the enzyme (Figure 4.6, right). 
Figure 4.6: ESI-MS spectra for the ManT reaction with a-methyl mannoside and 
GDP-mannose (left) or GDP-4-azidomannose (right) showing the formation of the 
desired products. 
One sensible hypothesis is that the 4-azidomannose isomer is the only compound 
tested displaying the azide below the mannose ring, where the enzymatic active 
site might have a pocket to accommodate this unnatural group. It is difficult to 
decide with more certainty whether the other isomers are inactive because of 
steric or electronic factors. Bearing in mind that the only available crystal 
structure of this enzyme is incomplete, as it lacks not only the mannose donor 
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but also part of the protein backbone itself, we can only speculate on the reason 
for this selective reactivity towards the unnatural GDP-azidomannoses, at least 
until more data are generated. 
The high polarity and the water solubility of the starting materials and products 
makes products isolation and characterisation extremely difficult. Possible ways 
to overcome these issues include scale up and derivatisation of products (e.g. 
acetylation). Another possibility would be to test acceptors other than methyl-a-
D-mannoside that can be more easily separated by HPLC and provide good 
chromophores for spectroscopic detection. 
This important result confirmed that the GDP-azidomannoses can indeed be 
processed as unnatural substrates by mannosyltransferases, and although we 
could detect the enzymatic transfer only for one of these compounds so far, we 
believe that the other isomers may similarly find applications with different 
mannosyltransferases. For instance, we could test these compounds on the f3-
1 ,4-ManT (N-glycosylation pathway) of which our group has the corresponding 
DNA, or the dolichol-P-Man synthase, which is another enzyme widely studied. 
At this stage, in order to establish all the milestones required for the development 
of a high throughput screen for mannosyltransferase activity via azide chemistry, 
we needed the proof that azidosugars can indeed be chemically ligated to a probe 
(e.g. fluorophore or antigenic peptide). For our purpose, it is sufficient that the 
azidomannose performs either the Staudinger ligation or the 1,3-dipolar 
cycloaddition to alkynes (either copper-catalysed or strain promoted). In the 
next paragraph we will outline our preliminary studies with regard to this 
chemistry applied to azidomannoses. 
4.3 Model ligation reactions on azidomannoses 
In recent years we have witnessed the rapid expansion of azide chemistry, which 
has been widely applied, including the field of modified carbohydrates. We have 
seen in the Introduction how different groups have successfully ligated the azide 
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functionality to a number of "reporter" molecules (e.g. FLAG, biotin, etc.) that 
could be detected by biochemical means. Both the Staudinger ligation and the 
1,3-dipolar cycloaddition to alkynes have been reported as reliable reactions to 
detect the presence of azides even in complex biological environments, while so 
far azido-deoxymannoses have never been reported as substrates for 
carbohydrates-modifying enzymes. 1 For this reason, we felt that our priority 
was first to test for their biological activity, and only if successful, we would 
dedicate future studies to the optimisation of the azide chemistry. 
We first tested the protected azidodeoxymannoses for chemical ligation to 
derivatives of a phosphine or an alkyne in organic solvent. Our main interest 
was to assay whether a secondary azide could also be ligated to a "reporter" 
molecule. A preliminary investigation was conducted on the fully protected 
2,3 ,4-tri-O-acetyl-6-azido-6-deoxymannose 3 and the 3,4,6-tri-O-acetyl-2-azido-2-
deoxymannose 7 as models of a primary and secondary 
azide. 
4.3.1 Staudinger ligation 
First, we reacted both compounds for the Staudinger ligation with the 1-methyl-
2-diphenylphosphinoterephthalate 37, which was prepared in two steps from the 
commercially available 1-methyl-2-aminoterephthalate (Scheme 4.8). 
Diazotisation followed by conversion of the diazonium salt to the iodide results 
in the formation of 1-methyl-2-iodoterephthalate 36 (85 % yield), a yellow solid 
which could be used without further purification. The iodide was then treated 
with TEA in dry methanol, and then reacted with palladium acetate and 
diphenyl phosphine at reflux overnight. After work-up, the 1-methyl-2-diphenyl-
phosphinoterephthalate 37 was precipitated as golden yellow solid from a 1:1 
mixture of methanol/water which was previously cooled at 4 °C. Spectroscopic 
analyses revealed the presence of the desired product 1-methyl-2-diphenyl-
phosphinoterephthalate 37, with only traces of the phosphine oxide. 
103 
Chanter 4: Mannosvltransferase tests 
'ff] 
0 	 1. cold conc. HCl, 	 Ph2PH, cat. Pd(OAc)2 , 
0-"-PYO 
aq. NaNO2 	Ho 	 MeOH, Et3N 
2. KIln water I OMe 	refiux 	 Ph 	OMe NH2 Me 
85% 	 36 	 76% 	 37 
Scheme 4.8: Synthesis of the reagent for the Staudinger ligation. 
When tested for the Staudinger ligation with compound 3 or 7 under the 
conditions described by Bertozzi,l"I only the primary azide 3 gave the desired 
product 38 in quantitative yield (Scheme 4.9). Compound 7 was converted into 
a complex mixture of products, not easy to characterise and whose separation 
proved rather challenging and therefore was not pursued any further. It is 
possible that the azide at C-2 of compound 7 increases the reactivity of the 
anomeric centre, leading to undesired side reactions. At this stage, our purpose 
was a simple proof of concept that also a secondary azide could be easily reacted 
with a "reporter" molecule, and since the time available did not allow for 







MeCN I HO = 95: 5 










Scheme 4.9: Staudinger ligation onto the peracetylated 6-azido-6-deoxymannose 3 
as model compound of primary azidomannose. 
4.3.2 .1.3-dipolar cycloaddition to alkvnes 
Our next step was to investigate the copper-catalysed 1,3-dipolar addition of both 
compounds 3 and 7 with propargyl bromoacetamide. We opted for the 
generation in situ of copper I from copper II sulphate and sodium ascorbate, in a 
mixture of chloroform, ethanol, and water. Surprisingly, the secondary azide of 
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7 reacted more readily than the primary of 3 and allowed for the identification of 
the desired substituted triazole in 50% yield (Scheme 4.10), while the 
corresponding product for 3 was formed only in 13% yield. This result is in 
agreement with our hypothesis of the enhanced reactivity of the azide group in 
closer proximity to the anomeric centre. This indicates that the fully protected 2-
azidodeoxymannose may not be a suitable model for the corresponding isomers 
3- or 4-azidodeoxymannoses. 
0 
CHCIEt0H/H20 	 N Br 




CuSO4*5H20 AcO N ) 
AcO 	 Na ascorbate 	AcO 
OAc 	 50% 	
ACL 
7 	 39 Oft 
Scheme 4.10: Copper-catalysed 1,3-dipolar cyctoaddition to propargyl 
bromoacetamide of the peracetylated 2-azido-2-deoxymannose 7. 
With these results in hand, we could now test the corresponding protected 3- and 
4-azidodeoxymannoses, but we reasoned that it would be more valuable to assay 
directly the unprotected compounds with a set of conditions more compatible for 
a high throughput screen for enzymatic activity. 
4.3.3 Azide reactions on unprotected 4-azido-4-deoxymannose derivatives 
In our enzymatic tests, we have confirmed that GDP-4-azido-4-deoxymannose 
could be successfully transferred onto the a-methyl mannoside by our 
recombinant soluble Kre2p/Mntlp. Therefore, we decided to attempt the 
detection of the azide in the 4-position on mannose with model reactions on the 
unprotected sugar, as we would do in a high throughput screen for enzymatic 
activity. 
We repeated the enzymatic transfer of GDP-4-azido-4-deoxymannose on a-
methyl mannoside by Kre2p/Mntlp under the same conditions used previously. 
Subsequently we attempted the Staudinger ligation with three equivalents of 
compound 37 dissolved with the addition of 5% v/v acetonitrile, and heated the 
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mixture overnight at 47 °C. The next day, MS analysis confirmed the presence 
of the unreacted starting materials, but no product was formed. 
Since the Staudinger ligation did not produce encouraging data not even in our 
model reactions on the protected secondary azidomannose 7, we decided to 
move on and try the reaction with alkynes. Considering the availability of the 
possible compounds to be tested, the choice fell on the 4-azidodeoxymannose-a-
1-phosphate as a model for the 4-azido disaccharide product of our enzymatic 
transfer. The first attempt was made on the alkyne-containing His 6tagged 
peptide shown in Figure 47,1  which offers the advantage of detection by 
biochemical means (with a specific anti-polyHis antibody). We tried to promote 
the formation of the product by using a ten-fold excess of the azidomannose 31, 
5 equivalents of copper sulphate and 5 equivalents of sodium ascorbate. After 24 
h at 37 °C we could detect neither the desired product, nor the unreacted 
peptide, while the unreacted azidomannose was the only species which could 
still be clearly identified from the ESI-MS spectrum. 





H 	 H 





o H 	j 	- 	H o H 
N 	 N- 
N 
H 	 H 	 H 
Figure 4.7: Alkyne-containing peptide displaying a His6 tag, useful for biochemical 
identification [48] 
Coordination of the alkyne-containing peptide to the copper centre is not to be 
ruled out. Mass spectroscopy analysis displayed ion clusters with the 
characteristic pattern of peptides, but with a mass/charge ratio smaller than the 
starting material. This suggested possible side reactions causing decomposition 
of the poly-histidine compound. 
106 
Chapter 4: Mannosyltransferase tests 
At this point it seemed reasonable to set up a range of experiments in order to 
identify the best reaction conditions. For this purpose we chose a simpler 
molecule containing the alkyne functionality, i.e. the propargyl bromoacetamide 
(2.5 mM) which was reacted with a two-fold excess of 4-azidomannose-a-l-
phosphate triethylammonium salt (5 mIvI). This time, we opted for the use of a 
copper I species, namely Cu(I)Br for its good solubility in a number of solvents, 
compared to the corresponding iodide salt. Varying conditions (catalyst loading, 
reducing agent, and solvent) were tested in a set of expertiments as shown in 
Table 4.1. 
It turned out that methanol or water were the best solvent, allowing for 
immediate detection of the desired product by ESI-MS. Unfortunately, when the 
same conditions were applied in tandem to the enzymatic transfer, detection of 
the product proved to be more problematic, as we could not detect it at all. The 
azido-containing disaccharide was not present anymore in the ESI-MS spectrum, 
indicating that reaction had clearly occurred. A number of peaks corresponding 
to higher mass species appeared in the spectrum, but none of these could be 
easily attributed to the desired product. The preliminary nature of these data 
could not provide us with more structured information, and further optimisation 
will be pursued in our group in the near future. 
Cu(l)Br 
Amount 
Reducing Agent Solvent 
(up to 100 iii) 
n 	ESI MS 
0.25 mM Sodium Ascorbate (2.5 mM) Methanol 
Small 	peak 	for 	the 
product 
2.5 mM Sodium Ascorbate (2.5 mM) Methanol Positive 
2.5 mm Sodium Ascorbate (2.5 mM) Water Positive 
2.5 mM Sodium Ascorbate (2.5 mM) DMF Negative 
0.25 mM TCEP (1 mM) DMF Negative 
2.5 mM TCEP (1 mM) DMF Negative 
Table 4.1: Set of experiments to test the 1 ,3-dipolar cycloaddition of 4-azidomannose-u-
1-phosphate (5 mM) and propargyl bromoacetamide (2.5 mM) in 100 j.tI reactions. 
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4.4 Conclusions 
During this project we addressed a number of research questions posed to develop 
a non-radioactive high throughput screen for mannosyltransferase (ManT) 
activity. In particular, we synthesised all the desired GDP-azidodeoxymannose 
with a novel chemoenzymatic protocol. The strategy we adopted was based on 
the production of the recombinant GDP-ManPP from S.enterica in E.coli, as a 
histidine-tagged fusion protein, to allow for ease of purification. The desired 
protein has been obtained and purified for the first time with a one-step protocol. 
We have demonstrated that all azidodeoxymannose-a-l-phosphates are substrates 
for the recombinant GDP-ManPP so produced, and are converted into the 
corresponding GDP-azidodeoxymannoses, although with variable efficiencies 
(41%, 52%, 55% and 63% yield for the 2-, 3-, 4-, and 6-isomer respectively). We 
adapted and optimised a colourimetric high throughput screen based on the 
malachite dye which could be used in the future to evolve a mutant enzyme capable 
of processing the azidodeoxymannose-a-1 -phosphates with higher efficiencies. 
Finally, having prepared and characterised by accurate ESI-MS, 'H-, 13C-, and 31P-
NMR these novel GDP-azidodeoxymannose compounds, we also tested them as 
unnatural substrates for ManT activity. For this purpose, we produced a 
recombinant soluble fragment of a-i ,2-ManT (Kre2p/Mntlp) from E.coli with a 
slightly modified version of the protocol developed by Wong and co-workers. Our 
preliminary studies confirmed that the soluble fragment of this recombinant protein 
so produced is capable of processing at least one of our unnatural compounds. 
GDP-4-azido4deoxymannose is the only isomer that we observed to be 
successfully transferred onto a-methyl mannoside as an acceptor, and the desired 
disaccharide product was detected by ESI-MS. At this stage, the small reaction 
scale prevented further characterisation by other spectroscopic techniques. 
We also carried out preliminary experiments for the detection of azides on the 
enzymatic products formed by ManT activity on unnatural azidodeoxymannoses. 
From our model reactions we could see that fully protected primary 6-
azidodeoxymannose could successfully perform a Staudinger ligation to a 
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substituted aryiphosphine in nearly quantitative yield, and protected secondary 2-
azidodeoxymannose could perform a 1,3-dipolar cycloaddition to propargyl 
bromoacetamide in 50% yield. Subsequent experiments on unprotected 4-
azidodeoxymannose-a-1-phosphate showed that the compound is able to perform 
a copper-catalysed 1,3-dipolar cycloaddition to propargyl bromoacetamide, as 
detected by ESI-MS analysis. In this way, we proved that it was not the secondary 
azide which is responsible for the fact that we could not detect the enzymatic 
transfer of GDP-4-azidodeoxymannose. 
Future work will be focussed on the detection of the azido-disaccharide product of 
the ManT activity, by means of azide chemistry with "reporter" molecules that 
can be detected by biochemical means, possibly in multi-well format. One could 
for instance transfer the azidomannose onto a mannosylated peptide, which could 
be linked to a coated 96-well plate. Examples are poly-histidine tagged peptides 
onto nickel-coated plates, or FLAG-tagged peptides onto ct-FLAG mAb coated 
plates. Next, the ligated azidosaccharide obtained from ManT could be detected 
by biochemical means, for instance by using an alkyne linked to a fluorophore or 
an antigenic peptide or a dye. It would be extremely interesting to explore the use 
of the other azidodeoxymannoses on different ManTs, in order to assess whether 
any of the other isomers can be successfully processed by different enzymes. 
Ultimately this project could lead to the development of a non-radioactive high 
throughput screen for ManT activity, with potential applications for biological 
studies. Moreover, use of the ManT coupled with the unnatural azidomannoses 
and their selective chemistry could prove useful for the alternative production of 
therapeutic glycoproteins. 
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Experimental section 
5.1 Organic chemistry 
	
5.1.1 	General techniques and reagents 
All reactions and manipulations of moisture- and air-sensitive compounds were 
carried out in an atmosphere of thy nitrogen using Schienk techniques. All 
solvents and reagents were standard laboratory grade purchased from Sigma-
Aldrich, Fischer or Acros and used as received unless otherwise stated Where a 
solvent was described as dry it was purchased as anhydrous grade. 
5.1.2 	Instrumentation 
'H NMR spectra were recorded at 250, 300, 360, or 500 MHz, 13C NMR spectra 
were recorded at 63, or 75 MHz and 31 P NMR spectra were recorded at 101, or 
121 MHz on a Bruker 250Y instrument. Chemical shifts () are reported in ppm 
relative to Si(CH 3)4 (5=0) and coupling constants (J) in Hz, signals are sharp 
unless stated as broad (br), 5: singlet, d: doublet, t: triplet, m: multiplet and q: 
quaternary. Residual protic solvent, CDC1 3 OH:  7.26, s) was used as the internal 
standard in 'H-NMR spectra unless otherwise stated. Low resolution 
electrospray mass spectroscopy was carried out on a Micromass Quattro LC 
electrospray mass spectrometer with an applied voltage of 35-50 V. High 
resolution electrosprayionisation (ESI) mass spectra were obtained at the Mass 
Spectrometry Facility at University College London. UV/Vis spectroscopy was 
carried out in an 8543 UV/Vis spectrophotometer (Hewlett Packard) using 
disposable cuvettes. Infrared spectra were obtained using a Perkin-Elmer 1600 
Paragon Series FT-IR spectrometer as liquid thin films. 
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5.1.3 	Chromatography 
Analytical TLC was carried out on Merck aluminium backed plates coated with 
silica gel 60F254 . Flash chromatography was carried out over Fisher silica gel 60 
A particle size 35-70 micron. Components were visualized using p-anisaldehyde 
dip and UV light (254 nm). Preparative purification of the sugar nucleotides was 
carried in a reverse phase gradient (water/ammonium formate 0.6 M). The 
HPLC was equipped with binary pump (P680 HPLC pump Dionex), a semi-
preparative colunm (SAX, lOu, lOOA, 250*10),  UV detector (UVD 170U/340U 
Dionex). 
5.1.4 	Experimental Procedures 
6-0-Toluensulfonyl-a-methyl-D-mannopyranoside (1)111 
OH 	 OTs 
OH 	TsCI, DMF 	 OH 
HOlT 0°C HOIT 
HO 
85% 
We 	 I We 
A solution of the a-methyl-D-mannopyranoside 1 (3.36 g, 17.3 mmol) in dry 
pyridine (20.0 ml) was cooled to 0 °C in an ice bath with stirring. A solution of 
p-toluensulfonyl chloride (3.61 g, 19.0 mmol) in dry pyridine (15.0 ml) was then 
added dropwise over 30 min and stirring was continued at 0 °C until the reaction 
seemed complete by TLC. The solvent was then removed in vacuo to afford a 
crude product, which was purified by flash chromatography over silica (15:2 
DCM/MeOH) to afford 6-0-toluensulfonyl-a-methyl-D-manno-pyranoside 2 
(4.99 g, 85%) as a colourless oil. 'H NMR (250 MHz, CDC1 3): 5 (ppm) = 7.77 
(2H, d, J= 8.3 Hz, 2 x ArH), 7.29 (2H, d, J = 8.1 Hz, 2 x ArH), 4.62 (1H, br s, 
Hl), 4.28 (2H, br s, H4, H5), 3.88 (1H, br s, H2), 3.68 (3H, m, H3, CH 2), 3.24 
(3H, s, OCH3), and 2.38 (3H, s, CH 3). ' 3C NMR (63 MHz, CDC1 3): 5 (PPM) = 
144.6 (qC, Ts), 132.3, 129.6, 127.7 (4CH, Ts), 100.7 (CH, Cl), 71.3, 70.1, 69.8, 
69.6, 66.7, 54.5 (4CH, C2-05), 30.4 (OCH 3), and 21.3 (CH3). MS (ESI): m/z 
370.8 (M+Na), C13H2008NSNa requires 371.4. 
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6-Azido-6-deoxy-a-methyl-D-mannopyranoside (2)1h1 
OTs 	 N3 
OH 	NaN3, DMF 	 OH 
HOI 100°C 
HO 	 quant. 	H 
I OMe 	 2 We 
To a solution of dry DMF (20.0 ml) and NaN 3 (4.5 g, 69.0 mmol), was added a 
solution of the tosylate 2 (3.45 g, 9.90 mmol) in dry DMF. The solvent had been 
dried over molecular sieves under Argon for 1 h prior to use. The reaction was 
heated to 100 °C with stirring behind a blast shield and heating continued at 100 
°C for 6 h. Upon cooling to r.t., the colourless precipitate was removed by 
filtration through a plug of silica under suction and the solvent was evaporated to 
dryness. The solid was dissolved in DCM, filtered and evaporated under 
vacuum. The product was purified by flash chromatography over silica (15:2 
DCM/MeOH) to afford 6-azido-6-deoxy-a-methyl-D-mannopyranoside 2 as a 
colourless syrup (2.45 g, >100 % due to DMF still present). 'H NMR (250 MHz, 
CDC13): 5(ppm) = 4.38 (1H, br s, Hi), 3.59 (1H, m), 3.35 (2H, m), 3.24 (2H, m, 
CH2), and 3.12 (3H, s, OCH3). ' 3C NMR (63 MHz, CDC1 3): 5 (PPM) = 100.3 
(CH, Cl), 71.1, 70.7, 69.7, 67.5 (4CH, C2-05), 53.9 (OCH3), and 50.8 (CH2). 
MS (EST): m/z 241.7 (M+Na), C 7H,3N3O5Na requires 242.2. 





Ac20, AcOH, H2SO4 
0 °C - r.t. 






The methyl glycoside 2 (2.45 g, 11.0 mmol) was dissolved in 1:1 Ac 20/AcOH 
(206 ml) and cooled to 0 °C. Concentrated H 2SO4 (2.2 ml) was added dropwise 
over 30 mm. with stirring. The reaction was then allowed to come to room 
temperature by removal of the ice bath and stirring was continued overnight. 
After 26 h the reaction mixture was poured into ice water (250 ml) and the 
aqueous phase was extracted with DCM (3 x 100 ml). The combined organic 
extracts were washed with cold water (200 ml), sat. aq . NaHCO 3 (200 ml) and 
dried (MgSO4). The solvent was removed under reduced pressure to afford the 
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crude product which was purified by flash chromatography over silica (60:40 pet. 
ether/EtOAc) to afford the peracetylated product 1 ,2,3,4-tetra-O-acetyl-6-azido-
6-deoxy-a-D-mannopyranoside 3 as a colourless oil (2.93 g, 72 % over 2 steps). 
'H NMR (250 MHz, CDC13): 5(ppm) = 5.97(1H, d, J = 1.5 Hz, Hi), 5.24-5.21 
(2H, m, H3, H4), 5.13 (1H, m, J = 2.09, H2), 3.90 (1H, m, H5), 3.30 (1H, dd, 
J gm= - 13.5 Hz, J = 2.8 Hz, H6a), 3.20 (1H, dd, .Tgem = 43.5, J = 5.6, H6b), 2.07 
(6H, s, 2 x COCH3), 1.99 (3H, s, COCH 3), and 1.90 (3H, s, COCH 3). 13C NMR 
(63 MHz, CDC13): 6 (PPM) = 169.6, 169.4, 169.2, 167.6 (qC, 4 x COCH 3), 89.9 
(CH, Cl), 71.4, 68.2, 67.9, 66.0 (4CH, C2-05), 50.3 (CH 2), 20.4, 20.3, 20.3, and 
20.2 (4CH3, 4 x COCH3). MS (ESI): m/z 395.9 (M+Na), C14H19 N3O9Na 
requires 396.3. 
2,3 ,4-Tri-O-acetyl-6-azido-6-deoxy-a-D-mannopyranose (4)131 
N3 	 N3 
	
I OAc 	BnNH2 , THE 	 ' OAc 
AcOA—kQ 50°C AcO..—IQ 
AcO.\....L. 	
81 % 	AcO 
10 
3 OAc 	 4 OH 
The peracetylated azidomannose 3 (2.93 g, 7.90 mmol) in dry THF (40.0 ml) 
was treated with benzylamine (1036 p1) under Ar. The solvent was further dried 
over molecular sieves under Ar for 1 h prior to use. The reaction mixture was 
warmed to 50 °C and stirring continued for 24 h under Ar. The solvent was then 
removed under reduced pressure and the crude product purified by flash 
chromatography over silica (60:40 pet. ether/EtOAc) to afford 4 as a colourless 
oil (2.10 g, 86 %). 'H NMR (250 MHz, CDC1 3): 5 (ppm) = 5.34 (iH, dd, J(1 . = 
10.0, Jae 3.0, H3), 5.22-5.14 (3H, m, Hi, H2, H4), 4.67 (1H, br s, OH), 4.14 
(1H, m, H5), 3.30-3.27 (2H, m, H6a, H6b), 2.10 (3H, s, COCH 3), 2.00 (3H, s, 
COCH3), and 1.93 (3H, s, COCH3). 13C NEVIR (63 MHz, CDC13): 5 (PPM) = 
170.1, 169.9, 169.8 (3qC, 3 x COCH 3), 91.3 (CH, Cl), 69.8, 68.9, 68.4, 66.8 
(4CH, C2-05),50.5 (CH 2), 20.3, 20.1, and 20.1 (3CH 3 , 3 x COCH3). MS (ESI): 
m/z 354.1 (M+Na), C, 2H17 N3O8Na requires 354.3. 
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'OH I 	69% 	
O 	
iib I 
OMe 	 5 OMe 
A mixture of the 4,6-0-benzylidene-a-D-glucopyranoside (847 mg, 3.0 mmol) 
and pyridine (485 j.tL, 6.0 mmol) in 20 ml of dry DCM was treated with triflic 
anhydride (580 p.L, 3.45 mmol) at -20 °C. Solvents were dried over molecular 
sieves for 1 h under Ar prior to use. The reaction was stirred under Ar for 6 h, 
then it was allowed to come to room temperature and subsequently quenched 
with water. The mixture was extracted with DCM and chromatographed over 
silica (1:3 EtOAc/hexane) to afford 5 as a white solid (798 mg, 69 %). 1H NMR 
(250 MHz, CDC13): 6 (ppm) = 7.49 (2H, m, ArH), 7.40 (3H, m, ArH), 5.53 (1H, 
s, CH benzyl), 4.96 (1H, d, J = 3.8 Hz, Hi), 4.69 (1H, dd, J0a = 9.5 Hz, Jae = 3.8 
Hz, H2), 4.32 (1H, dd, J = 9.8 Hz, faa = 4.4 Hz, H6a), 4.24 (1H, dd, Joo = 9.4, 
= 9.4 Hz, H4), 3.84 (1H, dd, J, = 9.5, J,. = 4.5 Hz, H6b), 3.74 (1H, dd, J = 
10.6, J. = 9.8 Hz, H3), 3.48 (3H, s, OCH 3), 3.48 (1 H, m, H5), and 2.91 (1H, br 
S, OH). 13C NMR (63 MHz, CDC13): ö = 137.1 (qC, Ar), 129.8, 128.8, 126.7 (3 
x CH, Ar), 102.4 (1CH, CHAr), 98.0 (CH, Cl), 84.6, 81.2, 68.5, 62.4 (4 x CH, 
C2 - CS), 68.9 (CH2, C6), and 56.1 (OCH3). MS (ESI): m/z 414.8 (M+H), 
C15H17F308S requires 414.4. 
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2-Azido-4,6-0-benzylidene-2-deoxy-a-methyl-D-mannopyranoside (6) 1" 1 
Ph---' 	NaN3, DMF Ph '-0 
100°C 	o; 
HO 	
TfOI 	90% 	 I 
5OMe 	 6 OMe 
To a solution of anhydrous DMF (5.0 ml) and NaN3 (1.76 g, 27.0 mmol), was 
added a solution of 5(816 mg, 2.0 mmol) in dry DMF (5.0 ml). The reaction was 
heated to 85 °C with stirring behind a blast shield and heating continued at 85 °C 
for 8 h. Upon cooling to r.t., the white precipitate was filtered off through a plug 
of silica under suction and the solvent was evaporated to dryness. The solid was 
dissolved in DCM, filtered and evaporated under vacuum. Product was purified 
by flash chromatography over silica (1:4 EtOAc/hexane) to afford 6as a pale 
yellow syrup (520 mg, 90 %). 'H NMR (250 MHz, CDC13): 6 (ppm) = 7.54-7.43 
(2H, m, Ar), 7.42-7.31 (3H, m, Ar), 5.48 (1H, s, CH benzyl), 4.59 (1H, s br, Hi), 
4.24-4.05 (2H, m, H5, H6a), 3.82-3.62 (4H, m, H2-H4, H6b), 3.37 (1H, br s, 
OH), and 3.31 (3H, s, OCH 3). 13C NIMR (63 MHz, CDC1 3): 6 (PPM) = 137.2 
(qC, Ar), 129.4 (CH, Ar), 128.5 (2CH, 2 x Ar), 126.5 (2CH, 2 x Ar), 102.3 (CH, 
acetal), 100.1 (CH, Cl), 79.0 (CH), 77.3 (CH 2), 68.6, 63.8, 63.4 (3CH), and 55.1 
(OCH3). MS (ESI): m/z 329.8 (M+Na), C 14H17N305Na requires 330.1. 
1,3 ,4,6-Tetra-O-acetyl-2-azido-2-deoxy-a-D-mannopyranoside (7)141 
OAc 
Ph'9N3 	Ac2H2SO4 ACOL 
-lo 
71 % over 2 steps AcO.'-. 
6 OMe 	 7 OAc 
A solution of 6(532 mg, 1.7 mmol) in Ac 20 (9.9 ml) and sulfuric acid (310 .tL) 
was stirred at room temperature for 2.5 h the reaction mixture was then diluted 
with EtOAc and with sat. aq . NaHCO 3 which was slowly added. The organic 
layer was washed with water, dried (MgSO 4) and concentrated in vacuo. TLC 
and ESI-MS showed that the aq. phase still contained some not fully acetylated 
intermediate, which was resubjected to reaction in the same conditions. Product 
7 as purified by flash chromatography over silica (3/1 petroleum ether/EtOAc) 
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to afford a pale yellow oil (388 mg, 78%). 'H NIvIR (250 MHz, CDC1 3): 6 (PPM) 
= 6.07 (1H, d, J= 1.8 Hz, Hi), 5.33 (2H, m, H3, H4), 4.21 (1H, dd, J = 12.4 Hz, 
J = 4.4 Hz, H6a), 4.07-3.94 (3H, m, H6b, H2, H5), 2.12 (3H, s, COCH 3), 2.07 
(3H, s, COCH3), 2.05 (3H, s, COCH3), and 2.01 (3H, s, COCH 3). 13C NMR (63 
MHz, CDC13): 5 (PPM) = 170.5, 169.9, 169.2, 168.1 (4qC, 4 x COCH3), 91.1 
(CH, Ci), 70.5, 70.4, 65.1, 60.3 (4CH, C2-05), 60.8 (CH 2), 20.7, 20.5, 20.4, and 
20.3 (4CH3, 4 x COCH3). MS (ESI): m/z 396.1 (M+Na), C 14H19 N3O9Na 
requires 396.3. 
3 ,4,6-Tri-O-acetyl-2-azido-2-deoxy-ct-D-mannopyranoside (8)1' 1 
OAc 	 OAc Me2NH, THE 	 N3 
	




7 OAc 	 8 OH 
The peracetylated azidomannose 7 (334 mg, 0.90 mmol) was dissolved in dry 
THF (2.0 ml) with stirring, and cooled at 0 °C. A solution of Me 2NIH in THF 
(0.963 ml, 2.0 M) was then added dropwise, and the reaction was allowed to 
reach r.t. After 2 h, analysis by TLC (2/1 hexane/EtOAc) indicated that the 
reaction was complete, and thus it was concentrated in vacuo. Product 8 was 
purified by flash chromatography over silica (2/1 petroleum ether/EtOAc) to 
afford a colourless syrup (258 mg, 87 %). 1H NMR (300 MHz, CDC13): S (PPM) 
= 5.40 (iH, dd, J00 = 9.9, J = 3.6 Hz, H3), 5.28 (iH, dd, 9.9, J00 = 9.9 Hz, 
H4), 5.21 (iH, d, J = 1.6 Hz, Hi), 4.58 (1H, br s, OH), 4.12 (3H, m, H5, H6a, 
H6b), 4.00 (1H, dd, J = 3.6, J = 1.6 Hz, H2), 2.05 (3H, s, COCH 3), 2.04 (3H, 
s, COCH3), and 1.99 (314, s, COCH3). ' 3C NMR (75 MHz, CDC13): S (PPM) = 
171.2, 170.2, 169.8 (3qC, 3 x COCH 3), 92.6 (CH, Cl), 70.8, 68.2, 66.1 (3CH, 
C3, C4, C5), 62.2 (CH2), 62.0 (CH, C2), 20.7, 20.5, and 20.4 (3CH 3, 3 x 
COCH3). MS (ESI): m/z 354.1 (M+Na), C, 2H, 7 N3O3Na requires 354.1. 
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1,2; 5,6-di-O-isopropylidene-a-D-allofuranose (9)161 
OH 	1. PCC, molec. sieves, DCM 






The 1,2; 5 ,6-di-O-isopropylidene-a-D-allofuranose (2.56 g, 9.84 mmol), powdered 
dried molecular sieves (5.00 g) and pyridinium chlorochromate (6.49 g, 29.5 
mmol) were stirred in dry DCM (30 ml) under nitrogen at room temperature for 
24h. At this point TLC (ether/hexane 1/2) showed complete conversion of the 
starting material (Rf 0.25) to a single product (Rf 0.08). The reaction mixture 
was triturated with ether (30 ml), filtered through a plug of silica topped with 
celite (ether eluant). The solvent was removed in vacuo, the residue dissolved in 
EtOH/water (9/1, 15 ml) and cooled to 0 °C. Sodium borohydride (1.00 g) was 
added and the solution allowed to warm slowly at room temperature. After 3h 
TLC (EtOAc/hexane 1/3) showed the formation of a single product (Rf 0.24) 
and the complete consumption of the starting material (Rf 0.08). The reaction 
was quenched with ammonium chloride until effervescence ceased. The solvent 
was removed in vacuo and the residue dissolved in chloroform (30 ml), and 
washed with water (2 x 30 ml). The organic fraction was dried over magnesium 
sulphate, filtered, and the solvent was removed in vacuo. The residue was 
purified by flash chromatography (EtOAc/hexane 1/3) to give the desired 
product 9 (3.50 g, 82%) as a colourless oil. 'H NMR (300 MHz, CDC13): 6 
(ppm) = 5.60 (1H, d, J— 3.7 Hz, Hl), 4.41 (1H, dd, J = 4.7, J = 3.7 Hz, H2), 
4.11 (1H, ddd, J = 6.6, J = 6.6, J = 4.6 Hz, H5), 3.78-3.90 (3H, m, H3, H4, H6a), 
3.64 (1H, dd, Jr,,, = - 8.5, J = 4.6 Hz, H6b), 2.78 (1H, d, J = 8.5 Hz, OH), 1.38, 
1.26, 1.18 and 1.17 (4 x 3H, s, CH 3). ' 3C NIMR (75 MHz, CDC13): ö (ppm) = 
112.5, 109.5 (2 x qC, C(CH3)2), 103.7 (CH, Cl), 79.4, 79.0, 75.4, 72.2 (4 x CH, 
C2-05), 65.5 (CH2, C6), 26.5, 26.4, 26. 1, and 25.1 (4 x CH 3, C(CH3)3). MS 
(ESI): m/z 283.2 (M+Na)+, C, 2H20N3O6Na requires 283.3. 
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9 	 10 
The diacetone a-D-allofuranose 9(1.00 g, 3.84 mmol) was dissolved in dry DCM 
(12 ml) under nitrogen. Pyridine (629 xl, 7.77 mmol) was added and the 
solution was stirred at - 35 °C for 30 minutes. Triflic anhydride (7710, 4.59 
mmol) was added dropwise with stirring and the mixture allowed to reach -10 
°C. After 2h TLC (ether/hexane 1/3) showed complete conversion of the 
starting material (Rf 0.07) to a single product (Rf 0.32). Methanol (1 ml) was 
added to quench the reaction and the resulting solution warmed to room 
temperature. The solution was washed with water (2 x 10 ml), pH 7 PBS 
solution (10 ml), and the aqueous layer re-extracted with chloroform (10 ml x 2). 
The organic fractions were combined, dried with magnesium sulphate, filtered, 
and the solvent was evaporated in vacuo. The residue was dissolved in DMF (8 
ml) under nitrogen and sodium azide (1.25 g, 19.2 mmol) was added. The 
resulting mixture was heated at 90 °C for 3h with stirring. The mixture was then 
allowed to cool down to room temperature, filtered through a plug of silica 
(DCM ads eluant), and the solvent was removed in vacuo. The residue was 
dissolved in chloroform (10 ml), washed with distilled water (10 ml x 2), and the 
aqueous layers were re-extracted with chloroform (10 ml x 2). The organic 
fractions were combined, dried with magnesium sulphate, filtered and the 
solvent was evaporated in vacuo. The crude product 10 (Rf 0.24 ethyl 
acetate/hexane 1/3) was purified by flash chromatography (DCM/MeOH 20/1) 
to give the desired product (1.07 g, 97%) as a colourless oil. 1H NMR (300 
MHz, CDC13): 5 (PPM) = 5.72 (1H, d, J = 3.6 Hz, Hi), 4.48 (1H, d, J = 3.6 Hz, 
H2), 4.11 (iH, ddd, J = 5.2, J = 5.2, J = 8.0 Hz, H5), 4.00 (1H, dd, J = 5.2, Jgem 
= 
- 8.7 Hz, H6a), 3.98 (1H, d, J= 3.1 Hz, H3), 3.96 (1H, dd, J= 8.0, J= 3.1 Hz, 
H4), 3.83 (1H, dd, J= 4.9, - 8.7 Hz, H6b), 1.33 (3H, s, CH 3), 1.24 (3H, s, 
CH3), 1.19 (3H, s, CH3), and 1.15 (3H, s, CH3). 13C NIvIR (75 MHz, CDC13): 5 
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(ppm) = 112.1, 109.4 (2 x qC, C(CH3)2), 105.0 (CH, Cl), 83.3, 80.4, 72.9 (3 x 
CH, C2, C4, C5), 67.5 (CR2, C6), 66.3 (CH, C4), 26.7, 26.5, 26.0 and 25.0 (4 x 
CR3, C(CH3)2). MS (ESI): m/z 303.2 (M+N}L), C 12H23N405 requires 303.3. 
3-azido-3-deoxy-D-glucose (11)"I 
	




99% 	 OH OHO__'r 
10 	 11 
A solution of the diacetone a-D-glucofuranose 10 (1.00 g, 3.51 mmol) in 2N HC1 
(15 ml) was stirred at room temperature for 24 h. Coevaporation of the solvent 
with toluene (2 x 5 ml) afforded a quantitative yield (719 mg) of the crude 
product as a white solid and as a mixture of the two anomers (Rf 0, ethyl 
acetate/hexane 1/3). 'H NMR (300 MHz, D 20): 5 (ppm) = 4.83 (0.5H, d, fee = 
3.6 Hz, Hla), 4.31 (0.5H, d, J = 7.9 Hz, H13), 3.52-3.27 (3.5H, m), 3.17 (0.5H, 
dd, = 10.2, J = 3.6 Hz, H2u), 3.14-3.04 (1.5H, m) and 2.84 (0.5H, dd, = 
8.0, 	= 9.4 Hz, H2). 13C NMR (75 MHz, CDC13): 5 (ppm) = 96.3, 91.8 (2 x 
CH, Cl), 76.8, 73.1, 71.5, 70.7, 69.0, 68.9, 68.8, 66.2 (8 x CH, C2-05), 61.2 and 
60.7(2 x CM2). MS (ESI): m1z228.3 (M+Na), C 6H,,N305Na requires 228.1. 
Methyl 3-azido-4,6-0-benzylidene-3-deoxy-D-glucopyranoside (12)R01 
1. MCI, MeOH 




N3-\A 	 76% 	
N3 	




Acetyl chloride (150 p.1) was added to a solution of the 3-azido-3-deoxy-D-
glucose 11(1.00 g, 4.88 mmol) in dry MeOH (15 ml) and refluxed for 24h under 
nitrogen. The reaction solution was cooled down to room temperature, 
neutralised with sodium bicarbonate, and the solvent was removed in vacuo. The 
crude was then dissolved in wthyl acetate, passed through a plug of silica (eluant 
ethyl acetate), and the solvent was removed in vacuo to afford a quantitative yield 
(1064 mg) of the crude product as a white solid and as a mixture of the two 
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anomers. Benzaldehyde dimethylacetal (2.74 ml, 17.8 mmol) was added 
dropwise to a solution of the glucopyranoside (1,300 mg, 5.94 mmol) in dry 
DMF (35 ml). The resulting solution was adjusted to pH 4 using 
camphorsulfonic acid, and stirring was continued at room temperature under 
nitrogen. After 3h, pH was neutralised by addition of TEA, and the solvent was 
removed in vacuo. The crude product is purified by flash chromatography 
(haxane/ethyl acetate 1/1) to give 12 as a colourless oil (1,386 mg, 76%). 1H 
NMR (300 MHz, CDC1 3): 5 (ppm) = 7.51 (2H, m, Ar), 7.39 (3H, m, Ar), 5.81 
(1H, s, CHAr), 4.74 (1H, d, J = 3.8 Hz, Hi), 4.35 (1H, dd, J = 4.6, Jgn  = - 10.7 
Hz, H6a), 4.29 (iH, dd, J = 4.6, J = - 10.5 Hz, H6b), 3.81 (1H, m, H5), 3.76 
(1 H, dd, Ja,, = 10. 1, J,4, = 10.1 Hz, H4), 3.72 (1 H, dd, J,4, = 10. 1, J4, = 10.1 Hz, 
H3), 3.55 (1H, m, H2), 3.47 (3H, s, OCH 3), and 2.71 (1H, s (br), OH). 13C NMR 
(75 MHz, CDC1 3): 5 (PPM) = 136.8 (iqC, Ar), 129.1, 128.3, 126.1 (3CH, 3 x 
ArH), 101.5 (CH, CHAr), 99.3 (CH, Cl), 79.6, 71.7, 63.5, 62.7 (4CH, C2, C3, 
C4, C5), 68.9 (CR2), and 55.6 (OCR 3). MS (ESI): m/z 330.4 (M+Na), C 14H17 
N305Na requires 330.1. 
Methyl 	 (13) 
TfO, pyr, DCM 
CsAc, toluene 
Ph- c9 	18-crown -6 	Ph''O 	OAc 
0 N3 	
OH 	69% 
OMe 	 OMe 
12 13 
The methyl a-D-glucopyranoside 12 (257 mg, 0.837 mmol) was dissolved in dry 
DCM (5 ml) under nitrogen. Pyridine (135 il, 1.67 mmol) was added and the 
solution was stirred at - 35 °C for 30 minutes. Triflic anhydride (162 pI,  0.963 
mmol) was added dropwise with stirring and the mixture allowed to reach -10 
°C. After 2h, methanol (1 ml) was added to quench the reaction and the 
resulting solution warmed to room temperature. The solution was washed with 
water (5 ml), pH 7 PBS solution (5 ml), and the aqueous layer re-extracted with 
chloroform (5 ml x 2). The organic fractions were combined, dried with 
magnesium sulphate, filtered, and the solvent was evaporated in vacuo. The 
residue was dissolved in toluene (5 ml); cesium acetate (241 mg, 1.26 mmol), 
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and 18-crown-6 (332 mg, 1.26 mmol) were added, and the resulting solution was 
refluxed for 2 h. After cooling down to room temperature, the solvent was 
removed in vacuo, the residue redissolved in DCM (10 ml), and washed with 
water (2 x 10 ml). The organic fractions were combined, dried (magnesium 
sulphate), and evaporated to dryness. Column chromatography (pet. Ether/ethyl 
acetate 3/2) afforded the product 13 as an off-white solid (201 mg, 69%). 1H 
NMR (300 MHz, CDC13): 5 (ppm) = 7.50 (2H, m, ArH), 7.38 (3H, m, ArH), 
5.67 (1H, s, CHAr), 5.17 (1H, dd, 3.1, Jee = 1.6 Hz, H2), 4.66 (1H, d, J = 
1.6 Hz, Hi), 4.31 (1H, dd, J = 2.9, J,,, = - 8.5 Hz, H6a), 4.07 (1H, m, H5), 4.00 
(1H, dd, Jaa = 10.3, J = 3.2 Hz, H3), 3.91 (1H, m, H6b), 3.86 (1H, dd, J = 
10.3, J. = 10.3 Hz, H4), 3.40 (3H, s, OCH 3), and 2.18 (3H, s, COCH 3). 13C 
NMR (75 MHz, CDC13): 5 (ppm) = 169.8 (lqC, COCH3), 136.9 (lqC, Ar), 
129.1, 128.3, 126.0 (3CH, 3 x Ar), 101.8 (1CH, CHAr), 98.8 (1CH, Cl), 77.2 
(1CH, C2), 70.9 (1CH, C5), 68.8 (CH 2), 63.8 (1CH, C4), 57.9 (CH, C3), 55.3 
(OCH3), and 20.9 (1CH3 , COCH3). JR (Vmax , thin film): 2995, 2978, 2926, 2948, 
2105, 1740, 1470, 1447, 1425, 1368, 1261, 1227, 1128, 1086, 1041, 1010, 974, 
909, 884, 747, 697. HR-MS (ESI): m/z 350.13405 (M+H) , C14H21N309 
requires 350.13521 (error: 3.31 ppm). 
1 ,2,4,6-tetra-O-acetyl-3-azido-3-deoxy-a-D-mannopyranoside (14) 
OAc 
Ph' 	 OAC 	Ac20, AcOH, H2SO4 	 OAc 
	
91 
0°C - r.t. 	AcO I
------- A.- 	--t~ 
74% 
We 	  
13 	 14 
The methyl a-D-mannopyranoside 13 (302 mg, 0.865 mmol) was dissolved in 
acetic anhydride (6.0 ml), and the solution was cooled down to 0 °C. 
Concentrated H2SO4 (175 0) was added dropwise and the reaction was allowed 
to come to room temperature by removal of the ice bath. Stirring was continued 
overnight. The reaction mixture was then diluted with chloroform (5 ml), cooled 
to 0 °C with an ice bath, and neutralised with sat. aq . NaHCO3 (careful!), which 
was slowly added. The organic layer was washed with distilled water (5 ml x 2), 
dried (MgSO4) and concentrated in vacuo. The product 14 was purified by flash 
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chromatography over silica (3/2 petroleum ether/EtOAc, Rf 0.3) to afford a pale 
yellow oil (242 mg, 74%). 'H NMR (300 MHz, CDC1 3): 5 (ppm) = 6.01 (1H, d, 
1.8 Hz, Hi), 5.27 (1H, dd, .J, = 10.4, J,4, = 10.4 Hz, H4), 5.14 (1H, dd, Jae = 
3.3 fee = 1.9 Hz, H2), 4.20 (iH, dd, J = 5.0, J = - 12.4 Hz, H6a), 4.04 (1H, dd, 
J = 2.6, J = - 12.4 Hz, H6b), 3.95 (1H, ddd, J = 10.4, J = 5.0, J = 2.5 Hz, 
H5), 3.81 (1 H, dd, = 10.4, J = 3.3 Hz, H3), 2.13 (3H, s, COCH 3), 2.10 (3H, 
s, COCH3), 2.09 (3H, s, COCH3), and 2.04 (3H, s, COCH 3). 13C NMR (75 
MHz, CDC13): 5 (PPM) = 170.6, 169.5, 169.4, 167.8 (4qC, 4 x COCH 3), 89.8 
(CH, Cl), 70.4, 69.4, 66.2 (3CH, C2, C4, CS), 62.1 (CH 2), 58.6 (CH, C3), 20.7, 
20.7, 20.6, and 20.6 (4CH3, 4 x COCH3). IR (Vmax , thin film): 3027, 2110, 1749, 
1435, 1372, 1214, 1148, 1048, 1026, 973, 754. HR-MS (ESI): mlz 396.10098 
(M+Na), C,,H,9N3O9Na requires 396.10190 (error: 2.32 ppm). 
2,4,6-Tri-O-acetyl-3-azido-3-deoxy-a-D-mannopyranoside (15) 
OAC 	 OAc 
OAc 	BnNH2, THE 	 OAc 




14 	 15 
The peracetylated azidomannose 14 (247 mg, 0.66 mmol) in dry THF (3.5 ml) 
was treated with benzylamine (86 p1) under nitrogen. The reaction mixture was 
warmed to 50 °C and stirring continued for 24 h under nitrogen. The solvent 
was then removed under reduced pressure and the crude product purified by 
flash chromatography over silica (3/2 pet. ether/EtOAc) to afford 15 as a 
colourless oil (186 mg, 85 %). 'H NMR (300 MHz, CDC1 3): S (ppm) = 5.22 
(1H, dd, J,,, = 10. 3, J = 10. 3, H4), 5.15 (1H, d, .J., = 1. 7, Hi), 5.10 (1H, dd, J., = 
1.7, J = 3.2, H2), 4.39 (1H, s (br), OH), 4.19-4.05 (3H, m, H6a, H6b, HS), 3.85 
(1H, dd, J, = 10.3, J = 3.2, H3), 2.10 (3H, s, COCH3), 2.08 (3H, s, COCH 3), 
and 2.06 (3H, s, COCH 3). 13C NMR (75 MHz, CDC13): 5 (PPM) = 171.0, 170.3, 
169.9 (3qC, 3 x COCH3), 91.3 (CH, Cl), 71.4, 68.3, 66.9 (3CH, C2, C4, C5), 
62.6 (CH2), 58.3 (1CH, C3), 21.0, 20.8 and 20.7 (3CH 3 , 3 X COCH3). JR (Vmax , 
thin film): 3430, 3024, 2960, 2111, 1749, 1651, 1432, 1373, 1225, 1121, 1048, 
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974, 756. HR-MS (ESI): m/z 354.09178 (M+Na) , C12H17 N308Na requires 




OH 	1. Ph2tBuSiCI, imidazole, DMF 
HO L 	
2. Me2C(OM:)2, CSA, acetone HO
j 
HO 
OMe 	 16 OMe 
Tert-butylchlorodiphenylsilane (10.43 g, 37.9 mmol) was added dropwise to a 
stirred solution of the methyl a-D-mannopyranoside (6.70 g, 34.5 mmol) and 
imidazole (5.17 g, 75.9 mmol) in DMF (140 ml) under nitrogen at room 
temperature. After 2h, TLC (methanol/EtOAc 1/9) showed the loss of starting 
material (Rf 0.1) and the formation of a major product (Rf 0.6). The reaction 
solvent was removed, the residue dissolved in chloroform (100 ml), and washed 
with HO 0.1 M (100 ml), and water (100 ml). The aqueous fractions were re-
extracted with chloroform (2 x 30 ml). The organic fractions were combined, 
dried over magnesium sulphate, filtered, and the solvent was removed in vacuo. 
The residue (12.0 g, 27.8 mmol) was dissolved in a solution of 2,2-dimethoxy-
propane in acetone (1:9 v/v 125 ml) and the resulting solution adjusted to pH 4 
using camphorsulfonic acid. The reaction solution was stirred under nitrogen at 
room temperature. After 2h, TLC (hexane/EtOAc 1/3) showed the loss of 
starting material and the formation of a major product. The solution was 
neutralised using aqueous ammonia solution (d = 0.880) and the solvent 
removed in vacuo, the residue dissolved in chloroform (100 ml), and washed 
water (2 x 100 ml). The aqueous fractions were re-extracted with chloroform (2 x 
30 ml). The organic fractions were combined, dried over magnesium sulphate, 
filtered, and the solvent was removed in vacuo. The residue was purified by flash 
chromatography (hexane/EtOAc 1/3) to give the desired product 16 (12.2 g, 
96%) as a colourless oil. 1H NIMR (300 MHz, CDC13): 5 (ppm) = 7.72 (4H, m, 
Ar), 7.39(6H, m, Ar), 4.89 (1H, d, Hi), 4.15 (1H, dd, J = 6.0, J = 6.0 Hz, H3), 
4.12 (1H, dd, J = 6.0 Hz, H2), 3.94 (iH, dd, Jgn = - 10.8, J = 4.8 Hz, H6a), 3.89 
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(1H, dd, J = - 10. 8, J = 4.9 Hz, H6b), 3.79 (1H, ddd, Jaa = 9.4, J, = 6. 0, JOH = 
3.5 Hz, H4), 3.63 (1H, ddd, J = 9.5, J = 4.8, J = 4.9 Hz, H5), 3.35 (3H, s, 
OCH3), 2.91 (1H, d, J4,OH = 3.5 Hz, OH), 1.51, 1.35, (2 x 3H, s, 2 x C(CH 3)), and 
1.07 (9H, s, SiC(CH 3)3). 13C NMR (75 MHz, CDC13): 6 (PPM) = 135.7 (CH, Ar), 
135.6 (CH, Ar), 133.1 (qC, Ar), 129.8 (CH, Ar), 127.8 (CH, Ar), 109.5 (qC, 
C(CH3)2), 98.3 (CH, Cl), 78.3, 75.3, 70.5, 69.6 (4CH, C2-05), 64.6 (CH2), 54.9 
(OCR3), 27.9 (CH3, C(CH3)), 26.8 (3CH3, SiC(CH3)), 26.1 (CH3, C(CH3)), and 
19.2 (qC, SiC(CH3)3). MS (ESI): m/z 495.5 (M+Na), C26H3606SiNa requires 
495.6. 
Methyl 6-O-te,-butyldiphenylsylyl-2,3-O-isopropylidene-a-D-talopyranoside (17)" 
ODPTBS 	 \I ,..ODPTBS 
1. PCC, molec. sieves, DCM HO 
HO L 	
2. NaB H4 , EtOH/H20 	 ijj-o 
90% 
16 OMe 	 17 OMe 
The methyl a-D-mannopyranoside 16 (3.88 g, 8.21 mmol), powdered dried 
molecular sieves (5.61 g) and pyridinium chlorochromate (5.42 g, 25.2 mmol) 
were stirred in dry DCM (27 ml) under nitrogen at room temperature for 5h. At 
this point TLC (ether/hexane /2) showed complete conversion of the starting 
materila (Rf 0.3) to a single product (Rf 0.5). The reaction mixture was 
triturated with ether (50 ml), filtered through a plug of silica topped with celite 
(ether eluant). The solvent was removed in vacuo, the residue dissolved in 
EtOH/water (9/1) and cooled to 0 °C. Sodium borohydride (570 mg) was 
added and the solution allowed to warm slowly at room temperature. After 3h 
TLC (EtOAc/hexane 1/3) showed the formation of a single product (Rf 0.4) and 
the complete consumption of the starting material (RI 0.5). The reaction was 
quenched with ammonium chloride until effervescence ceased. The solvent was 
removed in vacuo and the residue dissolved in chloroform (40 ml), and washed 
with water (2 x 40 ml). The organic fraction was dried over magnesium 
sulphate, filtered, and the solvent was removed in vacuo. The residue was 
purified by flash chromatography (EtOAc/hexane 1/3) to give the desired 
product 17 (3.50 g, 90%) as a colourless oil. 1H NMR (300 MHz, CDC1 3): 5 
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(ppm) = 7.70 (4H, m, Ar), 7.36 (6H, m, Ar), 4.97 (1H, d, Hi), 4.19 (1H, dd, J= 
6.2, J= 5.5 Hz, H3), 4.05 (1H, dd, J = 6.2 Hz, H2), 3.95 (1 H, dd, J = 6.5, J, = - 
10.3 Hz, H6a), 3.90 (1H, dd, J = 5.8, J = -10.3 Hz, H6b), 3.84 (1H, m, H4), 
3.81 (1H, ddd, J = 6.5, J = 5.8, J = 5.5 Hz, H5), 3.36 (3H, s, OCH3), 2.39 (1H, d, 
J = 6.4 Hz, OH), 1. 55, 1.35, (2 x 3H, s, 2 x C(CH 3)), and 1.06 (9H, s, SiC(CH 3)3). 
' 3C NIIv1R (75 MHz, CDC13): 5 (PPM) = 135.6 (CH, Ar), 135.5 (CH, Ar), 133.3 
(qC, Ar), 129.8 (CH, Ar), 127.8 (CH, Ar), 109.3 (qC, C(CH 3)2), 98.5 (CH, Cl), 
77.6, 73.7, 72.7, 69.5 (4 x CH, C2-05), 63.5 (CH2), 54.9 (OCH3), 26.9 (3CH3 , 
SiC(CH3)), 25.9, 25.3 (2 x CH3 , C(CH3)2), and 19.2 (qC, SiC(CH3)3). MS (ESI): 




ODPTBS 	 (ODPTBS 
1. TfO, pyr, DCM 
- 	 2. NaN3 , DMF 	N 
90% 
17 OMe 	 18 We 
The methyl a-D-mannopyranoside 17 (3.94 g, 8.32 mmol) was dissolved in dry 
DCM (80 ml) under nitrogen. Pyridine (2.7 ml, 33.28 mmol) was added and the 
solution was stirred at - 35 °C for 30 minutes. Triflic anhydride (1.62 ml, 9.65 
mmol) was added dropwise with stirring and the mixture allowed to reach -10 
°C. After 2h TLC (ether/hexane 1/3) showed complete conversion of the 
starting material (PS 0.4) to a single product (Rf 0.5). Methanol (1 ml) was 
added to quench the reaction and the resulting solution warmed to room 
temperature. The solution was washed with water (100 ml), pH 7 PBS solution 
(100 ml), and the aqueous layer re-extracted with chloroform (30 ml x 2). The 
organic fractions were combined, dried with magnesium sulphate, filtered, and 
the solvent was evaporated in vacuo. The residue was dissolved in DMF (31 ml) 
under nitrogen and sodium azide (2.16 g, 33.28 mmol) was added. The resulting 
mixture was heated at 90 °C for 3h with stirring. The mixture was then allowed 
to cool down to room temperature, filtered through a plug of silica (]JCM ads 
eluant), and the solvent was removed in vacuo. The residue was dissolved in 
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chloroform (100 ml), washed with distilled water (100 ml x 2), and the aqueous 
layers were re-extracted with chloroform (30 ml x 2). The organic fractions were 
combined, dried with magnesium sulphate, filtered and the solvent was 
evaporated in vacuo. The crude product 18 (Rf 0.6 ethyl acetate/hexane 1/3) 
was purified by flash chromatography (DCM/MeOH 20/1) to give the desired 
product (3.72 g, 90%) as a colourless oil. 'H NMR (300 MHz, CDC1 3): 5 (PPM) 
= 7.88-7.80 (4H, m, Ar), 7.47-7.43 (6H, m, Ar), 5.07 (1H, d, Hi), 4.30 (1H, dd, J 
= 8. 1, J = 5.4 Hz, H3), 4.19 (1H, dd, J = 5.4 Hz, H2), 3.99 (2H, m, H6a, H6b), 
3.89 (1H, dd, J = 10.6, J = 8.4 Hz, H4), 3.57 (1H, ddd, J 10.5, J = 2.8, J = 2.8 
Hz, H5) 3.39 (3H, s, OCH3), 1.66, 1.51 (2 x 3H, s, C(CH3)2), and 1.19 (9H, s, 
SiC(CH3)3). 13C NMR (75 MHz, CDC13): S (PPM) = 135.8 (2 x CH, Ar), 133.3 (2 
x qC, Ar), 129.9 (2 x CH, Ar), 127.8 (2 x CH, Ar), 110.0 (qC, C(CH 3)2), 98.3 
(CH, Cl), 76.9, 75.0, 69.0 (3 x CH, C2, C3, C5), 63.3 (CH 2), 60.7 (CH, C4), 54.9 
(OCH3), 28.3 (2 x CH3, C(CH3)2), 26.9 (3CH 3 , SiC(CH3)), and 19.5 (qC, 
SiC(CH3)3). MS (ESI): m/z 520.4 (M+Na), C26H35N305SiNa requires 520.7. 
Methyl 4-azido-4-deoxy-2,3-0-isopropylidene-a-D-mannopyranoSide (19)" 
(0 DPTBS 	 (OH 
N3 j 	1. BuNFITHF 	N 3- j 
18 We 	 19 We 
The methyl a-D-mannopyranoside 18 (1.12 g, 2.25 mmol) was dissolved in dry 
THF (12.5 ml) under nitrogen. A 1.0 M solution of tetrabutylammonium 
fluoride (TBAF) in T}IF was slowly added (4.4 ml), and stirring was continued 
under nitrogen. After lh TLC (ether/hexane 3/1) showed complete conversion 
of the starting material (Rf 0.5) to a single product (Rf 0.1). The solvent was 
evaporated in vacuo. The residue was dissolved in chloroform (20 ml), washed 
with distilled water (20 ml x 2), and the aqueous layers were re-extracted with 
chloroform (10 ml x 2). The organic fractions were combined, dried with 
magnesium sulphate, filtered and the solvent was evaporated in vacuo. The crude 
product 19 was purified by flash chromatography (ether/hexane 3/1) to give the 
desired product (513 mg, 88%) as a colourless oil. 1 H NMR (300 MHz, CDC13): 
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5 (ppm) = 4.88 (1H, d, Hi), 4.15 (1H, dd, J = 8. 0, J = 5.4 Hz, H3), 4.01 (1H, dd, 
J = 5.4 Hz, H2), 3.77 (1H, dd, J = 2.4, J = - 12.1 Hz, H6a), 3.66 (1H, dd, J 
4.2, J, = - 12.1 Hz, H6b), 3.49 (1H, dd, J = 10.5, J = 8.0 Hz, H4), 3.38 (1H, 
ddd, J = 10. 5, J = 4.2, J = 2.4 Hz, H5) 3.29 (3H, s, OMe), 2.68 (1H, br s, OH), 
1.48 (3H, s, C(CH3)), and 1.29 (3H, s, C(CH 3)). 13C NIvIR (75 MHz, CDC1 3): 5 
(ppm) = 110.0 (lqC, 4 x C(CH 3)), 98.1 (CH, Cl), 76.7, 74.0, 68.3 (3 x CH, C2, 
C3, C5), 61.7 (CH2), 60.4 (CH, C4), 55.0 (OCH3) 28.1, and 26.1 (2 x CH3 , 
C(CH3)2). MS (ESI): m/z 282.3 (M+Na), C 10H17N305Na requires 282.3. 
1,2,3 ,6-O-tetraacetyl-4-azido-4-deoxy-a-D-mannopyranoside (20) 
'LL 	1. TFA, water/dioxane 	
AC 	OAc 
N3 7A~~ C - r.t. 	 N3 41 
19 OMe 	 20 OAc 
The methyl a-D-mannopyranoside 19 (750 mg, 2.90 mmol) was dissolved in 0.3 
ml 1,4-dioxane and aqueous TFA (TFA/water 1/1, 10 ml), and stirring was 
continued at room temperature. After ih TLC (ether/hexane 3/1) showed 
complete conversion of the starting material (Rf 0.1) to a single product (Rf --0). 
The solvent was co-evaporated with toluene (5 ml x 2) to dryness in vacuo. The 
residue was dissolved in acetic anhydride (16.5 ml), and the solution was cooled 
down to 0 °C. Concentrated H2SO4 (0.5 ml) was added dropwise and the 
reaction was allowed to come to room temperature by removal of the ice bath. 
Stirring was continued overnight. The reaction mixture was then diluted with 
chloroform (10 ml), cooled to 0 °C with an ice bath, and neutralised with sat. aq . 
NaHCO3 (careful!), which was slowly added. The organic layer was washed 
with distilled water (20 ml x 2), dried (MgSO 4) and concentrated in vacuo. The 
product 20 was purified by flash chromatography over silica (3/2 petroleum 
ether/EtOAc, Rf 0.3) to afford a pale yellow oil (702 mg, 65% over two steps). 
'H NIMR (300 MHz, CDC1 3): S(ppm) = 5.98 (1H, d, Jee = 1.8 Hz, Hi), 5.19 (1H, 
dd, J = 9.7, J = 3.4 Hz, H3), 5.16 (iH, dd, J€ = 3.4, Jee = 1.8 Hz, H2), 4.28 
(iH, dd, J = 2.5, J = - 12.3 Hz, H6a), 4.23 (1H, dd, J = 4.0, J = - 12.3 Hz, 
H6b), 3.84 (1H, dd, J4, = 10.5, J,4,= 9.7 Hz, H4), 3.75 (lH, ddd, J = 10.5, J = 
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4.0, J = 2.5 Hz, H5), 2.10, 2.08, 2.05, and 2.02 (4 x 3H, s, COCH3). ' 3C NMR 
(63 MHz, CDC13): 5 (PPM) = 169.8, 169.6, 169.5, 168.1 (4 x qC, COCH 3), 90.5 
(CH, Cl), 68.4, 67.7, 67.5 (3 x CH, C2, C3, C5), 62.8 (CH 2), 56.5 (CH, C4), 
20.8, 20.7, 20.7, and 20.6 (4 x CH 3 , COCH3). JR (v, thin film): 3022, 2958, 
2113, 1749, 1434, 1371, 1235, 1154, 1077, 1022, 977, 903, 756, 700. HR-MS 
(ESI): m/z 396.10098 (M+Na), C 14H19 N309Na requires 396.10190 (error: 2.32 
ppm). 
2,3 ,6Tri-O-acety1-4-azido-4-deoxy-a-D-mannOpyraflOSide (21) 




20 OAc 	 21 OH 
The peracetylated azidomannose 20 (700 mg, 1.88 mmol) in dry THF (10.0 ml) 
was treated with benzylamine (246 p1) under nitrogen. The reaction mixture was 
warmed to 50 °C and stirring continued for 24 h under nitrogen. The solvent 
was then removed under reduced pressure and the crude product purified by 
flash chromatography over silica (3/2 pet. ether/EtOAc) to afford 21 as a 
colourless oil (523 mg, 84 %). 'H NMR (300 MHz, CDC1 3): 5 (ppm) = 5.34 
(1H, dd, J. = 10.3, J 3.2 Hz, H3), 5.23 (1H, dd, J€ = 3.1, Je, = 1.8 Hz, H2), 
5.19 (1H, d, Jee = 1.6, Hi), 4.39 (1H, dd, J= 2.2, J = - 12.3 Hz, H6a), 4.26 (iH, 
dd, J= 4.6, J = - 12.3 Hz, H6b), 3.99 (1H, ddd, .J = 10. 5, J = 4.5, J = 2.2 Hz, 
H5), 3.93 (iH, br s, OH), 3.82 (1H, dd, J = 10.3, J, = 10.3 Hz, H4), 2.14, 2.12, 
and 2.07 (3 x 3H, s, COCH3). ' 3C NMR (75 MHz, CDC13): S (PPM) = 170.9, 
170.0, 169.8 (3 x qC, COCH3), 92.2 (CH, Ci), 70.2, 69.3, 68.7 (3 x CH, C2, C3, 
C5), 63.4 (CH2), 57.0 (CH, C4), 20.8 (3 x CH 3, COCH3). JR (v,,,, thin film): 
3443, 3022, 2958, 2113, 1748, 1646, 1434, 1371, 1235, 1154, 1121, 1075, 903, 
796, 756, 700. HR-MS (ESI): m/z 354.09047 (M+Na), C, 2H17 N3O8Na requires 
354.09133 (error: 2.43 ppm). 
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mCPBA, - 40°C - r.t. 
44% 
AcO 	-+° 
AcO 	 9 
22 6'0j< 
A solution of the hemiacetal 4 (1.55 g, 4.67 mmol) in anhydrous DCM (50 ml) 
was added to a flask containing 1-H-tetrazole (1.63 g, 23.4 mmol) under Ar and 
stirred at r.t for 10 mm. NN-diisopropyl-di-tert-butyl phosphoramidite (3.73 ml, 
11.2 mmol) was then added dropwise and stirring continued for a further 5 h at 
r.t. The reaction mixture was then cooled -40 °C and m-CPBA (4.68 g, 23.4 
mmol) was added. The reaction was then allowed to come slowly to room 
temperature over aprox. 1 h. The reaction was then diluted with DCM (100 ml) 
and washed with 10 % aq. NaHS0 3 (2 x 100 ml), sat. aq. NaHCO3 (2 X 100 ml) 
and water (2 x 100 ml). The organic phase was then separated, dried with 
Na2SO4 , filtered and evaporated to afford the crude product as an off white solid 
that was purified by flash chromatography over silica (1:1 - 2:1 EtOAc / pet. 
ether). Subsequent chromatography over silica (7/1 EtoAc / pet. Ether) 
separated the desired product from the contaminants PHO (OtBu)2 and 
PHO(OtBu)NiPr. The purified a-monophosphate ditetrabutyl-2,3,4-0-acetyl-6-
azido methyl-D-mannopyranoside 22 was isolated as a white solid (1.07 g, 44 %). 
'H NMR (250 MHz, CDC13): 8 = 5.52 (1H, dd, J,, = 1.8, JH.P = 7.3 Hz, Hi), 
5.33 (1H, dd, J1, = 9.3, J 3.0 Hz, H3), 5.31 (1H, dd, J = 3.0, fee = 2.0 Hz, 
H2), 5.27 (1H, dd, J = 9.3, J = 9.3 Hz, H4), 4.12 (1H, ddd, J = 9.4, J— 5.3, J 
= 3.1 Hz, H5), 3.35 (1H, dd, J = 3. 1, J, = - 13.1 Hz, H6a), 3.28 (1H, dd, J 
5.3, Jr,,, = - 13.2 Hz, H6b), 2.12 (3H, s, OCH 3), 2.00 (3H, s, OCH 3), 1.94 (3H, s, 
OCH3), 1.71 (18H, s, 2 x t-Bu). 13C NMR (63 MHz, CDC1 3): ö = 170.1, 170.0, 
170.0 (qC, 3 x OAc), 94.4 (1CH, Cl), 84.2 (qC, tBu), 71.5, 69.3, 68.6, 66.8 
(4CH, C-2, C-3, C-4, C-5), 51.3 (CH 2, C6), 30.1 (6xCH 3 , t-Bu) and 21.0 (3x CH3 , 
Ac) . 31P NMR (101 MHz, CDC13): 5 (ppm) = -11.6. MS m/z (ESI): 546.2 MNa 
C20H34N30 11NaP requires 546.5. 
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A solution of the hemiacetal 4 (266 mg, 0.80 mmol) in dry DCM (20.0 ml) was 
added to a flask with 1-H-tetrazole (280 mg, 4.0 mmol) under Ar and stirred at 
room temperature for 10 minutes. Di-allyl-NN-diisopropyl-phosphoramidite 
(510 p.L, 1.9 mmol) was then added dropwise and stirring was continued for 
further 4.5 h at room temperature. The reaction mixture was then cooled at 
- 40 °C and m-chloroperbenzoic acid (MCPBA, 690 mg, 4.0 mmol) was added. 
The reaction was allowed to come slowly to room temperature over 
approximately 111, then it was diluted with DCM (15.0 ml) and washed with 10 
% NaHS0 3 (2 x 15.0 ml), sat. aq. NaHCO 3 (2 x 15.0 ml), and water (2 x 15.0 
ml). The organic phase was separated, dried (Na 2SO4), and evaporated to afford 
the crude as an off-white solid that was purified by flash chromatography over 
silica (1:1 - 2:1 EtOAc/petroleum ether). NMR and ES-MS analysis revealed 
contamination by PHO(OAll)2 which was successfully removed by further 
column chromatography over silica (7:1 EtOAc/petroleum ether). The purified 
a-monophosphate 23 was isolated as a colourless syrup (240 mg, 72 %). 'H 
NMR (250 MHz, CDC1 3): 5 (PPM) = 5.96-5.80 (2H, m, 2 x CH allyl), 5.57 (1H, 
dd, J = 1.0, JH-P = 5.6 Hz, Hi), 5.35 (lH, dd, J= 10.0 Hz, H3), 5.28-5.19 (5H, 
m, H2, 2 x CH2 allyl), 4.56-4.50 (5H, m, H4, 2 x PO-CH2), 4.06 (lH, m, H5), 
3.36 (1H, dd, J, = - 13.5, J = 2.8 Hz, H6a), 3.28 (iH, dd, - 13.5, J = 5.5 
Hz, H6b), 2.08 (3H, s, COCH 3), 2.02 (3H, s, COCH 3), and 1.96 (3H, s, 
COCH3). 13C NMR (63 MHz, CDC13): 5 (PPM) = 169.7, 169.5, 169.4 (3qC, 3 x 
COCH3), 131.9, 131.8 (2CH, 2 x CH allyl, Jcp = 6Hz), 118.9, 118.7 (2CH 2 , 2 x 
CH2 allyl), 94.6 (C 1, 	= 6 Hz), 71.5, 68.6, 67.9, 66.1 (4CH, C2-05), 68.8, 68.5 
(2CH2 , 2 x CH2 vinyl, 	= 5 Hz), 50.6 (CH2), 20.6, 20.5, and 20.4 (3CH 3 , 3 x 
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COCH3). 31 P NMR (101 MHz, CDC1 3): 5 (ppm) = -1.8. IR (v, thin film): 
2960, 2950, 2856, 2103, 1751, 1632, 1454, 1425, 1370, 1242, 1224, 1159, 1071, 
1040, 1020, 980, 971, 960, 882, 820, 746 cm'. HR-MS (ESI): m/z 492.13834 
(M+}{)4 , C18H27N30 11P requires 492.139492 (error: 2.34 ppm). 












A L O 
11 
24 HOOH 
Trifluoroacetic acid (11.0 ml) was added to the t-butyl protected phosphate 22 
(774 mg, 1.48 mmol) and the reaction mixture stirred at r.t. for 25 mm. The 
excess TFA was then removed under reduced pressure and the crude product 
coevaporated with toluene. ES-MS analysis confirmed the presence of 2,3,4-Tn-
0-acetyl-6-azido-6-deoxy-a-D-mannopyranose which was extracted from the 
product with DCM. The aqueous phase was then freeze-dried to afford the 6-
azidomannose-1-phosphate 24 as a pale yellow syrup (247 mg, 41 %) that was 
used without further purification. 1 H NMR (250 MHz, CDC13): 8 = 9.08 (2H, s 
br, P(OH)2), 5.60 (1H, d, JHP = 6.2, Hi), 5.45 (1H, dd, J,. = 10.0, J = 3.0, H3), 
5.37 (2H, m, H2, H4), 4.20 (1H, m, H5), 3.52 (1H, m, H6a) 3.33 (1H, m, H6b), 
2.14 (3H, s, OCH3), 2.05 (3H, s, OCH 3), 1.99 (3H, s, OCH3). 13C NMR (63 
MHz, CDC1 3): ö = 170.2, 170.0, 169.8 (qC, 3 x OAc), 91.8 (CH, C-i), 69.8, 
69.6, 68.5, 67.0 (4CH, C2 - C5), 51.0 (CH 2 , C6) and 20.7, 20.6 (3CH 3, Ac) . 31P 
NMR (101 MHz, CDC1 3): 5 (ppm) = -0.38. mlz (ESI): 410.0 [M—H] 
C 12H 17N3011P requires 410.3. 
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9 * TEA 
Q—P\ 
25 HOOH 
To a 100 ml round bottom flask containing 23 (384 mg, 0.78 mmol), under Ar, 
were added: a solution of thy 1:1 THF/MeOH (32.0 ml), p-toluensulfinic acid 
sodium salt (278 mg, 1.56 mmol), and tetrakis-triphenyiphosphine palladium (68 
mg, 0.06 mmol). The reaction mixture was stirred under Ar for 6.5 h, 
concentrated in vacuo and coevaporated with toluene (3 x 20.0 ml). The crude 
was resuspended in a mixture of 5:2:1 MeOH/H 20/TEA (40.0 ml), and stirred 
at room temperature for 18 h. The solution was filtered to remove a black 
precipitate, then concentrated in vacuo. The resulting syrup was dissolved in 
water and washed with DCM (3 x 50.0 ml) to remove organic products. The aq. 
layer was then concentrated and coevaporated with toluene (3 x 25.0 ml) to 
afford 25 as a pale yellow foam (339 mg, 86 % considering the bis-
triethylammonium salt). 'H NMR (250 MHz, CDC1 3): 5 (ppm) = 5.21 (1H, d, J 
= 1.7 Hz, Hi), 3.86-3.78 (3H, m, H2-4), 3.64-3.45 (3H, m, H5, H6ab), 3.06 (6H, 
s, N(CH2CH3)3), and 1.14 (9H, s, N(CH2CH3)3). 13C NMR (63 MHz, CDC13): 5 
(ppm) 95.1 (d, Cl, Jp = 4 Hz), 71.4, 70.8, 69.7, 67.3 (4CH, C2-05), 51.1 
(CH2), 46.5 (N(CH2CH3)3), and 8.2 (N(CH2CH3)3). 31P NMR (101 MHz, 
CDC13): 5 (ppm) = +1.9. HR-MS (EST): m/z 284.02894 (M–H), C 12H17N3011 P 
requires 284.02838 (error: 1.97 ppm). 
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mCPBA, - 40°C - r.t. 
46% 
Ac 0" N3 
Ac0 I 	0 AcO 
11 
26 00 
A solution of the hemiacetal 11 (456 mg, 1.38 mmol) in dry DCM (15.0 ml) was 
added to a flask with 1-H-tetrazole (482 mg, 6.88 mmol) under Ar and stirred at 
room temperature for 10 minutes. Di-allyl-NN-diisopropyl-phosphoramidite 
(169 .iL, 0.63 mmol) was then added dropwise and stirring was continued for 
further 4 h at room temperature. The reaction mixture was then cooled at -40 °C 
and m-chloroperbenzoic acid (MCPBA, 1.19 g, 6.88 mmol) was added. The 
reaction was allowed to come slowly to room temperature over approximately 1 
h, then it was diluted with DCM (15.0 ml) and washed with 10 % NaHS0 3 (2 x 
15.0 ml), sat. aq . NaHCO3 (2 x 15.0 ml), and water (2 x 15.0 ml). The organic 
phase was separated, dried (Na 2SO4), and evaporated to afford the crude as an 
off-white solid that was purified by flash chromatography over silica (1:1 - 2:1 
EtOAc/petroleum ether). NMR and ES-MS analysis revealed contamination by 
PHO(OAII)2 as well as the 3 isomer (34 mg, 5%) of the desired product; both 
contaminants were successfully removed by further column chromatography 
over silica (7:1 EtOAc/petroleum ether). The purified a-monophosphate 6 was 
isolated as a colourless syrup (310 mg, 46 %). 'H NMR (300 MHz, CDC1 3): 5 
(ppm) = 5.93-5.78 (2H, m, 2 x CH vinyl), 5.58 (1H, dd, J = 1.7, 6.4 Hz, Hi), 
5.29 (4H, m, 2 x CH2 vinyl), 5.26 (2H, m, H3, H4), 4.50 (4H, m, 2 x CH 2 allyl), 
4.14 (1H, dd, J = 4.3, Jge,m = - 12.1 Hz, H6a), 4.04 (iH, m, H5), 3.98 (iH, dd, J 
2.2, J = - 13.5 Hz, H6b), 2.00, 1.97, and 1.95 (3 x 3H, s, COCH 3). 13C NMR 
(75 MHz, CDC13): ó (PPM) = 170.4, 169.7, 169.3 (3qC, 3 x COCH 3), 131.9, 
131.8 (2CH, 2 x CH vinyl, J = 5Hz), 119.0, 118.8 (2CH2, 2 x CH2 vinyl), 95.4 
(C 1, Jp = 5 Hz), 77.4, 70.2, 65.1, 61.2 (4CH, C2-05), 68.8, 68.6 (2CH 2, 2 x CH2 
allyl, = 5 Hz), 61.6 (CH2), 20.6, 20.5, and 20.4 (3CH3 , 3 x COCH3). 31P 
NMR (121 MHz, CDC13): S (ppm) = -2.1. m/z. IR (Vmax , thin film): 3018, 2961, 
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2856, 2113, 1749, 1649, 1455, 1425, 1413, 1368, 1242, 1224, 1160, 1070, 1042, 
1028, 972, 958, 879, 833, 822, 759, 700 cm'. HR-MS (EST): m/z 514.12191 









mCPBA, - 40°C - r.t. 
49% 
AcO" OAc 




A solution of the hemiacetal 15 (170 mg, 0.51 mmol) in dry DCM (11.0 ml) was 
added to a flask with 1-H-tetrazole (179 mg, 2.55 mmol) under nitrogen and 
stirred at room temperature for 10 minutes. Di-allyl-N,N-diisopropyl-
phosphoramidite (325 .tL, 1.21 mmol) was then added dropwise and stirring was 
continued overnight at room temperature. The reaction mixture was then cooled 
at -40 °C and m-chloroperbenzoic acid (MCPBA, 440 mg, 2.55 mmol) was 
added. The reaction was allowed to come slowly to room temperature over 
approximately 1 h, then it was diluted with DCM (10.0 ml) and washed with 10 
% NaHS03 (2 x 10.0 ml), sat. aq. NaHCO 3 (2 x 10.0 ml), and water (2 x 10.0 
ml). The organic phase was separated, dried (Na 2SO4), and evaporated to afford 
the crude as an off-white solid that was purified by flash chromatography over 
silica (1:1 - 2:1 EtOAc/petroleum ether). NMR and ES-MS analysis revealed 
contamination by PHO(OA11) 2 which was successfully removed by further 
column chromatography over silica (7:1 EtOAc/petroleum ether). The purified 
a-monophosphate 27 was isolated as a colourless syrup (123 mg, 49 %). 'H 
NMR (300 MHz, CDC13): 5 (PPM) = 5.93-5.82 (2H, m, 2 x CH allyl), 5.54 (1H, 
dd, fee = 1.6, JHP = 6.4 Hz, Hi), 5.35-5.21 (5H, m, H4, 2 x CH 2 allyl), 5.17 (1H, 
dd, fee = 1.6, J,, = 2.8 Hz, H2), 4.564.51 (4H, m, 2 x PO-CH2), 4.18 (1 H, dd, J 
5. 0, J = -12.3 Hz, H6a), 4.08 (1H, ddd, f,,4, = 10. 3, J = 5. 0, J = 2.2 Hz, H5), 
4.04 (1H, dd, J= 2.2, .J,,, = -12.3 Hz, H6b), 3.81 (iH, d, J,,,, = 10.4, J,, = 2.8 Hz, 
H3), 2.10, 2.06, and 2.01 (3 x 3H, s, 3 x COCH 3). 13C NMR (75 MHz, CDC1 3): 
136 
Chapter 5: Experimental section 
o (ppm) = 170.4, 169.4, 169.4 (3qC, 3 x COCH 3), 131.9 (2CH, 2 x CH ally!, Jcp 
= 7 Hz), 119.0 (2CH2 , 2 x CH2 allyl, JCP 7 Hz), 94.3 (Cl, JCP = 6 Hz), 70.2, 
68.6, 66.0 (3CH, C2, C4, C5), 68.8, 68.7 (2CH 2 , 2 x CH2 vinyl), 61.9 (CH2 , C6), 
20.6, 20.6, and 20.6 (3CH 3 , 3 x COCH 3). 31P NMR (101 MHz, CDC1 3): 5 (PPM) 
= -2.2. JR thin film): 3088, 2984, 2110, 1739, 1649, 1456, 1426, 1373, 
1215, 1161, 1071, 1040, 1020, 970, 958, 887, 757 cm'. HR-MS (ESI): m/z 
5 14.12092 (M+Na), C 18H26N3011PNa requires 514.12026 (error: 1.28 ppm). 
Diallylmonophosphate-2,3 ,4-tri-O-acetyl-4-azido-4-deoxy-a-D-manno- 
pyranoside (28) 












 o-P\ J o 
A solution of the hemiacetal 21 (440 mg, 1.33 mmol) in dry DCM (30.0 ml) was 
added to a flask with 1-H-tetrazole (465 mg, 6.64 mmol) under nitrogen and 
stirred at room temperature for 10 minutes. Di-allyl-N,N-diisopropyl-
phosphoramidite (846 tL, 3.15 mmol) was then added dropwise and stirring was 
continued overnight at room temperature. The reaction mixture was then cooled 
at - 40 °C and m-chloroperbenzoic acid (MCPBA, 1145 mg, 6.64 mmol) was 
added. The reaction was allowed to come slowly to room temperature over 
approximately 1 h, then it was diluted with DCM (30.0 ml) and washed with 10 
% NaHS0 3 (2 x 30.0 ml), sat. aq. NaHCO 3 (2 x 30.0 ml), and water (2 x 30.0 
ml). The organic phase was separated, dried (Na 2SO 4), and evaporated to afford 
the crude as an off-white solid that was purified by flash chromatography over 
silica (1:1 - 2:1 EtOAc/petroleum ether). NMR and ES-MS analysis revealed 
contamination by PHO(OAII) 2 which was successfully removed by further 
column chromatography over silica (7:1 EtOAc/petroleum ether). The purified 
ci-monophosphate 28 was isolated as a colourless syrup (313 mg, 48 %). 1H 
NIVIR (300 MHz, CDC1 3): 5 (PPM) = 5.98-5.80 (2H, m, 2 x CH vinyl), 5.58 (lH, 
dd, Jee = 1.6, JHP = 6.7 Hz, Hi), 5.35-5.15 (6H, m, H2, H3, 2 x CH2 vinyl), 4.56- 
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4.51 (4H, m, 2 x CH2 allyl), 4.28 (1H, dd, J = 2. 1, J = - 12.3 Hz, H6a), 4.21 
(1H, dd, J= 4. 1, J = - 12.2 Hz, H6b), 3.81 (1H, m, H5), 2.08 (3H, s, COCH 3), 
2.03 (3H, s, COCH3), and 1.99 (3H, s, COCH 3). ' 3C N1vIR (75 MHz, CDC13): ö 
(ppm) = 170.4, 169.5, 169.4 (3 x qC, COCH3), 131.9, 131.8 (2 x CH, CH vinyl), 
118.9, 118.7 (2CR 2, CH2 vinyl), 95.0 (C 1, JCP = 5 Hz), 70.5, 69.6, 68.7, (3 X CH, 
C2, C3, C5), 67.9 (CR2, C6), 62.8 (2 x CR2 , CR2 allyl), 56.3 (CH, C4), 20.7, 
20.6, and 20.5 (3 x CH3, COCH3). 31P NMR (121 MHz, CDC1 3): 5 (ppm) = -2.0. 
IR (v, thin film): 3087, 3018, 2968, 2958, 2114, 1755, 1650, 1455, 1426, 1372, 
1232, 1163, 1081, 1023, 974, 964, 756. HR-MS (ESI): m/z 514.12026 (M+Na), 
C 18H26N3011PNa requires 514.12132 (error 2.06 ppm). 
Monophosphate-2-azido-2-deoxy-a-D-mannopyranoside (29) 
AcO" N3 
AcO 1T  
AcO 	 0 








* TEA 11 
29 HOOH 
To a 100 ml round bottom flask containing 26 (293 mg, 0.60 mmol), under Ar, 
were added: a solution of dry 1:1 THF/MeOH (24.0 ml), p-toluensulphinic acid 
sodium salt (213 mg, 1.20 mmol), and tetrakis-triphenyiphosphine palladium 
(51.7 mg, 0.05 mmol). The reaction mixture was stirred under Ar for 17 h, 
concentrated in vacuo and coevaporated with toluene (3 x 20.0 ml). The crude 
was resuspended in a mixture of 5:2:1 MeOH/H20/TEA (30.0 ml), and stirred 
at room temperature for 22 h. The solution was filtered to remove a black 
precipitate, then concentrated in vacuo. The resulting syrup was dissolved in 
water and washed with DCM (3 x 35.0 ml) to remove organic products. The aq. 
layer was then concentrated and coevaporated with toluene (3 x 15.0 ml) to 
afford 29 as a pale yellow foam (220 mg, 86 % considering the bis-
triethylammonium salt). 'H NMR (300 MHz, CDC1 3): S (PPM) = 5.49 (1H, dd, 
J,, = 1. 7, Jp = 6.9 Hz, Hi), 4.24 (1H, dd, J, = 9.6, J, = 3.5 Hz, H3), 4.12 (1 H, 
dd, Jae = 3.5, ice = 1.7 Hz, H2), 3.94 (1 H, dd, J 2.2 Hz, H6a), 3.94 (1 H, m, H5), 
3.78 (1 H, dd, J = 6.4, J = - 12.6 Hz, H6b), 3.68 (1H, dd, Jaa = 9.6, J = 9.6 Hz, 
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H4), 3.06 (6H, s, N(CH2CH3)3), and 1.14 (9H, s, N(CH 2CH3)3). 13C NMR (75 
MHz, CDC13): 5 (ppm) 93.6 (d, Cl, JCP = 4 Hz), 73.4, 70.5, 67.2, 65.2 (4CH, 
C2-05), 61.2 (CH 2), 46.5 (N(CH2CH3)3), and 8.2 (N(CH2CH3)3). 31P NMR (121 
MHz, CDC13): 5 (PPM) = +2.7. HR-MS (ESI): mlz 284.02894 (M—H), 
C12H17N3011P requires 284.02838 (error: 1.97 ppm). 
Monophosphate-3-azido-3-deoxy-ct-D-mannopyranoside (30) 













To a 25 ml round bottom flask containing 27 (116 mg, 0.24 mmol), under Ar, 
were added: a solution of dry 1:1 THF/MeOH (10.0 ml), p-toluensulphinic acid 
sodium salt (84 mg, 0.47 mmol), and tetrakis-triphenyiphosphine palladium 
(20.4 mg, 0.02 mmol). The reaction mixture was stirred under Ar for 24 h, 
concentrated in vacuo and coevaporated with toluene (3 x 5.0 ml). The crude 
was resuspended in a mixture of 5:2:1 MeOH/H20/TEA (11.5 ml), and stirred 
at room temperature for 24 h. The solution was filtered to remove a black 
precipitate, then concentrated in vacuo. The resulting syrup was dissolved in 
water and washed with DCM (3 x 15.0 ml) to remove organic products. The aq. 
layer was then concentrated and coevaporated with toluene (3 x 5.0 ml) to afford 
30 as a pale yellow foam (120 mg, quantitative yield considering the bis-
triethylammonium salt). 'H NMR (500 MHz, D 20): 5 (PPM) = 5.30 (1H, d, 
= 2.1, JHP = 8.5 Hz, Hi), 4.05 (lH, dd, J = 3.2, fee = 2.1 Hz, H2), 3.93 (iH, 
ddd, .4, = 9.9, J= 6. 1, J = 2.3 Hz, H5), 3.89 (iH, dd, J = 2.3, J = - 12.1 Hz, 
H6a), 3.85 (1H, dd, J,. = 10.3, J = 3.1 Hz, H3), 3.76 (1H, dd, J = 10.3, J = 
9.9 Hz, H4), 3.73 (lH, dd, J = 6.1, J = -12.3 Hz, H6b), 3.16 (2H x2, q, 
N(CH2CH3)3), and 1.28 (3H x 2, s, N(CH 2CH3)3). 13C NIVIR (125.7 MHz, 
CDC13): 5 (ppm) 95.0 (d, Cl, = 4Hz), 73.5, 70.7, 66.3, 63.0 (4CH, C2-05), 
61.5 (CH2), 46.5 (N(CH 2CH3)3), and 8.2 (N(CH 2CH3)3). 31P NMR (101 MHz, 
139 
Chapter 5: Experimental section 
CDC13): 5 (ppm) = +2.9. HR-MS (ESI): m/z 284.02893 (M—H), C 12H17N3011P 








Pd(PhP)4 , THF/MeOH 
p-toluensulfinic acid 




9 * TEA HO 
31 H6 OH 
To a 50 ml round bottom flask containing 28 (174 mg, 0.37 mmol), under Ar, 
were added: a solution of dry 1:1 THF/MeOH (26 ml), p-toluensuffinic acid 
sodium salt (131 mg, 0.74 mmol), and tetrakis-triphenylphosphine palladium (26 
mg, 0.025 mmol). The reaction mixture was stirred under Ar for 17 h, 
concentrated in vacuo and coevaporated with toluene (3 x 10.0 ml). The crude 
was resuspended in a mixture of 5:2:1 MeOH/H 20/TEA (15.0 ml), and stirred 
at room temperature for 22 h. The solution was filtered to remove a black 
precipitate, then concentrated in vacuo. The resulting syrup was dissolved in 
water and washed with DCM (3 x 18.0 ml) to remove organic products. The aq. 
layer was then concentrated and coevaporated with toluene (3 x 10.0 ml) to 
afford 31 as a pale yellow foam (133 mg, 88 % considering the bis-
triethylammonium salt). 1H NMR (500 MHz, CDC13): S (ppm) = 5.36 (1 H, dd, 
J,, = 2.0, JHP = 8.4 Hz, Hl), 4.05 (lH, dd, 10.2, 3.3 Hz, H3), 3.94 (lH, 
dd, fat = 3.3, J, = 2.1 Hz, H2), 3.87 (1H, dd, J = 1.7, Jr,,, = - 11.9 Hz, H6a), 3.80 
(1H, ddd, J = 10. 2, J = 5. 0, f = 1.7 Hz, H5), 3.76 (1H, dd, J = 5. 0, Jgn = - 11.9 
Hz, H6b), 3.62 (1H, dd, J4, = 10.2, 10.2 Hz, H4), 3.06 (6H, s, N(CH2CH3)3), 
and 1.14 (9H, s, N(CH 2CH3)3). ' 3C NMR (125 MHz, CDC13): S (ppm) 95.7 (d, 
Cl, Jcp = 5 Hz), 71.9, 70.9, 70.0, 59.6 (4 x CH, C2-05), 61.8 (CE!2), 46.5 
(N(CH2CH3)3), and 8.2 (N(CH2CH3)3). 31P NMR (121 MHz, CDC13): S (PPM) = 
+2.8. HR-MS (ESI): m/z 284.02885 (M—H), C 12H17N30 11P requires 284.02838 
(error: 1.86 ppm). 
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General Procedure for the enzymatic synthesis of GDP-azidodeoxymannoses 
(32_35)h121 
Mannose-a-D-1-phosphate / Azidomannose-a-D- 1 -phosphate TEA salt 20 mM 
GTP 20 mM 
GDP-ManPP 1.6 mg 
iPPase 40 Ti 
M9028 mM 
DTT 5 mM 
BSA 4mg 
TRIS 50 mM pH 7.6 up to 4 ml (final volume). 
The reaction was heated at 37 °C with shaking (250 rpm). After 60 h, the 
reaction was centrifuged at 3000 pm for 15 minutes at 4 °C, and the supernatant 
was filtered using a Pall device (MWCO 10 kDa) prior to purification by HPLC. 
HPLC: (Sphereclone SAX 5 t, 250 mm x 10 mm, flow = 5mL/min; solvent A = 
dH20; solvent B = 0.6 M ammonium formate). Gradient: from t0 to t5', B 
increases from 0% to 10%; from t=5' to t=25' B increases from 10% to 25%; from 
t=25' to t=30' B increases from 25% to 100%; then B is kept at 100% until t35 1 , 
when it changes at once to 0% and is kept 0% until t40'. Absorbance is 
monitored at 230 and 254 nm. The product has tR = 12' (m/z = 629.3). Note: On 
the semi-preparative column GDP has tR = 18', and GTP has tR = 22'. 
The fractions containing the product are freeze-dried and then stored at —20 °C. 
GDP-6-azido-6-deoxy-a-D-mannopyranoside (32) 




~ OH -JO 
 OH OH 
1H NMR (500 MHz, D 20): 5 (ppm) = 8.10 (1H, s, H8), 5.82 (1H, d, J 5.9 Hz, 
Hi'), 5.47 (1H, dd, Jee = 1. 5, JHP = 6.9 Hz, Hi), 4.75 (1H, dd, J— 5.9, J = 5.1 
Hz, H2'), 4.49 (1H, dd, J = 5. 1, J 3.6 Hz, H3'), 4.33 (iH, m, H4'), 4.19 (2H, 
m, H5'a, H5'b), 4.02 (1H, dd, J = 3.2, J = 1.5 Hz, H2), 3.91 (1H, ddd, = 
9.9, J = 4.4, J = 2.5 Hz, H5), 3.89 (1H, dd, J = 9.8, J. = 3.4 Hz, H3), 3.70 
(1H, dd, J = 9.9, J4, = 9.9 Hz, H4), 3.63 (1H, dd, J = 2.5, Jgem = -13.6 Hz, H6a), 
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and 3.55 (1H, dd, J= 4.6, Jg = -13.6 Hz, H6b). 13C NMR (126 MHz, D 20): a 
(ppm)= 97.1 (CH, d, JC.P = 6 Hz, Cl), 87.6 (CH, Cl'), 84.4 (CH, d, Jcp = 8 Hz, 
C4'), 74.3 (CH, C2'), 72.8 (CH, C5), 71.0 (CH, C3'), 70.8 (CH, C3), 70.3 (CH, 
C2), 67.6 (CH, C4), 65.9 (CR2, d, JCP = 5 Hz, C5'), and 51.4 (CR2, C6). 31P 
NMR (101 MHz, CDC13): 5 (ppm) = -10.3, -12.8. HR-MS (ESI): m/z 629.0745 
(M—H), C 16R23N80 15P2 requires 629.0758 (error: 2.1 ppm). 
GDP-2-azido-2-deoxy-a-D-mannopyranoside (33) 
0 







'H NMR (500 MHz, D20): 5 (ppm) = 8.11 (1H, s, H8), 5.93 (1R, d, J = 6.2 Hz, 
Hi'), 5.57 (iH, dd, Jee = 1.8, = 6.0 Hz, Hi), 4.77 (1H, dd, J = 5.9, J = 5.1 
Hz, H2'), 4.51 (iH, dd, J = 5. 1, J= 3.6 Hz, R3'), 4.35 (1R, m, H4'), 4.21 (2H, 
m, H5'a, H5'b), 4.14 (1R, dd, J,. = 9.5, J = 3.9 Hz, H3),4.11 (1R, dd, J,, = 3.8, 
= 1.8 Hz, H2), 3.84 (2H, m, R5, H6a), 3.73 (1H, dd, J = 5.7, = - 13.1 Hz, 
H6b), and 3.66 (iR, dd, J, = 9.7, J, = 9.7 Hz, H4). 13C NMR (126 MHz, D20): 
o (ppm)= 95.2 (CH, d, Jp = 5 Hz, Cl), 87.5 (CH, Cl'), 84.4 (CH, d, = 9Hz, 
C4'), 74.3 (CH, C2'), 74.2 (CH, C5), 71.0 (CH, C3'), 70.5 (CH, C3), 66.9 (CH, 
C4), 65.9 (CR2, d, Jc.p = 5 Hz, C5'), 64.6 (CH, d, J = 9 Hz, C2) and 61.0 (CR2 , 
C6) . 31P NMR (101 MHz, CDC1 3): S (ppm) = -10.2,-12.9. HR-MS (ESI): m/z 
629.0745 (M—H), C 16H23N8015P2 requires 629.0758 (error: 2.1 ppm). 
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GDP-3-azido-3-deoxy-a-D-mannopyranoside (34)1131 
0 
HOOH 	 NANH 
HO I 	
9 9 	LNLNH N 3 
cO 
HOH 
1H NMR (500 MHz, D20): ö (ppm) = 8.10 (1H, s, H8), 5.92 (1H, d, J 5.8 Hz, 
Hi'), 5.47 (1H, dd, Jee = 1.8, JHP 6.0 Hz, Hi), 4.72 (1H, dd, J = 6.0, J = 5.1 
Hz, H2'), 4.50 (iH, dd, J = 5. 1, J = 3.6 Hz, H3'), 4.35 (1H, m, H4'), 4.22 (2H, 
m, H5'a, H5'b), 3.99 (1H, dd, Jae = 3.2, J,, = 1.9 Hz, H2), 3.91 (1H, dd, J = 9.5, 
Jae = 3.2 Hz, H3), and 3.88-3.68 (4H, m, H4, H5, H6a, H6b). 13C NMR (125 
MHz, D20): ö (ppm)= 159.6, 154.5, 152.4, (3Cq, C2, C4, C6), 138.1 (1 CH, C8), 
116.9 (lCq, C5), 97.1 (1 CH, d, Jp = 6Hz, Ci), 87.5 (1 CH, Cl'), 84.2 (1 CH, d, 
Jc-p = 8 Hz, C4'), 74.4 (1 CH, C2'), 72.7 (1 CH, C5), 70.9 (1 CH, C3'), 70.1 (1 CH, 
C2), 69.8 (1CH, C3), 65.9 (1CH 2 , d, JC.P = 5 Hz, C5'), 61.5 (1CR 2 , C6), 59.1 
(I CH, C4) . 31 P NMR (101 MHz, D 20): ö (ppm) = -10.1, -12.7 HR-MS (ESI): 










'H NMR (500 MHz, D 20): 5(ppm) = 8.10(iH, s, H8), 5.92 (1H, d, J 5.8 Hz, 
Hi'), 5.49 (1H, dd, Jee = 1.9, JHP = 6.0 Hz, Hi), 4.72 (1H, dd, J = 5.9, J = 5.1 
Hz, H2'), 4.48 (1H, dd, J = 5. 1, J = 3.8 Hz, H3'), 4.33 (1H, m, H4'), 4.19 (2H, 
m, H5'a, H5'b), 3.99 (1H, dd, J = 3.2, J = 1.9 Hz, H2), 3.91 (1H, dd, J. = 9.5, 
= 3.3 Hz, H3), 3.80 (1H, dd, J = - ii Hz, H6a), and 3.68 (3H, m, H4, H5, 
H6b). 13C NMR (126 MHz, D20): 5 (ppm) 97.1 (CH, d, Jc.p = 6 Hz, Cl), 87.5 
(CH, Cl'), 84.2 (CH, d, Jp = 8 Hz, C4'), 74.4 (CH, C2'), 72.7 (CH, CS), 70.9 
(CH, C3'), 70.1 (CH, C2), 69.8 (CH, C3), 65.9 (CH 2, d, Jc.p = 5 Hz, CS'), 61.5 
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(CH2, C6),59.1 (CH, C4) . 31PNMR(101 MHz, CDC13): ö(jpm)= -10.1, -12.7. 
HR-MS (ESI): m/z 629.0745 (M—H), C 16H23N30 15P2 requires 629.0758 (error: 
2.1 ppm). 
1-Methyl-2-Iodoterephthalate (36)"' 
1. cold conc. HCI, 
HO TL 
	aq. NaNO2 	HO 
	




1-Methyl-2-aminoterephthalate (1.00 g, 5.18 mmol) was added to a solution of 
10 ml cold conc. HC1. A solution of NaNO 2 (374 mg, 5.42 mmol) in water (2 ml) 
was added dropwise resulting in the evolution of a small amount of orange gas. 
The mixture was stirred for 30 min at room temperature and then filtered 
through cotton wool into a solution of KI (8.53 g, 51.4 mmol) in 14 ml H 20. The 
dark red solution was stirred for 1 h and then diluted with DCM (200 ml) and 
washed with sat. NaHS0 3 (2 x 20 ml). The organic layer was washed with water 
(2 x 40 ml) and brine (1 X 40 ml). The combined organic layers were then dried 
over Na2SO4 and concentrated in vacuo. The crude product was dissolved in a 
minimum amount of methanol, and water was added until the solution appeared 
slightly cloudy. Cooling to 4°C and subsequent filtration afforded the product 36 
as a bright yellow solid (1.33 g, 85 %), 'H NMR (250 MHz, CDC1 3): ö 8.69 (d, 
lH, J= 1.6 Hz, ArH), 8.12 (dd, 1H, J= 8. 1, J = 1.6 Hz, ArH), 7.83 (d, 1H, J 
8.1 Hz, ArH), 3.98 (s, 3H, OMe),. 13C NMR (63 MHz, CDC13): 8  168.9 (qC), 
166.6 (qC), 142.3 (CH), 139.8 (qC), 132.4 (qC), 130.3 (CH), 129.2 (CH) and 52.6 
(CH3),. m/z (ESI): 304.9 M C9H604 requires M 305.0. 
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1-Methyl-2-diphenyl-phosphinoterephthalate (37)1"41 
0 	 0 
Ph2PH, cat. Pd(OAc) 2 , 
H0 Ho 	 MeOH, Et3N 	 1 L 0  
çJ 
I OMe 	reflux 	 Ph2P OMe 
36 	 76% 	 37 
Dry MeOH (3m1), TEA (0.3 ml) and 1-Methyl-2-Iodoterephthalate 36 (300 mg, 
1.00 mmol) were added to a flame dried flask. Palladium acetate (2.2 mg, 0.01 
mmol) was then added and the mixture degassed in vacuo under high vacuum. 
While stirring under an atmosphere of Ar, diphenyiphosphine (0.17 ml, 1.0 
mmol) was added to the flask with a syringe. The resulting solution was heated 
at reflux overnight and then allowed to come to room temperature. The solution 
was then concentrated and the residue dissolved in 250 ml 1:1 mixture of 
DCM/water. The organic layer was washed with 1 M HO (1 x 10 ml) and the 
solvent removed under reduced pressure. The crude product was then dissolved 
in a minimum amount of MeOH and an equal amount of water was added. The 
solution was cooled to 4°C for 2 h and the resulting solid 37 was collected by 
filtration and isolated as a golden yellow solid (355 mg, 76 %), 1H NMR (250 
MHz, CDC13): 6 8.01 - 8.10 (1H, m, ArH), 7.65 - 7.68 (1H, m, ArH), 7.25 - 7.37 
(11H, m, ArH), 3.73 (3H, s, OMe) , 31P NMR (100 MHz, CDC1 3): ö -2.70, m/z 
(ESI): 363.5M- C21H 1604P requires M 363.3. 
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MeCN / H20  = 95: 5 










To a round bottom flask containing the peracetylated 6-azidomannose 3 (99 mg, 
0.265 mmol), were added 5 ml of a solution of the phosphine 37 (97 mg, 0.265 
mmol) in acetonitrile with 5% v/v water. The mixture was stirred at 47 °C for 
6h. The crude solution was evaporated to dryness under reduced pressure, and 
the product purified by column chromatography (DCM/acetone 1:1 with 5% 
acetic acid, Rf = 0.5). Fractions containing the ligated product were co-
evaporated with toluene to yield a yellow oil (178.8 mg, 0.257 mmol, 97%). 
Found m/z (ESI): 694.6. C 34H33N0 13P requires m/z 694.2 (M -H). 'H NMR 
(300 MHz, CDC13): 9.71 (1H, s (br), COOH), 8.05 (1H, m, Ar), 7.99 (1H, s (br), 
NH), 7.81 (1H, m, Ar), 7.61 - 7.39 (9H, m, Ar), 7.16 (2H, m, Ar), 6.04 (1H, d, Jee 
= 1.8 Hz, Hi), 5.35 (1H, dd, Jae = 3.5, J = 1.8 Hz, H2), 5.26 (1H, dd, Jaa 10.0, 
= 3.5 H3), 5.11 (1H, dd, J = 10.0, J = 10.0, H4), 3.95 (1H, m, H5), 3.06 
(2H, m, H6a, H6b), 2.13, 2.11, 2.07, 1.98 (4 x 3H, s, Ac). 13C NMR (75 MHz, 
CDC13): 193.1 (COOH), 170.3, 169.9, 169.6, X (CO, Ac), 134.7 (CONE!), 132.4, 
132.0, 131.9, 131.8, 129.0, 128.7, 128.6, 128.5, 128.2, 125.3 (Ar), 90.5 (CH, Cl), 
70.9, 68.8, 68.5, 66.6 (C2-05), 40.2 (C6), 21.1, 21.0, 20.8, 20.7 (COCH3) . 31P 
NMR (101 MHz, CDC13): 34.7. IR thin film): 3390 (br), 2947, 2836, 2520, 
2036, 1734, 1653, 1550, 1437, 1375, 1255, 1150, 1120, 1025, 723, 697. HR-MS: 
694.1718 (caic. C 34H33N0,3P is 694.1690, error 4.0 ppm). 
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5.2 General microbiology 
	
5.2.1 	General techniques 
Standard techniques were performed as described in Molecular Cloning - A 
Laboratory Manual (Sambrook, Fritsch, and Maniatis, 2' Edition, 1989, Cold 
Spring Harbour Press, USA). Standard sterile technique was maintained during 
all microbiological routine work. Media, glassware, and equipment were 
sterilised by autoclaving at 121 °C for 15 mm. in an Astell autoclave. 
Thermolabile solutions were sterilised by filtration through Sartorius minisart 
0.22 J.tm filters. Plates were prepared and media inoculated either on ethanol 
swabbed surfaces or in a Class II environmental cabinet. Ampicillin antibiotic 
stock solutions were stored at -20 °C and were used at a concentration of 100 
jig/mi. Shake flask fermentations were carried out in a New Brunswick 
Scientific INNOVA 4000 incubator shaker (37 °C, 250 rpm). Large scale 
fermentations (10 L) were carried out in a New Brunswick Scientific BioFlow 
1000 fermenter at 37 °C, stirred at 250 rpm with an air flow of 2 Lmin 1 . 
5.2.2 	Growth Media 
L.B. (Luria-Bertani) medium. Per litre: Bacto Tryptone (10.5 g), Bacto yeast 
extract (5 g), NaCl (10 g). Adjust pH to 7.5 with NaOH. Autoclave. 
M9 (minimal salts) medium. Dissolve 5.64 g of 5 x M9 salts (Sigma-Aldrich) in 
500 ml of deionised water. Autoclave. 
S.O.C. medium. 0.5 % Yeast extract, 2.0 % tryptone, 10 mM NaCl, 2.5 mM 
KC1, 10 mM MgCl2 , 20 MM MgSO4, 20 mM glucose. 
T.B. (Terrific Broth) medium. Per 900 ml deionised water: Bacto Tryptone (12 
g), Bacto yeast extract (24 g), Glycerol (4 ml). Autoclave. Add 100 ml of a 
sterile solution of 0.17 M KH2PO4, 0.72 M K2HPO4 . 
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5.2.3 	General Procedures 
5.2.3.1 	Preparation of E. coli competent cells 
L.B. medium (10.0 ml) was seeded with 10 0 of the bacterial host cell line. This 
was grown at 37 °C overnight with shaking (250 rpm). An aliquot of the 
overnight culture was used to seed 10.0 ml of fresh L.B. medium containing 200 
p.! of 1.0 M MgCl2. This was grown as above until A600 = 0.2. The cells were 
then collected by centrifugation for 15 mm. at 3,000 rpm at 4 °C. The 
supernatant was then discarded and the cells were resuspended in 4.0 ml of fresh, 
ice-cold transformation buffer (50 mM CaC1 2, 10 mlvi Tris, pH 8.0). The cells 
were left on ice for 30 min. with occasional agitation. The cells were then 
collected by centrifugation for 15 min. at 3,000 rpm at 4 °C. The supernatant 
was then discarded and the cells were resuspended in 400 0 of ice-cold 
transformation buffer (50 mM CaC1 2, 10 mM Tris, pH 8.0) and kept on ice until 
required. 
5.2.3.2 	Transformation of DNA into competent cells 
A 100 0 aliquot of competent cells was transferred to a sterile 1.5 ml Eppendorf 
tube and left on ice for 30 min. 5 0 of the DNA sample was then added, the 
tube was tapped gently, and then left on ice for further 30 mm. The sample was 
then heat shocked for 5 mm. at 37 °C. L.B. medium (1.0 ml) was then added and 
the sample was incubated at 37 °C for 1 h. The cells were then collected by 
centrifugation for 15 min. at 3,000 rpm at 4 °C. The supernatant was discarded 
and the cells were resuspended in 100 p.1 of fresh L.B. medium. The cells were 
then spread to dryness on selective (containing 100 p.g/ml ampicilhin) L-agar 
plates and the plates were grown inverted at 37 °C overnight. 
5.2.3.3 	Transformation of DNA into One Shot competent cells 
A 50 p.1 aliquot of One Shot chemically competent TOP 10 cells was transferred 
to a sterile 1.5 ml eppendorf tube and left on ice for 30 minutes. 5 p.1 of the DNA 
sample was added, the tube was tapped gently, and then left on ice for further 30 
minutes. The sample was then shocked for 30 seconds at 42 °C. The vial was 
then placed on ice. Prewarmed S.O.C. medium (250 p.1) was then added and the 
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sample was incubated at 37 °C, 250 rpm, for 1 h. Cells (75 t1) were then spread 
to dryness in selective L-agar plates (containing 100 pg/ml ampicillin) and the 
plates were grown inverted at 37 °C overnight. 
5.2.3.4 	Cloning of plasmid DNA 
A single colony, transformed with the engineered plasmid was used to seed 10.0 
ml of fresh L.B. medium containing 100 tg/ml ampicillin. The culture was then 
incubated at 37 °C with shaking overnight. Cells were collected by 
centrifugation at 3,000 rpm at 4 °C. Cloned plasmid DNA was then purified by 
using "Quiagen spin column DNA purification kit" according to the 
manufacturers' instructions. 
5.3 Molecular biology 
5.3.1 	Instruments and general techniques 
Centrifugation of small samples in eppendorf tubes was carried out at maximum 
speed in an Eppendorf centrifuge 5410. Larger samples (up to 50 ml) were 
centrifuged in an Eppendorf 5410R. Large scale (15 ml - 0.3 L) samples were 
centrifuged in a Beckmann Avanti J-25 centrifuge. 
Sonication was performed using a Sanyo Soniprep 150 at 50 % of maximum 
power. Cells were sonicated on ice for 10 periods of 30 seconds separated by 30 
seconds intervals. 
Horizontal gel electrophoresis was carried out in ANACHEM model H3-SET 
apparatus at 100 V according to the manufacturers' instructions. 100 ml agarose 
gel were 1 % agarose in TAE (0.04 M Tris-Acetate, 0.001M EDTA; pH 8) buffer 
containing 4 tL of 5 mgmt1 ethidium bromide. DNA was excised from the gel 
and purified using the "Quiagen gel extraction kit" according to the 
manufacturers' instructions. 
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Protein electrophoresis was carried out using Invitrogel XCeII SureLock Mini-
Cell or Bio-Rad Mini-PROTEAN III vertical gel electrophoresis apparatus. 
Polyacrylamide resolving gels were run for approximately 1 h at 200 V. SDS-
PAGE gels were stained (0.1 % w/v Coomassie blue R-250, 40 % v/v MeOH, 
10 % v/v AcOH) for 1 h and destained with several washings of 40 % v/v 
MeOH, 10 % v/v AcOH. Destained gels were stored in water prior to drying. 
5.3.2 	Reagents 
The RJbM gene (in pT7-6) from S. typhimurium group B, strain LT2 was donated 
by Prof. Lothar Elling (Institute of Enzyme Technology, JUlich, GERMANY). 
E.coli clones containing the plasmid pManFLAG20 were purchased from ATCC. 
All restriction enzymes and DNA modifying enzymes were purchased from New 
England Biolabs and were used according to the suppliers' instructions. IPTG 
was from Eppendorf. All antibodies and other reagents were from Sigma-
Aldrich. 
5.3.3 	General Procedures 
5.3.3.1 Endonuclease digestions 
For analytical digests, 5 p1 of plasmid DNA, 0.5 j.tl of restriction enzyme, 2 p1 of 
1 Ox NEB buffer, 12.5 p1 of deionized water, were transferred to a 1.5 ml 
eppendorf tube. Reactions were incubated at 37 °C for 1 h, and the linearised 
DNA was observed by horizontal agarose electrophoresis. Preparative 
restriction endonuclease digestions were carried out with a similar procedure: 30 
p1 of plasmid DNA, 1 t1 of restriction enzyme, 5 p1 of lOx NEB buffer, 14 p1 of 
deionized water, were transferred to a 1.5 ml Eppendorf tube. Reactions were 
incubated at 37 °C for 2-3 h, and the linearised DNA was separated by 
horizontal agarose electrophoresis. The band containing the required DNA was 
excised and the DNA purified from the gel by using "Quiagen spin column DNA 
purification kit" according to the manufacturers' instructions. 
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5.3.3.2 	Ligation reactions 
Ligation reactions. Ligations were performed using the Roche "Rapid Ligation" 
kit according to the manufacturers' instructions. 
5.3.3.3 	PCR reactions 
DNA fragments were amplified using the PCR in a Master CyclerTM Personal. 
The high fidelity DNA polymerase "Deep Vent" (New England Biolabs) was 
used for gene amplification. Reactions were prepared in sterile 0.5 ml thin 
walled PCR tubes. Reactions were carried out on a 50 .tl scale, and were 
typically set up as follows: 10 x reaction buffer (5 tl), dNTP mix (5 .i1, initial 
concentration of 10 mM each), template DNA (1 tl), primers (5 tl of a 100 tl 
aq. solution), polymerase (1 j.il, 5 U4t1), deionized water (28 p.0, M902  solution 
100 mM (2.5 p.!). PCR cycles: 96 °C for 5 minutes (1 cycle); 96 °C for 30 
seconds, 54 °C for 15 seconds, and 72 °C for 30 seconds (30 cycles); 72 °C for 2 
minutes (1 cycle); 4 °C hold. 
5.3.3.4 	DNA sequencing 
Sequencing of DNA was accomplished by using the Big Dye Terminator 3.1 
(Applied Biosystems) according to the manufacturers' instructions. The 
sequencing mix used was as follows: Terminator Reaction Mix (4 p.1), template 
(15 p.1), primer (1 p.1). The sequencing program was as follows: 95 °C for 1 
minute (1 cycle); 96 °C for 30 seconds, 55 °C for 30 seconds, and 60 °C for 5 
minutes (30 cycles); 4 °C hold. The sequencing reaction mixture (10 p.1) was 
then diluted with 10 p.1 of deionized water, and was submitted to the Automated 
DNA Sequencing Service (School of Biological Sciences, University of 
Edinburgh) for analysis. 
5.3.3.5 	His10-GDPMP protein expression 
Small scale production of His 10-GDPMP. Expression of His 10-tagged proteins 
was carried out according to the manufacturers- instructions (PET system 
manual, Novagen). A single colony of E. coli (Strain BL21(DE3) or B34 or 
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ER2566) transformed with the cDNA encoding GDPMP (NdeI/BamHl inserted 
into pET 16b) was used to inoculate a 10 ml culture of LB medium containing 
100 tg/m1 ampicillin. The culture was incubated at 37 °C with shaking (250 
rpm) overnight. This culture was then used to inoculate 2 x 500 ml of fresh LB 
medium containing the required antibiotic and incubated at 37 °C with shaking 
until A 0 =0.6. IPTO was added to a concentration of 1 mM and the incubation 
was continued with shaking at variable temperatures and times. Cells were 
harvested by centrifugation at 8000 rpm (10,000 G) at 4 °C for 10 minutes. The 
pellet could then be stored at -20 °C prior to purification. 
Large scale production of His 10-GDPMP. A single colony of E. coli 
transformed with RJbM-pET16b was used to inoculate 10 ml of LB medium 
containing the required antibiotic. The culture was then grown at 37 °C with 
shaking overnight. It was then used to inoculate 100 ml of fresh LB medium 
with ampicillin and after 1 day this was used to inoculate 10 1 of fresh LB 
medium, which was transferred to a fermenter and induced as described above 
for small scale work. 
5.3.3.6 	Preparation of a cell-free extract (CFE) 
A pellet derived from a 11 induced culture was thawed on ice and resuspended 
in 35 ml binding buffer (5mM imidazole, 500 mM NaCl, 20 mM Tris-HC1, pH 
8) containing 10 mM PMSF. The cells were sonicated on ice for 15 periods of 30 
seconds separated by 30 seconds intervals. Triton X-100 was added to a final 
concentration of 0.1% v/v and the resulting solution was rocked on ice for 10 
minutes. The cells were then sonicated again on ice for 15 periods of 30 seconds 
separated by 30 seconds intervals. Inclusion bodies and cellular debris were 
collected by centrifugation at 10,000 rpm for 15 mm. at 4 °C. The resulting 
pellet was discarded and the CFE supernatant was stored at -20 °C prior to 
affinity chromatography. 
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5.3.3.7 	Column chromatography of His 10-GDPMP 
The CFE supernatants were purified under non-denaturing conditions using Ni"  
immobilized on a metal chelation resin as described in the manufacturer's 
instructions (Sigma-Aldrich). The column (2.5 ml bed volume) was charged with 
7 ml aqueous NiSO4 and equilibrated with 12.5 ml binding buffer. The CFE was 
then loaded onto the column and unbound proteins were washed with binding 
buffer containing 1mM PMSF, and then wash buffer (50 mM imidazole, 500 
mM NaCl, 20 mlvi Tris-HC1, 1 mM PMSF, pH 7.8) until A280 < 0.1. The target 
protein was then eluted in 1.5 ml fractions using eluting buffer (500 mlvi 
imidazole, 500 mlvi NaCl, 20 mlvi Tris-HO, pH 7) until A280 < 0.1. The fractions 
were then analyzed by SDS-PAGE: 10 1 aliquots were mixed with 10 p1 of SDS 
loading buffer. The fractions containing the desired protein were combined, 
exchanged 3 times against fresh buffer (50 mM Tris pH 7.6), and concentrated to 
a final volume of 1 ml using a Vivaspin (MWCO 30 kDa) concentrator, which 
was previously passivated with 5% Tween 20 according to the manufacturers 
instructions. 
5.3.3.8 	His10-GDPMP Activity Assay 
M1P / AzM1P-TEA salt / GTP 100 .tM 
GDPManPP 10 tg 
iPPase 0.5 U 
M9028 mlvi 
DTT1mM 
TRIS 50 mlvi pH 7.6 up to 500 0 (final volume). 
The reaction was carried out in triplicates in 1.5 ml Eppendorf tubes in a 
Thermomixer, at 37 °C, 300 rpm. Every 10 minutes, 25 tl samples were taken 
and added to a 96-wells plate with 100 0 of malachite reagent (calibrated the 
same day). The malachite assay was carried out in a plate reader (SpectraMax 
Plus 384, Molecular Devices) at 37 °C, with mixing, for 15 minutes, then the 
absorbance at 650 nm was read. Values were plotted over time. 
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5.3.3.9 	Preparation and calibration of the malachite reagent 
To a 100 ml volumetric flask were added: 34.0 mg of malachite green oxalate 
salt (Sigma), 1235.9 mg of ammonium molybdate, 3.4 ml of absolute ethanol, 
about 80 ml of deionized water, 8.59 ml of concentrated HCl (37%), 1 ml of 
Tween 20 and deionized water up to 100 ml total volume. The resulting mixture 
was stirred at room temperature for lh, then it was filtered (0.2 gm) and stored at 
4 °C for at least 7 days prior to use. The same day to be used, the reagent was 
calibrated by using a standard series of KH 2PO4 solutions (in deionized water) at 
variable concentrations. On a 96-well plate, 25 .tl of each standard was added to 
a well containing 100 il of malachite reagent, in triplicate. The plate was 
incubated at 37 °C with mixing (SpectraMax Plus 384, Molecular Devices), and 
the absorbance was read at 650 nm over 30 minutes. Typically, the absorbance 
maximum was reached within the first 15 minutes. The absorbance values at 15 
minutes were plotted against the phosphate concentration, and from linear fitting 
an equation was obtained, where the slope gave the conversion factor. 
5.3.3.10 	Western blotting analysis 
Following SDS-PAGE, proteins were transferred to a nitrocellulose membrane 
(Whatman) in a Bio-Rad Mini-Trans-Blot module in a Mini-Protean 3 vertical 
cell at 100 V, 350 mA for 1 h in blotting buffer (25 mM Tris-HC1, 10 MM 
glycine, 20 % v/v MeOH, pH 8.3). The membrane was then incubated 
overnight at room temperature with shaking in blocking buffer (PBS pH 7.3 with 
3 % w/v non-fat milk powder) and then incubated with the primary antibody 
according to the manufacturers' instructions. The membrane was then washed 
with fresh blocking buffer (3 x 15 minutes) and then incubated for a further 1 h 
with the secondary antibody (according to the suppliers' instructions). The 
membrane was then washed with blocking buffer containing 0.05 % Tween 20 (3 
x 15 minutes) and then the detection solution DAB/H 202 (Sigma-Aldrich) was 
added and the reaction was developed according to the suppliers' instructions. 
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5.3.3.11 	ManT expression 
A single colony of pManFlag2O in XL-! Blue cells was used to seed 10 ml of 
fresh L.B. medium containing Ampicillin (100 tg/ml). The culture was 
incubated at 37°C overnight with shaking at 250 rpm. The overnight culture was 
then spun down (3000 rpm, 4 °C, 15 mm), the supernatant was discarded, and 
the cells pellet was resuspended in 10 ml of fresh M9-CA modified medium (M9 
salts with 20 g/l casamino acids, 0.4% glycerol, 2 mM MgSO 4) containing 
Ampicillin (100 p.g/ml). This was grown as above until 0D 600=0.5, then protein 
expression was induced with 5 jiM IPTG at 30 °C for 12h. Cells were harvested 
by centrifugation at 8000 rpm (10,000 G) at 4 °C for 15 minutes. The pellet 
could then be stored at -20 °C prior to purification. 
5.3.3. 12 	ManT purification 
The cells pellet from 11 culture was thawed on ice and resuspended in 20mL of 
ice-cold 20% sucrose, 10mM tris pH 7.6, containing 2 mM PMSF 2 mM. 0.4 ml 
of 0.5M EDTA was slowly added. Cells were incubated on ice for 30 minutes, 
and then collected by centrifugation at 8000 rpm for 20 minutes. The supernatant 
was dialysed against 0. 1M ammonium formate, pH 7.5, and then concentrated 
down to 1 ml on a Vivaspin concentrator (MWCO 10 kDa). 
5.3.3.13 	ManT Activity Assay 
One 1.5 ml Eppendorf tube containing ManT (107.2 jiL), the GDP-mannose 
donor (1.25 mM of GDPMan, GDP-2-AzMan, GDP-3-AzMan, GDP-4-
AzMan, or GDP-6-AzMan) and the a-methyl mannoside acceptor (7.5 mM), in 
a total volume of 160 jil of 50 mM ammonium formate buffer pH 7.5, 10 mM 
MnC12, was incubated at 30 °C for 24 h. The proteins were then separated by 
membrane filtration (MWCO 10 kDa), and the filtrate was analyzed by direct 
infusion ESI-MS (35 V). 
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GDP-2, 3-, 4- or 6-azidomannoses can be successfully prepared 
from the corresponding azidomannose-1-phosphates and GTP 
using the enzyme GDP-Mannosepyrophosphorylase (GDP
-
ManPP) from Salmonella enterica and may serve as useful 
probes for mannosyltransferase athivity. 
The discovery of promiscuous carbohydrate processing 
20 enzymes has provided chemists with powerful tools to readily 
access unnatural glycocoojugates with complete regio- and 
stereoselectivity, in water, and with minimal protecting group 
manipulation.' It has also facilitated metabolic engineering 
approaches employing tagged sugars displaying functional 
25 groups, such as ketones, which may alter the properties of 
various targeted cellular components. 2 This methodology was 
rapidly extended to sugars containing asides or acetylenes 
combined with the Staudinger ligation, or "click" chemistry 
for further manipulation? Such methods have also been used 
to explore glycosyltransferase activity and substrate specificity 
in vitro and in vivo. In most cases, it is the N-acetyl group of 
glucosamine, mannosamine or galactosamine which carries 
the azide functionality. 4 Herein we report the first chemoenzy-
matic synthesis of four GDP.asidodeoxymannoses and hives- 
5 tigate their use as substrates for a mannosyltransferase 
(ManT). Being a common constituent of N-Linked glycopro-
teins, and a direct modification of mammalian glycoproteins in 
the extracellular matrix, it is clear that the availability of tools 
to profile mannose transfer may have valuable applications in 
40 disease diagnosis, discovery of novel mannosyltransferase 
activities and in glycoprotein remodeling.' 
A key requirement is access to activated sugar nucleotides. 
We investigated the potential for GDP-mannose pyropho-
sphorylase (GDPManPP, EC. 2.7.7.13) 6 to produce our 
45 desired asidodeoxy products. Ultimately this provides the 
potential for conducting GDP-azidomannose synthesis and 
glycosyl transfer in one pot, which in not likely to be possible if 
they were prepared synthetically.' First, the snide was installed 
at four positions on the pyranose ring (1-4), by using dis- 
50  reactions of sodium aside on suitably protected 
tosylate and trifiate precursors (Scheme I).' Phosphoramidite 
chemistry at the anomeric centre allowed for the insertion of 
Department of Chemistry, University College London, 20 Gordon 
55 Street, London, UK WCIH OAf. E-maiL d.macmiIlm®ad.ac.uk  
TeL 020 7679 4684 
5 Electronic supplementary information (ESI) available: Experimental 
details for synthesis of compounds 1-9, expression, purification and 
use of GDP-ManPP and MasT and for the enzymatic activity. See 
DOS: 10.1039/b807016d 
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the n-phosphate group, required for GDP-ManPP activity, to 
yield 2-, 3-, 4- and 6-aridodeoxy enannose compounds S-S 
respectively. 
To test 5-8 as unnatural substrates for GDP-ManPP, we 
overexpressed the protein in E. coli (strain ER2566(DE3)) 
transformed with the plasmid pET16b.GDP-M5OPP. Induc-
tion at ODom = 0.6 with 1 mM IPTG at 30 'C for 5 It yielded 
the poly.histidine tagged protein, which was purified from the 
cell free extract by Nickel affinity chromatography. SDS-
PAGE and Western blot analysis (using an antibody raised 
against the poly-histidine tag) confirmed the identity and 
purity of GDP-ManPP. Typical yields of 1.1 mg L' GDP-
ManPP were obtained using this method. The enzyme was 
concentrated and the solution exchanged against 50 m Tris; 
p1-i 7.6, 8 mM M902, 1 mM DTI' to test for activity, initially 
with 6-azidomannose-1 -phosphate (8). The reaction was mon-
itored by H1'LC and the formation of the corresponding 
GDP-6-azidodeoxy derivative 9 was observed (Fig. 1(a)). 
After 60 It at 37 'C, the protein content was removed by 
filtration of the reaction mixture through a 10 kDa molecular 
weight cut-off membrane, and the resulting solution was 
purified by anion-exchange HPLC in a gradient of amnionium 
formate. The desired GDP-6-azidodeoxymannose 9 (33 mg, 
63%), was confirmed by 'H, ' 3C and 35p  NMR spectroscopy 
and high-resolution mass spectrometry. Having demonstrated 
enzymatic activity with 6-azidomannose.l.phosphate, we next 
optimised a colourimetric activity assay in order to compare 
the remaining isomers with the natural substrate in a high 
throughput fashion (Fig. 1(b)). The screen was based on the 
Tate, 
OM,_ 	 d 
so 
S 	 ,-O.o" 	 1 04— 
he 	55 
Sdse,ne 1 lteagenL, andeondit ions: (a) i.Pr,NPO(OAll),, I ff-tetrazole, 
DCM. -40 'C to room temp., 46-72%. (b) p-ToIS02Na, Pd(PP1s, 
THF-McOH, room temp.; then M)H-HO-Et 3N (5 : 2 : I), 
86-99%. 
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fl5. I(a) Anion.encbaoge H]'LC monttormg of the GOP-Man?!' catalyzed synthesis of GOP.ddoxymannose 9 (peak at 13 nun = 9, 
peak at 22 rein = OT?). (b) This methodology is applicable to synthesis of all the azsdodooxymaanose isomers as observed by a colonotetsic 
activity assay: B = blank. MIP = mannose-l-phosphate as substrata. 6/2-N3 = 6/2-aztdodeoxy maitnoset as substrates. (c) ESI-MS analysis of 
the enzymatic reaction mixture shows that GO}'-4-aatdodeoxymanuose is incorporated most readily by the s'1,2.MaoT into the disaccharide 
4-AzMan(e-1,2)Mau.s.OMn 
inorganic pyrophosphatase-mediated hydrolysis of this reac-
tion byproduct. and subsequent formation of a complex 
between phosphate, ammonium molybdate, and malachite 
green dye, which shifted the dye absorbance maximum to 
650 am.' Typically, the reagent was calibrated against a series 
of phosphate standards and a standard curve was generated 
against which 25 !'L reaction samples were analysed at timed 
intervals. t Subsequently the 2 3- and 4-aaido derivatives were 
also isolated in 41, 52 and 55% yield, respectively, and 
characterised by tH  ' 3C and Stp  NMR spectroscopy and 
high-resolution mass spectrometry. 
If the GOP azidomaitnose products were to find utility, for 
example, as probes for mannosyltransferase activity or glyco-
protein retuodeUing, it was essential to investigate whether they 
can subsequently be transferred by ManTs to potential sub-
strates. In a model system we over-expressed the soluble 
fragment of the S. cocevistae a-I .2-ManT from E. coIi. t° After 
partial purification, the protein was concentrated (to I ml L' 
culture), exchanged against an appropriate buffer for subse-
quent MS analysis (100 mM ammonium formate, pH 7.5), and 
characterised by SOS-PAGE and Western blot, The reaction 
mixture containing the protein (107.2 !'L), the GDP-mannose 
donor (1.25 mM) and the u-methyl mannoside acceptor 
(7.5 mM), in a total volume of 160 al of 50 m ammonium 
formate buffer pH 7.5,10mM MaCl2, was incubated at 30'C 
for 24 h. The protein content was removed and the filtrate was 
analysed by ESI-MS. Unsurprisingly, not all the isomers 
appeared to be converted to the desired product, however 
GDP-4-azidodeoxymannose was successfully incorporated 
into the disaccharide 4-AzMan(u-1,2)Man-u-OMe (Fig. 1(c)). 
This preliminary observation opens the door to in vitro profil-
ing of mannosyltransferase activity and to the remodelling of 
mannose-containing glycoconjugates such as glycoproteins by 
using the azide as a synthetic handle. 
2 I Omen, Comn,un., 2008, 1-3 
In conclusion, we have developed an effective chemoenzy-
matic route to four GOP-azadodeoxymannoses. The colouri-
metric GDP-ManPP activity assay proved to be a useful 
analytical tool to monitor product formation and will facilitate 
optimisation of the enzymatic syntheses of azide-containing 
compounds. We also demonstrated that a recombinant a- 1,2-
ManT from S. cererisiae can successfully process GOP-4-
azidomanoose. Consequently GDP-aztdomannoses should 
function as useful non-radioactive probes to investigate ManT 
activity and, when successfully transferred to substrates, these 
compounds provide useful synthetic handles for further 
engineering via azide chemi stry. tt 
The authors acknowledge financial support from The Royal 
Society, The University of Edinburgh and UCL. The RJ1'M 
gene from S. rewrite strain LT2, encoding the GOP-Man?!' 
was originally obtained as a gift from Prof. L. Elling. 
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C.! Summary of the PhD research project: results and medicinal relevance 
C. 1.1 Aims of the research project and relevance in medicinal science 
This PhD research project is focussed on the development of a new technology 
that can be applied for the study, engineering, and applications of a class of 
enzymes called mannosyltransferases. These enzymes transfer the carbohydrate 
mannose from a precursor building block onto a more complex structure, which is 
generally a glycolipid or a glycoprotein. 
Mannosyltransferases are widely distributed in living organisms, yet their 
characterisation is far from being complete. Due to handling difficulties 
associated with the fact that they usually occur in lipid membranes, only some of 
them have been identified to date, and even fewer have been characterised. 
Nevertheless, they are object of intense scientific effort due to their involvement 
in a number of pathological processes. Indeed mannose is very relevant for 
medicinal applications as its biological function is involved in abnormal 
immunological response (from the failed clearance of infecting agents to 
autoimmune reaction), 111 in tumour proliferation, '2' and in the cellular uptake of 
vaccines [31  and drugs for gene therapy. 14' For similar reasons, recent studies 
emphasised the potential of mannosyltransferases as novel drug targets especially 
since they are crucial for the virulence of pathogens responsible of malaria, 151 
tuberculosis, 161 leishmaniasis, salmonellosis, 181 and infections by Candida, ['l and 
Cryptococcus. 1101 Moreover, defective human mannosyltransferases have been 
linked to muscular dystrophy, 1111 Congenital Disorders of Glycosylation (CDG)," 2 
181 and also other genetic disease states. [17, 19, 20] Most of these pathological 
conditions do not find a satisfactory pharmaceutical treatment, and many of 
VI 
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them are a widespread plague in densely populated tropical countries. In 
conclusion, there is clearly an existing need of novel technologies to be able to 
study mannosyirransferases in order to develop new medicines for various disease 
states. In addition, the same technologies could also be applied to engineer these 
enzymes, so that they can be applied for the production of mannosylated species, 
in particular therapeutic glycoproteins, as we will see later on in this chapter. 
C-1.2 Scientific results achieved during the PhD and potential applications 
This Phil) research project discussed the development of an innovative 
chemoenzymatic technology for the production of unnatural GDP-
azidomannoses. These compounds mimic the naturally occurring GDP-mannose 
(Figure C. 1), which is a sugar building block that many organisms use to add the 
carbohydrate mannose onto more complex structures, usually glycolipids or 





















GDP 	 GOP 	GDP 	GDP 
Figure C.1: The unnatural GDP-azidomannoses, prepared during this PhD, mimic 
the natural analogue GDP-mannose. 
When an unnatural GDP-azidomannose is processed by a mannosyltransferase (as 
we demonstrated for the GDP-4-azidomannose and (x-i ,2-mannosyltransferase 
Kre2p/Mntlp from S.cerevisiae), then a specific chemical reaction can be 
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performed on the azido moiety (in red in Figure C. 1) which will be displayed on the 
product. This will result in a stable linkage between the structure containing the 
unnatural azido-mannose (generally a glycoprotein), and another compound of 
choice. Depending on the nature of the latter, this methodology can serve either of 
two scopes: 
Diagnostic screen (Figure C.2) for disease states where 
mannosyltransferase activity is impaired. In this case the second 
compound will have any property that allows for detection (i.e. 
fluorescence, colour, etc.), and therefore will act as a "reporter'. 
Reporter 
N 
ON 	 I OH 
4nnosyltransfe 	
HO I Reporter 	H0 
	
H—N& 
Glycoprotein 	 Glycoprotein 	Azide 	Glycoprotein 
Chemistry 
The "reporter" 





Figure C.2: Example of diagnostic screen for mannosyltransferase. If the enzyme 
transfers GDP-azidomannose, it can be detected after reaction with a "reporter". 
Glycoprotein production (Figure C.3). 	In this case the second 
compound can be another sugar: the chemical reaction will then yield 
complex glycoproteins not easily produced with other technologies. 
N, 	 Sugars 
OH 	 0)1 
1.10 
Mannosyltransferase 	 Sugars 
Glycoprotein Glycoprotein 	A.zid' 	Glycoprotein 
( 	 chemistry 
- 	
Glycoprotein 
OH 	 GDP  
HO L._ - - 	 displaying 
HO 	 complex 
carbohydrates 
Figure C.3: Application for glycoprotein production. The unnatural azidomannose 
can be reacted with other sugars to yield a complex glycoprotein (for instance, a 
drug) that otherwise cannot be easily produced. 
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For any of the scopes above, there are two essential requirements: 
The mannosyltransferase enzyme of study transfers the unnatural 
azidomannose efficiently. There are many different enzymes that use 
GDP-mannose as a building block to form complex structures. In 
principle, this protocol can be applied to all of them, but in practice it is 
not known a priori whether an enzyme will be able to process all, some, 
just one, or even none of these unnatural compounds. For instance, in 
our experiments, the a-1,2-mannosyltransferase from S.cerevisiae could 
use only one (GDP4-azidomannose) as a substrate. Each enzyme will 
therefore have to be tested individually, and the experimental data 
cannot be generalised to other mannosyltransferase enzymes. 
The chemical reaction on the azide is reliable and efficiently links the two 
desired compounds. This kind of chemistry has been widely studied and 
a number of condition sets are available for their successful performance 
also in complex environments, such as in vivo. 1211  Indeed, a class of these 
reactions is so reliable and efficient, that they have been referred to as 
"click" chemistry. 122, 231 	Most importantly, they possess all the 
requirements for a facile industrial application: they can be performed at 
standard conditions of temperature and pressure, and in water; they are 
convergent and high-yielding, thus they produce minimal waste; the 
product purification is generally straightforward. 
C.2 Analysis of the potential applications 
C.2.1 Diagnostic tool 
The main issue associated with this application is the efficiency and reliability of 
the enzymatic transfer. The weakness of our technology is that it involves the 
assumption that the unnatural azidomannose has the same biological action of its 
natural analogue. We simply do not know to what extent this is true: for 
instance, in our preliminary experiments, we tested our compounds on the a-1,2- 
mannosyltransferase from the yeast S.cerevisiae, and assisted to the efficient 
I P.11 
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transfer onto the product only of one of the isomers (the GDP4-azidomannose). 
The scientific implication is that the unnatural analogues do not have exactly the 
same biological action of their natural counterparts, hence the technology can be 
reliably applied only to specific mannosyltransferase enzymes, for which it will 
have to be thoroughly tested first. 
At present, the most widely used technology to screen for mannosyltransferase 
activity relies on radioactivity. Despite the issues associated with safety hazards 
and the management of radioactive waste, this competitive technology is 
extremely reliable and can be universally applied to any enzyme for which a 
radioactive substrate can be prepared. Biochemists interviewed are simply not 
willing to switch to our method, since it does not guarantee the same universal 
validity and reliability. 
In conclusion, at the current state of the art, our methodology is simply not 
competitive enough to succeed against existing methods used to screen for 
mannosyltransferase activity. 
C.2.2 Glycoprotein production 
Glycoproteins are of vital importance to the pharmaceutical industry: sales of 
biologically active glycoproteins command a 70% share of the therapeutic 
proteins market ($57b in 2006).L24 251 The majority of glycoproteins have a 
common core structure that contains five units of the carbohydrate mannose. 261 
Correct glycoprotein architecture is essential for therapeutic activity, especially 
in the clinical setting, as glycoproteins without the sugars exhibit a poor 
pharmacokinetics profile (which affects the rapidity and duration of their 
biological effects) J241  One synthetic approach to produce these molecules 
involves the replacement of the sugars with unnatural hydrophilic polymers (i.e. 
Poly Ethylene Glycol = PEG, Figure CA), although their application in vivo may 
be limited, for example by the generation of immune response (i.e. allergic 
reaction). [2'1 Thus, the synthesis of natural glycoproteins presents a pressing 
challenge to the pharmaceutical industry: costs are high, and the rate of 
production is struggling to meet demand. 124 ' 281 Consequently, development of a 
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rapid, cost-effective method for the production of glycoproteins constitutes a 
promising business opportunity. 
C.3 Innovation of the business opportunity 
C.3.1 Existing technologies for therapeutic glycoproteins production 
It is well-known that the technical challenge in the production of therapeutic 
glycoproteins regards the assembly of the complex sugar structures naturally 
occurring in humans. At present, two different approaches are mainly employed 
to tackle this issue: 
* synthetic methods, based on the use of polymers in place of the sugars; 
* biotechnologies, which exploit genetic engineering techniques combined 
with cellular machinery to assemble sugars and proteins together. 
The first possible solution consists of substituting the sugars with unnatural 
hydrophilic polymers (PEG, Figure C.4). It has been shown that the attachment 
of such structures (i.e. PlEGylation) indeed improves the pharmacokinetic 
profiles of therapeutic proteins (such as their absorption, their half life, and their 
clearance from the patient's body), in a similar fashion as carbohydrates do. 1291 
The main advantage of this technology is certainly its simplicity and low cost, 





Poly-Ethylene Glycol = PEG 
Figure C.4: Poly-Ethylene Glycol (PEG) is a polymer of Ethylene Glycol, and is 
used as a substituent of sugars in synthetic glycoproteins. 
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unnatural polymer PEG, a real concern regards possible allergic reactions, which 
indeed occur amongst treated patients.130' 31j  As we will see in the industry 
analysis, there are only a few pegylated products available in the market, 
especially due to the robust patent protection of existing players in this field. 
Nevertheless, the technology is rapidly being applied to a wider range of 
therapeutic proteins, which are currently under development. 
It is well-known that biotechnologies are advantageous compared to synthetic 
chemical procedures as they allow for the production of much more complex 
structures in a faster, simpler, cheaper, and more environmentally friendly way. 
The general approach is based on the construction of genetically modified 
organisms that produce the glycoprotein of interest. Depending on the nature of 
the organism, the technology presents different strengths and weaknesses: 
Mammalian cells. They have all the required cellular machinery to 
produce glycoproteins of the highest level of complexity desired, and 
therefore are the preferred choice for the production of therapeutic 
glycoproteins. On one hand, this type of cells offers important 
advantages, such as an established infrastructure of the biotech industry, 
process scalability, and the ability to produce glycoproteins very similar to 
the human ones. On the other, the associated costs are very high, they 
are very delicate as susceptible to propagation of infections, and especially 
they offer little control over the nature of the carbohydrate structure that 
is displayed in the glycoprotein of choice. Finally, the glycoproteins 
produced with this method are highly heterogeneous and this limits the 
process reproducibility. 1`3 
Insect and plant cells. Although they have been reported as successful 
hosts for the production of therapeutic glycoproteins, they do not possess 
the required machinery to produce all the complex structures that can be 
made by mammalian cells. Furthermore, the possibility of the presence 
of non-human carbohydrates in the glycoproteins so produced raises 
Appendix C: Commercial Assessment 
concerns over immunogenicity and safety. Ongoing engineering studies 
are addressing these issues. [241 
3. Yeast cells. This kind of cells is the most promising option for the future 
of the production of therapeutic glycoproteins. Yeast offers robust and 
scalable protein production, and has the ability to perform complex 
glycosylation. In particular, P.pastoris is the organism of choice and has 
been very well characterised and applied to this scope. The main 
drawback is that yeast cells naturally produce proteins with characteristic 
carbohydrate structures rich in mannose, which are capable of triggering 
an allergic reaction. To date this issue has been addressed by different 
studies which aim at engineering the cellular machinery in order to 
produce human-like glycoproteins [24] 
C.3.2 Definition and innovation of the business opportunity 
After careful consideration of the existing methods for glycoprotein production, 
we reasoned that the most attractive system to apply our technology is the yeast 
P.pastoris. It is known that the main drawback of recombinant glycoproteins 
produced in this system is the presence of carbohydrate structures rich in 
mannose. It is also known that commercially available enzymes called 
mannosidases are capable of digesting such structures, practically eliminating the 
undesired mannose units. In our rationale, a hyper-mannosylated glycoprotein 
so obtained from yeast could be subjected to the action of a mannosidase first, 
and then a mannosyltransferase, together with one of our unnatural GDP-
azidomannoses, in order to display the unnatural azide appendage (Figure C.5). 
Next, a chemical reaction with another carbohydrate (for instance a unit of sialic 
acid chemically modified to react with the azide) would finally yield to a 
glycoprotein decorated with carbohydrate structures potentially less antigenic 
and better mimics of the ones occurring in humans (Figure C.5, bottom). This 
technology could then be applied to any therapeutic glycoprotein of interest 
which can be produced in the host P.pastoris. 
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Figure C.5: A hyper-mannosylated glycoprotein produced in yeast modified with the 
use of our unnatural GDP-azidomannoses in order to display complex sugars that 
mimic the structures occurring in humans. 
As regards to the business model, we reasoned that a biotech start-up would 
probably be appropriate, as our research group has already filed a patent 
application for another technology for the production of the therapeutic protein 
erythropoietin, and has the required scientific know-how relevant to the 
chemistry and biology of glycoproteins. 
C.4 Macro-market analysis: the biotech market 
Biotech drugs are defined as those "produced through recombinant DNA 
technology from substances naturally occurring in living organisms". This sector 
is relatively new and still dwarfed compared to the pharmaceutical industry. 
Nevertheless, it is rapidly growing and since 2000 it recorded a remarkable 
annual growth rate >15%, surpassing the pharmaceutical industry (Chart C.1). 
Despite a negative trend in recent years, the annual growth rate over the next 5 
years is forecasted to be higher than 6%.1321 
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Global Market Trends: Biotech versus Pharma 
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Chart C.1: Since 2000 the biotech industry has shown higher growth rates than phana. 31 
The major drivers of this growth are the issues faced nowadays by the pharma 
industry: poor R & D productivity and blockbuster patents expiry. These 
phenomena led the big pharmas to seek collaborations, licensing agreements, 
merges or acquisitions with the more innovative biotechs (Chart C.2)J 32 
Interestingly, in the past pharmas were seeking licensing agreements at late 
development stages in order to minimise the financial risks by investing in a new 
technology that had already successfully passed the bottlenecks of the "proof of 
concept" (Phase II - Phase III clinical trials). Recently, the scarcity of innovative 
technologies, together with the increasing demand for them, has led to a 
dramatic raise of the cost of the licensing agreements. As a result, many 
pharmaceutical companies find more convenient to seek collaborations or other 
deals at earlier stages of development (Phase I trials), before the technology 
becomes well known to other competitors and increases the competitivity of the 
offers (as well as the value of the agreements) [32}  This trend results very 
advantageous for biotech companies, now able to make profits at earlier R & D 
stages. In this way, not only do the biotechs save part of the clinical trials 
expenditure, but also they are able to sell a bigger portion of their technological 
products, including those destined to fail at later developmental stages. 
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Chart C.2: Biotech companies are more innovative than pharmas 34 
C.5 Macro-industry analysis: the biotech industry 
C.5.1 Biotech industry: business model 
The business model of biotechs typically follows the evolution from technology 
developers, to service providers, to finally out-license their best candidates to big 
corporations. A few successful companies, instead, will capitalise on their 
products to become a fully integrated business (such as Amgen). 132 
The first challenge is raising the capital (typically from venture capitalists and 
angel investors) for a biotech venture. The reason being it is a high-risk 
investment, which involves substantial costs, and presents the threat of 
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aggressive competitors: the pharmaceutical corporations. Other challenges are 
cost containment and reimbursement, pointed out as the biggest barriers for the 
growth of this industry, as well as the threat of biogenerics, whose entrance in 
the market is forecasted to be as early as 20 10.1321 
C.5.2 Biotech industry: Porter's five forces analysis 
An analysis of Porter's five forces indicates that, despite the low threat of 
entrants, buyers' and suppliers' power, overall the industry is not attractive. The 
starting capitals required are high, as well the risks of the investment, and the 
major threat is the aggressive competition of pharmaceutical corporations. 
Threat of entrants: LOW. The biotech field requires a rather complex set 
of know-how and expertise, as well as very high R & D costs (equipment, 
specialised personnel, materials, etc.) and it involves rather complicated 
regulations to abide with. 
Supplier power: LOW. The value of biotech companies relies in their 
Intellectual Property, and although they do need highly specialised 
starting materials, there are various suppliers, and there is a minimum 
risk that they will invade the biotech business. 
Buyer power: LOW. The end-user of biotech products is the patient, who 
has very little power in the drugs industry. Nevertheless, drugs are 
heavily regulated by the government and large organisations such as 
hospitals and private clinics, and the legislation varies amongst countries. 
Compared to other industries, it is highly unlikely that these buyers will 
invade the business of the biotech, and hence their power is generally low. 
Availability of Substitutes: MEDIUM. Depending on the specific area of 
business, the number of companies providing valid alternative products is 
variable. The major concern for biotech companies is adequate IP 
coverage, and, after that, the threat of biogenerics entry into the market. 
R & D are the main costs for players in this field and they are 
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compensated by the products revenues, hence the IP protection is 
essential for the financial stability of the company. 
5. Competition: HIGH. This is probably the most negative aspect of 
Porter's five forces analysis. The industry is very concentrated, with the 
top 10 players (biotech or pharma) holding a combined market share of 
83% in 2004. 1121  The major competitors are aggressive big corporations 
and it is a real challenge to be able to secure a position in this industry. 
Moreover, small ventures simply do not possess the required 
infrastructure for successful marketing and distribution, and often an 
agreement with major companies is necessary. 
B.6 Micro-market analysis: the therapeutic proteins market 
The global biotech market is represented by the revenues generated by biologicals, 
which are typically large molecules (compared to the more traditional drugs). 
The vast majority of biologicals are constituted by proteins, followed by glycans 
(complex carbohydrates), lipids, and nucleic acids for antisense therapy. Indeed 
the global market of therapeutic proteins ($57b in 2006) represents 78% of the 
biotech ($73b in 2006), as shown in Chart B.3. Glycoproteins represent about 
70% of the therapeutic proteins market, accounting for $40b in 2006 . [24,25,33] 
Biotech global market segments 
$73b in 2006 
nucleic 
$11' 
Chart B.3: Therapeutic proteins represent the vast majority of biologicals marketJ242 ' 33 ' 
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The trends of the proteins market are therefore a good reflection of the trends of 
the biotech market. In addition, there are technological barriers related to the 
industrial production of complex sugars that are present in glycoproteins and that 
influence the pharmacokinetics of proteic drugs. As a consequence, the main 
growth barriers of this sector are: drug delivery issues, manufacturing shortfall, 
and gene therapy competition (Chart CA). We feel that our technology would 
provide a solution to the first two, while the third barrier will not represent a 
serious threat for a few years to come. 1281 
Drug delivery issues. Currently therapeutic proteins have to be injected to 
be effective drugs, since they suffer from inactivation by our organism. 
The presence of sugars has the ability to mask the protein from enzymatic 
digestion, and therefore prolong its half-life, but at present this is often not 
a viable solution due to the difficulties associated with glycoprotein 
production. 
Manufacturing shortfall. The rapid expansion of the monoclonal antibody 
segment is leading towards a manufacturing shortfall, since at present 
Timeline of impact: growth barriers for the therapeutic proteins market 
2002 	2003 	2004 	2005 	2006 	2007 	2008 	2009 	2010 
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Chart C.4: Timeline of impact of growth barriers for the therapeutic proteins market.128 
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production capacity is not able to satisfy the demand for therapeutic 
proteins. In particular, this is due to the fact that monoclonal antibodies 
are produced without sugars (i.e. they are proteins, and not glycoproteins). 
Consequently, they present such poor pharmacokinetic profiles (e.g. 
absorption, hall-life, etc.) to require their use in sensibly higher doses: of 
the vast amount of protein which is injected into the patient, only a small 
portion will be able to exert the desired therapeutic activity. 1281 This is an 
important "customer pain" which can be solved by new technologies that 
will enable cheaper and more efficient production of glycosylated proteins, 
so that smaller doses will be required, and capital will be saved from the 
production costs. 
3. Gene therapy competition. The development of nucleic-acid therapeutics 
could in theory supercede the requirement for proteins drugs, by acting 
earlier in the biological chain of events. In practice, the gene therapy 
market is still immature (there are only four marketed products to date, 
and none of these in Europe) and has failed to realise the promise of early 
scientific research. 1351 The geographic segment which is more mature 
is China, with the leading product Gendicine® showing record sales 
growth rate, and estimated to enter the Indian market in 2008. 
Oncorine®, the other Chinese product, has been more disappointing and 
showed a limited market share (sales records not disclosed).' 361 Similarly, 
the US market features a success story in Macugen®, which recorded 
$103m revenues in 2006, and a failed promise in Vitravene®, for which 
no sales were recorded in the same year. 1371 In conclusion, it is unlikely 
that gene therapy will be a real threat for the therapeutic proteins market 
at least for a few years to come. [281 
C.7 Micro-industry analysis: the therapeutic proteins industry 
As regards Porter's five forces analysis, the therapeutic proteins segment has the 
same features as the biotech industry. In particular, since our business 
opportunity regards the production of glycoproteins, we will analyse the existing 
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competitive technologies to produce proteins displaying sugars or other synthetic 
analogues (i.e. PEG), and the industry players of the field. 
As mentioned above, at present there are two main methods used to produce 
glycoproteins: 
PEGylation, which consists of attaching unnatural polymers to the 
protein in order to mimic the sugars. 
Recombinant technologies, which use different organisms to produce the 
desired glycoproteins. 
C.7.1 The therapeutic glycoproteins industry: PEGylation 
The main industry players in the field are: 
* Amgen, with Neulasta (pegylated colony stimulating factor)' 381 
* Roche, with Pegasys®  (pegylated interferon) 1391 
* 	 ® 	 i 	
1401 Schering-Plough, with PEG-Intron (pegylated nterferon) 
* Enzon/Aventis, with Oncaspar®  (pegylated asparaginase)' 31 ' 
* Neose (Merck), with GlycoPEG-EPO ® (pegylated eiythropoietin), which 
is still at the stage of clinical trials, hence not yet in the market. 1411 
The 2006 global sales of these pegylated products (Chart C.5) reached all 
together $4.8b, with Amgen product leading with $2.7b, followed by Roche 
($1.2b), Schering-Plough ($0.8b), and Enzon ($30m), which also receives 
royalties from the sales of PEG-Intron, produced using their licensed 
technology. [25, 38421 
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2006 Global Sales 
Pegylated Therapeutic Proteins ($4.8 b) 
• Neulasta, Amgen 
($2.7b) 





• Oncaspar, Enzon 
($ 0.031 b) 
Chart C.5: 2006 Global sales of pegylated therapeutic proteins, with Amgen product 
leading over the others. Note: PEG-Intron is produced with a technology licensed 
from Enzon, which receives royalties for its revenues. [25, 38-421 
PEGylation is a proprietary technology of Enzon Pharmaceutics which is out-
licensed to Nektar Therapeutics, which in turn has agreements with third parties 
for the production of the marketed pegylated products listed above. [311  
C.7.2 The therapeutic proteins industry: recombinant technology 
The main stream of glycoprotein production uses recombinant strategies: 
genetically modified organisms will produce the glycoprotein of interest. The 
biggest industry player in the field is Amgen, whose sales are well-ahead 
compared to the other competitors (Chart C. 6).[431 
We should not forget that also big pharmas (Novartis, Roche, Pfizer, etc.) 
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with venture companies. Their presence in the field accounts for more than half 
of global sales, while Amgen reaches only 18% (Chart C.7)J431 
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Chart C.6: Amongst the global top 10 biotech companies, Amgen is a clear leader. [431  
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In conclusion, although the therapeutic proteins industry is concentrated with 
big phannas as aggressive players, their current innovation crisis brings them to 
seek new affiances with biotech ventures that hold new technologies, especially 
at early stages of development. Our business opportunity would be ideally 
positioned to benefit from this situation. 
C.8 	Team analysis 
The team which will carry on the studies on this technology is currently 
comprised of two scientists. The group leader D.M. has extensive experience in 
the field of glycoproteins chemistry, and has already filed a patent application 
regarding the production of therapeutic erythropoietin. Besides a proven record 
of innovative ideas in the field of therapeutic glycoproteins, this personality is 
marked by a passionate attitude and a set of personal aspirations of high level 
(the standard is of the best research institutes in the US - University of Berkeley 
and Caltech - where D.M has worked as research fellow). The post-doctoral 
fellow J.R. is at his third post-doctoral appointment, and has a very solid 
background in the biochemical field, especially as regards genetics and molecular 
biology (recombinant) techniques. As a result, the team has definitely the 
scientific knowledge, as well as the passionate spirit, required for the 
development of a successful biotech venture which integrates the fields of 
chemistry and biology concerning therapeutic glycoproteins. 
A valuable addition would complete the team with industrial expertise, in order 
to build the required network for a successful venture. The ideal third member 
would be a person with management experience that could provide integration 
through the value chain, as well as an industrial mind set and connections across 
the industry segment. 
A team of this composition would possess all the abilities to execute on the 
critical success factors associated with a biotech venture in the segment of novel 
biotechnologies for therapeutic glycoproteins production. 
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C.9 Possible patents infringement and possible solutions 
The technology developed in this Phi) is based on the preparation of novel 
compounds (GDP-azidomannoses) using an innovative chemoenzymatic 
strategy. The key process makes use of a recombinant enzyme (GDP-Mannose 
Pyrophosphorylase, GDP-ManPP) in the final step. To the best of our 
knowledge, it is the first time that this enzyme (RJbM gene product from 
S.enterica) is obtained as poly-histidine-tagged fusion in the bacterium E.coli, and 
also the first time it is used to produce these unnatural GDP-azidomannoses. 
In the literature there is only one patent (WO 9627670, J. E. Ritter et al., 1996) 
which covers the very same gene (RJbM) and its use in a recombinant technology 
to obtain the enzyme we have used from the bacterium E.coli. One possible 
solution comes from the fact that during this Phi) we have also optimised a 
colourimetric screen which can be applied to directed evolution studies of the 
enzyme. This technique is based on the generation of gene mutations —which will 
effectively change the DNA sequence of the gene of interest to produce a new 
one - in order to improve a desired enzymatic activity (in our case, the 
preparation of the unnatural GDP-azidomannoses). If new DNA sequences were 
produced showing an improved enzymatic activity towards our unnatural 
compounds, these would constitute novel intellectual property and would not 
infringe the existing patent. 
As regards the application of our technology for therapeutic glycoprotein 
production, there are various patents which are generally specific of a target 
glycoprotein (for instance, erythropoietin), an organism where it is produced (for 
instance, P.pastoris), and the specific chemistry used (for instance, PEGylation). 
The key success for this business opportunity is to find the appropriate set of 
conditions that are not currently covered by existing patents. The opportunities 
are numerous. 
A good example is an existing patent of a very similar technology used for 
glycoprotein remodelling (WO 2006106348, B. G. Davis, 2006). This patent 
covers the use of azide chemistry to generate glycoproteins by introducing the 
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azide on the protein backbone (with an unnatural azidoaminoacid), rather than on 
a sugar (as in our technology). This document simply illustrates the unmet need 
for new protein glycosylation technologies as well as the advantages of the 
convenient azide chemistry. 
C. 10 Conclusions 
We have developed a novel chemoenzymatic technology for the production of 
the unnatural GDP-azidomannoses. Three of these compounds have been 
prepared for the first time, and this is the first example of the use of a GDP-
mannose pyrophosphorylase enzyme to produce unnatural compounds bearing 
an azide group. It is well established that azide chemistry is an efficient and 
valuable tool that can be applied for biological studies.' 451  Moreover, patents 
already exists that cover its use for biotechnological applications, especially 
related to recombinant glycoproteins.t' 471 
We have demonstrated for the first time that a GDP-azidomannose can be 
successfully transferred by a mannosyltransferase, and we believe that this result 
can be strategically exploited for the production of therapeutic glycoproteins. In 
particular, the business opportunity we identified consists of remodelling 
hypermannosylated recombinant proteins produced in yeast, first by 
enzymatically digesting the carbohydrates, then by adding our unnatural 
azidomannoses by means of a mannosyltransferase, and finally by adding 
human-like sugar structures via azide chemistry. 
Therapeutic glycoproteins constitute the majority of the current biotech market, 
which shows very favourable growth trends. 124' 25, 331 At present, the industrial 
production of therapeutic glycoproteins is limited by technical issues to which we 
believe we could provide an original and convenient solution. [281 
In conclusion, the technology herein discussed is very promising as applied for 
therapeutic glycoproteins production to address currently unsolved "customer 
pain" issues, as outlined in the industry and market analysis, but appropriate 
patent protection is required in a timely manner. 
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